0001493152-24-018382.txt : 20240509 0001493152-24-018382.hdr.sgml : 20240509 20240509140855 ACCESSION NUMBER: 0001493152-24-018382 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 63 CONFORMED PERIOD OF REPORT: 20240331 FILED AS OF DATE: 20240509 DATE AS OF CHANGE: 20240509 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Syra Health Corp CENTRAL INDEX KEY: 0001922335 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-EMPLOYMENT AGENCIES [7361] ORGANIZATION NAME: 07 Trade & Services IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-41822 FILM NUMBER: 24929854 BUSINESS ADDRESS: STREET 1: 1119 KEYSTONE WAY N. STREET 2: #201 CITY: CARMEL STATE: IN ZIP: 46032 BUSINESS PHONE: (317) 922-0922 MAIL ADDRESS: STREET 1: 1119 KEYSTONE WAY N. STREET 2: #201 CITY: CARMEL STATE: IN ZIP: 46032 10-Q 1 form10-q.htm
false --12-31 Q1 0001922335 P5Y P3Y P3Y P3Y 0001922335 2024-01-01 2024-03-31 0001922335 2024-05-06 0001922335 2024-03-31 0001922335 2023-12-31 0001922335 us-gaap:NonrelatedPartyMember 2024-03-31 0001922335 us-gaap:NonrelatedPartyMember 2023-12-31 0001922335 us-gaap:RelatedPartyMember 2024-03-31 0001922335 us-gaap:RelatedPartyMember 2023-12-31 0001922335 us-gaap:CommonClassAMember 2024-03-31 0001922335 us-gaap:CommonClassAMember 2023-12-31 0001922335 SYRA:ConvertibleClassBCommonStockMember 2024-03-31 0001922335 SYRA:ConvertibleClassBCommonStockMember 2023-12-31 0001922335 2023-01-01 2023-03-31 0001922335 us-gaap:PreferredStockMember 2022-12-31 0001922335 us-gaap:CommonStockMember us-gaap:CommonClassAMember 2022-12-31 0001922335 us-gaap:CommonStockMember SYRA:ConvertibleClassBCommonStockMember 2022-12-31 0001922335 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001922335 us-gaap:RetainedEarningsMember 2022-12-31 0001922335 2022-12-31 0001922335 us-gaap:PreferredStockMember 2023-12-31 0001922335 us-gaap:CommonStockMember us-gaap:CommonClassAMember 2023-12-31 0001922335 us-gaap:CommonStockMember SYRA:ConvertibleClassBCommonStockMember 2023-12-31 0001922335 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001922335 us-gaap:RetainedEarningsMember 2023-12-31 0001922335 us-gaap:PreferredStockMember 2023-01-01 2023-03-31 0001922335 us-gaap:CommonStockMember us-gaap:CommonClassAMember 2023-01-01 2023-03-31 0001922335 us-gaap:CommonStockMember SYRA:ConvertibleClassBCommonStockMember 2023-01-01 2023-03-31 0001922335 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-03-31 0001922335 us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0001922335 us-gaap:PreferredStockMember 2024-01-01 2024-03-31 0001922335 us-gaap:CommonStockMember us-gaap:CommonClassAMember 2024-01-01 2024-03-31 0001922335 us-gaap:CommonStockMember SYRA:ConvertibleClassBCommonStockMember 2024-01-01 2024-03-31 0001922335 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-03-31 0001922335 us-gaap:RetainedEarningsMember 2024-01-01 2024-03-31 0001922335 us-gaap:PreferredStockMember 2023-03-31 0001922335 us-gaap:CommonStockMember us-gaap:CommonClassAMember 2023-03-31 0001922335 us-gaap:CommonStockMember SYRA:ConvertibleClassBCommonStockMember 2023-03-31 0001922335 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0001922335 us-gaap:RetainedEarningsMember 2023-03-31 0001922335 2023-03-31 0001922335 us-gaap:PreferredStockMember 2024-03-31 0001922335 us-gaap:CommonStockMember us-gaap:CommonClassAMember 2024-03-31 0001922335 us-gaap:CommonStockMember SYRA:ConvertibleClassBCommonStockMember 2024-03-31 0001922335 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0001922335 us-gaap:RetainedEarningsMember 2024-03-31 0001922335 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember SYRA:FamilyAndSocialServicesAdministrationMember 2024-01-01 2024-03-31 0001922335 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember SYRA:FamilyAndSocialServicesAdministrationMember 2023-01-01 2023-03-31 0001922335 SYRA:HealthcareWorkforceMember SYRA:FSSANeuroDiagnosticInstituteMember 2024-01-01 2024-03-31 0001922335 SYRA:HealthcareWorkforceMember SYRA:FSSANeuroDiagnosticInstituteMember 2023-01-01 2023-03-31 0001922335 SYRA:PopulationHealthMember SYRA:FSSADivisionOfMentalHealthAndAddictionMember 2024-01-01 2024-03-31 0001922335 SYRA:PopulationHealthMember SYRA:FSSADivisionOfMentalHealthAndAddictionMember 2023-01-01 2023-03-31 0001922335 us-gaap:CustomerConcentrationRiskMember us-gaap:AccountsReceivableMember SYRA:FamilyAndSocialServicesAdministrationMember 2024-01-01 2024-03-31 0001922335 us-gaap:CustomerConcentrationRiskMember us-gaap:AccountsReceivableMember SYRA:FamilyAndSocialServicesAdministrationMember 2023-01-01 2023-12-31 0001922335 SYRA:HealthcareWorkforceMember 2024-01-01 2024-03-31 0001922335 SYRA:HealthcareWorkforceMember 2023-01-01 2023-03-31 0001922335 SYRA:PopulationHealthMember 2024-01-01 2024-03-31 0001922335 SYRA:PopulationHealthMember 2023-01-01 2023-03-31 0001922335 SYRA:DigitalHealthMember 2024-01-01 2024-03-31 0001922335 SYRA:DigitalHealthMember 2023-01-01 2023-03-31 0001922335 SYRA:BehavioralAndMentalServicesMember 2024-01-01 2024-03-31 0001922335 SYRA:BehavioralAndMentalServicesMember 2023-01-01 2023-03-31 0001922335 SYRA:HealtheducationMember 2024-01-01 2024-03-31 0001922335 SYRA:HealtheducationMember 2023-01-01 2023-03-31 0001922335 2023-01-01 2023-04-30 0001922335 2023-10-03 2023-10-03 0001922335 SYRA:SahasraTechnologiesCorpMember 2024-01-01 2024-03-31 0001922335 SYRA:STLogicsMember 2024-03-31 0001922335 SYRA:STLogicsMember 2023-12-31 0001922335 SYRA:STVenturesMember 2021-07-01 0001922335 SYRA:STVenturesMember 2022-05-01 2022-05-01 0001922335 SYRA:STVenturesMember 2024-01-01 2024-03-31 0001922335 SYRA:STVenturesMember 2023-01-01 2023-03-31 0001922335 SYRA:InformationTechnologyServicesMember SYRA:RadCubeLLCMember 2024-01-01 2024-03-31 0001922335 SYRA:InformationTechnologyServicesMember SYRA:RadCubeLLCMember 2023-01-01 2023-03-31 0001922335 SYRA:RecruitmentAndHumanResourceServicesMember SYRA:NLogixMember 2024-01-01 2024-03-31 0001922335 SYRA:RecruitmentAndHumanResourceServicesMember SYRA:NLogixMember 2023-01-01 2023-03-31 0001922335 us-gaap:WarrantMember 2024-01-01 2024-03-31 0001922335 us-gaap:WarrantMember 2023-01-01 2023-03-31 0001922335 us-gaap:EmployeeStockOptionMember 2024-01-01 2024-03-31 0001922335 us-gaap:EmployeeStockOptionMember 2023-01-01 2023-03-31 0001922335 SYRA:EmployeeRetentionTaxCreditMember 2024-01-01 2024-03-31 0001922335 SYRA:EconomicDevelopmentGrowingEconomyMember 2024-01-01 2024-03-31 0001922335 us-gaap:OfficeEquipmentMember 2024-03-31 0001922335 us-gaap:OfficeEquipmentMember 2023-12-31 0001922335 SYRA:STVenturesMember 2024-03-31 0001922335 SYRA:STVenturesMember 2022-05-01 0001922335 SYRA:STVenturesMember 2022-07-01 2022-07-01 0001922335 SYRA:STVenturesMember 2021-07-01 2021-07-01 0001922335 SYRA:STVenturesMember 2022-07-01 0001922335 SYRA:InsurancePolicyFinancingArrangementsMember 2023-12-31 0001922335 srt:MinimumMember SYRA:InsurancePolicyFinancingArrangementsMember 2023-12-31 0001922335 srt:MaximumMember SYRA:InsurancePolicyFinancingArrangementsMember 2023-12-31 0001922335 SYRA:InsurancePolicyFinancingArrangementsMember 2023-01-01 2023-12-31 0001922335 SYRA:TwoInvestorsMember us-gaap:CommonClassAMember 2024-03-31 0001922335 SYRA:TwoInvestorsMember us-gaap:CommonClassAMember 2024-01-01 2024-03-31 0001922335 SYRA:NovemberTwoThousandTwentyThreeMember 2024-01-01 2024-03-31 0001922335 SYRA:ConvertibleCommonStockBMember 2024-03-31 0001922335 SYRA:ConvertibleClassBCommonStockMember 2022-05-03 0001922335 SYRA:ConvertibleClassBCommonStockMember 2022-05-03 2022-05-03 0001922335 SYRA:OmnibusEquityIncentivePlanMember srt:MaximumMember 2022-04-11 2022-04-11 0001922335 SYRA:TwoThouandTwentyTwoPlanMember 2024-01-01 2024-03-31 0001922335 SYRA:TwoThouandTwentyTwoPlanMember 2024-03-31 iso4217:USD xbrli:shares iso4217:USD xbrli:shares utr:sqft xbrli:pure

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

FORM 10-Q

 

(Mark One)

 

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended March 31, 2024

 

OR

 

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from _________to ___________

 

Commission File Number: 001-41822

 

SYRA HEALTH CORP.

(Exact Name of Registrant as Specified in its Charter)

 

Delaware   85-4027995

(State or other jurisdiction of

incorporation or organization)

  

(I.R.S. Employer

Identification No.)

     
1119 Keystone Way N. #201, Carmel, Indiana    46032
(Address of principal executive offices)   (Zip Code)

 

(463) 345-8950

(Registrant’s telephone number, including area code)

 

Not applicable

(Former name, former address and former fiscal year, if changed since last report)

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Class A Common Stock, $0.001 par value   SYRA   The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☐ No ☒

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer ☐   Accelerated filer ☐
Non-accelerated filer ☒   Smaller reporting company ☒
      Emerging growth company ☒

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes ☐ No ☒

 

The number of shares of registrant’s common stock outstanding as of May 6, 2024 was 6,421,632.

 

 

 

 

 

 

    Page No.
PART I. FINANCIAL INFORMATION  
     
Item 1. Financial Statements F-1
     
  Condensed Balance Sheets as of March 31, 2024 (Unaudited) and December 31, 2023 F-1
     
  Condensed Statements of Operations for the Three Months ended March 31, 2024 and 2023 (Unaudited) F-2
     
  Statements of Changes in Stockholders’ Equity (Deficit) for the Three Months ended March 31, 2024 and 2023 (Unaudited) F-3
     
  Condensed Statements of Cash Flows for the Three Months ended March 31, 2024 and 2023 (Unaudited) F-4
     
  Notes to the Condensed Financial Statements (Unaudited) F-5
     
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations 4
     
Item 3. Quantitative and Qualitative Disclosures About Market Risk 9
     
Item 4. Controls and Procedures 9
     
PART II. OTHER INFORMATION 10
     
Item 1. Legal Proceedings 10
     
Item 1A. Risk Factors 10
     
Item 2. Unregistered Sales of Equity Securities, Use of Proceeds and Issuer Purchases of Equity Securities 10
     
Item 3. Defaults Upon Senior Securities 10
     
Item 5. Other Information 10
     
Item 6. Exhibits 11
     
Signatures 12

 

-2-

 

 

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS AND INDUSTRY DATA

 

This Quarterly Report on Form 10-Q contains forward-looking statements which are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). These statements may be identified by such forward-looking terminology as “may,” “should,” “expects,” “intends,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “potential,” “continue” or the negative of these terms or other comparable terminology. Our forward-looking statements are based on a series of expectations, assumptions, estimates and projections about our company, are not guarantees of future results or performance and involve substantial risks and uncertainty. We may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements. Our business and our forward-looking statements involve substantial known and unknown risks and uncertainties, including the risks and uncertainties inherent in our statements regarding:

 

  ● our projected financial position and estimated cash burn rate;
  ● our estimates regarding expenses, future revenues and capital requirements;
  ● our ability to continue as a going concern;
  ● our need to raise substantial additional capital to fund our operations;
  ● our ability to compete in the healthcare industry;
  ● the timing, cost and success or failure of new product and service introductions, development and product upgrade releases;
  ● competitive pressures including offerings and pricing;
  ● our ability to establish and maintain strategic relationships;
  ● undetected errors or similar problems in our software products;
  ● compliance with existing laws, regulations and industry initiatives and future changes in laws or regulations in the healthcare industry;
  ● the possibility of services-related liabilities;
  ● our ability to obtain, maintain and protect our intellectual property rights and the potential for us to incur substantial costs from lawsuits to enforce or protect our intellectual property rights;
  ● our reliance on third-party content providers;
  ● the success of competing products or services that are or become available;
  ● our ability to expand our organization to accommodate potential growth and our ability to retain and attract key personnel; and
  ● the successful development of our sales and marketing capabilities.

 

All of our forward-looking statements are as of the date of this Quarterly Report on Form 10-Q only. In each case, actual results may differ materially from such forward-looking information. We can give no assurance that such expectations or forward-looking statements will prove to be correct. An occurrence of, or any material adverse change in, one or more of the risk factors or risks and uncertainties referred to in this Quarterly Report on Form 10-Q or included in our other public disclosures or our other periodic reports or other documents or filings filed with or furnished to the U.S. Securities and Exchange Commission (the “SEC”) could materially and adversely affect our business, prospects, financial condition and results of operations. Except as required by law, we do not undertake or plan to update or revise any such forward-looking statements to reflect actual results, changes in plans, assumptions, estimates or projections or other circumstances affecting such forward-looking statements occurring after the date of this Quarterly Report on Form 10-Q, even if such results, changes or circumstances make it clear that any forward-looking information will not be realized. Any public statements or disclosures by us following this Quarterly Report on Form 10-Q that modify or impact any of the forward-looking statements contained in this Quarterly Report on Form 10-Q will be deemed to modify or supersede such statements in this Quarterly Report on Form 10-Q.

 

This Quarterly Report on Form 10-Q may include market data and certain industry data and forecasts, which we may obtain from internal company surveys, market research, consultant surveys, publicly available information, reports of governmental agencies and industry publications, articles and surveys. Industry surveys, publications, consultant surveys and forecasts generally state that the information contained therein has been obtained from sources believed to be reliable, but the accuracy and completeness of such information is not guaranteed. While we believe that such studies and publications are reliable, we have not independently verified market and industry data from third-party sources.

 

-3-

 

 

ITEM 1. FINANCIAL STATEMENTS

 

SYRA HEALTH CORP.

CONDENSED BALANCE SHEETS

 

   March 31,   December 31, 
   2024   2023 
ASSETS   (Unaudited)       
           
Current assets:          
Cash  $3,237,957   $3,280,075 
Accounts receivable, net   745,683    1,060,634 
Accounts receivable related party   82,124    50,614 
Other current assets   381,887    389,787 
Total current assets   4,447,651    4,781,110 
           
Property and equipment, net   72,048    78,974 
Right-of-use asset   31,826    63,199 
           
Total assets  $4,551,525   $4,923,283 
           
LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT)          
           
Current liabilities:          
Accounts payable  $645,567   $462,991 
Accrued expenses   319,698    198,978 
Deferred revenue   6,108    - 
Current portion of operating lease liability, related party   31,826    63,199 
Notes payable   99,021    184,904 
Total current liabilities   1,102,220    910,072 
Total liabilities   1,102,220    910,072 
           
Commitments and contingencies   -    - 
           
Stockholders’ equity (deficit):          
Preferred stock, $0.001 par value, 10,000,000 shares authorized, no shares designated, issued and outstanding   -    - 
Class A common stock, $0.001 par value, 100,000,000 shares authorized, 5,769,087 and 5,588,298 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively   5,769    5,588 
Convertible class B common stock, $0.001 par value, 5,000,000 shares authorized, 833,334 shares issued and outstanding   833    833 
Additional paid-in capital   9,954,708    9,071,745 
Accumulated deficit   (6,512,005)   (5,064,955)
Total stockholders’ equity (deficit)   3,449,305    4,013,211 
           
Total liabilities and stockholders’ equity (deficit)  $4,551,525   $4,923,283 

 

See accompanying notes to condensed unaudited financial statements.

 

F-1

 

 

SYRA HEALTH CORP.

CONDENSED STATEMENTS OF OPERATIONS

(Unaudited)

 

   2024   2023 
   For the Three Months Ended 
   March 31, 
   2024   2023 
         
Net revenues  $1,752,340   $1,188,351 
Cost of services   1,573,053    1,041,195 
Gross profit   179,287    147,156 
           
Operating expenses:          
Salaries and benefits   736,303    457,745 
Professional services   194,580    236,660 
Research and development expenses   277,548    - 
Selling, general and administrative expenses   402,265    215,463 
Depreciation   12,545    11,763 
Total operating expenses   1,623,241    921,631 
           
Operating loss   (1,443,954)   (774,475)
           
Other income (expense):          
Interest income   981    2 
Interest expense   (4,077)   (11,419)
Total other income (expense)   (3,096)   (11,417)
           
Net loss  $(1,447,050)  $(785,892)
           
Weighted average common shares outstanding - basic and diluted   6,495,213    4,353,717 
Net loss per common share - basic and diluted  $(0.22)  $(0.18)

 

See accompanying notes to condensed unaudited financial statements.

 

F-2

 

 

SYRA HEALTH CORP.

STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY (DEFICIT)

(Unaudited)

 

   Shares   Amount   Shares   Amount   Shares   Amount   Capital   Deficit   (Deficit) 
           Class A   Convertible Class B   Additional       Total
Stockholders’		 
   Preferred Stock Common Stock   Common Stock   Paid-in   Accumulated   Equity 
   Shares   Amount   Shares   Amount   Shares   Amount   Capital   Deficit   (Deficit) 
                                     
Balance, December 31, 2022     -   $   -    3,568,758   $3,569        833,334   $833   $2,832,308   $(2,126,612)  $      710,198 
                                              
Class A common stock options issued for services   -    -    -    -    -    -    18,246    -    18,246 
                                              
Net loss   -    -    -    -    -    -    -    (785,892)   (785,892)
                                              
Balance, March 31, 2023   -   $-    3,568,758   $3,569    833,334   $833   $2,850,554   $(2,912,504)  $(57,249)

 

           Class A   Convertible Class B   Additional       Total Stockholders’ 
   Preferred Stock   Common Stock   Common Stock   Paid-in   Accumulated   Equity 
   Shares   Amount   Shares   Amount   Shares   Amount   Capital   Deficit   (Deficit) 
                                     
Balance, December 31, 2023      -   $    -    5,588,298   $5,588        833,334   $833   $9,071,745   $(5,064,955)  $4,013,211 
                                              
Warrants exercised for cash   -    -    130,789    131    -    -    849,998    -    850,129 
                                              
Class A common stock awarded for services   -    -    50,000    50    -    -    18,825    -    18,875 
                                              
Class A common stock options issued for services   -    -    -    -    -    -    14,140    -    14,140 
                                              
Net loss   -    -    -    -    -    -    -    (1,447,050)   (1,447,050)
                                              
Balance, March 31, 2024   -   $-    5,769,087   $5,769    833,334   $833   $9,954,708   $(6,512,005)  $3,449,305 

 

See accompanying notes to condensed unaudited financial statements.

 

F-3

 

 

SYRA HEALTH CORP.

CONDENSED STATEMENTS OF CASH FLOWS

(Unaudited)

 

   2024   2023 
   For the Three Months Ended 
   March 31, 
   2024   2023 
CASH FLOWS FROM OPERATING ACTIVITIES          
Net loss  $(1,447,050)  $(785,892)
Adjustments to reconcile net loss to net cash used in operating activities:          
Depreciation   12,545    11,763 
Common stock issued for services   18,875    - 
Non-cash lease expense   31,373    29,624 
Stock-based compensation, stock options   14,140    1,367 
Changes in operating assets and liabilities:          
Accounts receivable   314,951    835,456 
Accounts receivable, related party   (31,510)   - 
Other current assets   7,900    (103,025)
Accounts payable   182,576    31,775 
Accounts payable, related parties   -    (1,600)
Deferred revenue   6,108    - 
Accrued expenses   120,720    (34,906)
Operating lease liability   (31,373)   (29,624)
Net cash used in operating activities   (800,745)   (45,062)
           
CASH FLOWS FROM INVESTING ACTIVITIES          
Purchase of property and equipment   (5,619)   (9,659)
Net cash used in investing activities   (5,619)   (9,659)
           
CASH FLOWS FROM FINANCING ACTIVITIES          
Proceeds received on exercise of warrants   850,129    - 
Payment of deferred offering costs   -    (155,260)
Proceeds received from line of credit   -    300,000 
Repayments on line of credit   -    (751,952)
Repayments on notes payable   (85,883)   - 
Proceeds received from convertible notes payable   -    1,255,000 
Net cash provided by financing activities   764,246    647,788 
           
NET CHANGE IN CASH AND CASH EQUIVALENTS   (42,118)   593,067 
CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD   3,280,075    3,344 
CASH AND CASH EQUIVALENTS AT END OF PERIOD  $3,237,957   $596,411 
           
SUPPLEMENTAL INFORMATION:          
Interest paid  $4,077   $9,850 
Income taxes paid  $-   $- 

 

See accompanying notes to condensed unaudited financial statements.

 

F-4

 

 

SYRA HEALTH CORP.

NOTES TO CONDENSED FINANCIAL STATEMENTS

(Unaudited)

 

Note 1 – Nature of Business and Significant Accounting Policies

 

Nature of Business

 

Syra Health Corp. (“Syra” or the “Company”) was incorporated in the state of Indiana on November 20, 2020 to provide workforce staffing solutions, health education and healthcare research consulting services to mental health hospitals and organizations, including government agencies, integrated health networks, managed care entities and pharmaceutical manufacturers. On March 11, 2022, the Company redomiciled to Delaware. The Company’s corporate office is located in Carmel, Indiana.

 

Basis of Presentation

 

The accompanying interim consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) and should be read in conjunction with the financial statements and notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2023, which was filed with the Securities and Exchange Commission (“SEC”) on March 25, 2024. Certain information and footnote disclosures normally included in the financial statements prepared in accordance with U.S. GAAP have been omitted from this report on Form 10-Q pursuant to the rules and regulations of the SEC.

 

Results for the interim periods in this report are not necessarily indicative of future financial results and have not been audited by our independent registered public accounting firm. In the opinion of management, the accompanying unaudited consolidated financial statements include all adjustments necessary to present fairly our interim financial statements as of March 31, 2024, and for the three ended March 31, 2024 and 2023. These adjustments are of a normal recurring nature and consistent with the adjustments recorded to prepare the annual audited financial statements as of December 31, 2023.

 

Use of Estimates

 

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that may affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates.

 

F-5

 

 

SYRA HEALTH CORP.

NOTES TO CONDENSED FINANCIAL STATEMENTS

(Unaudited)

 

Concentrations of Credit Risk

 

The Company maintains cash in bank deposit accounts, the balances of which at times may exceed federally insured limits. Accounts are guaranteed by the Federal Deposit Insurance Corporation (“FDIC”) up to $250,000 under current regulations. The Company did not have any cash in excess of FDIC insured limits at March 31, 2024. The Company has not experienced any losses in such accounts.

 

Fair Value of Financial Instruments

 

Accounting Standards Codification (“ASC”) 820 defines fair value, establishes a three-level valuation hierarchy for disclosures of fair value measurement and enhances disclosure requirements for fair value measures. The three levels are defined as follows:

 

  - Level 1 inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets.
  - Level 2 inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the financial instrument.
  - Level 3 inputs to valuation methodology are unobservable and significant to the fair measurement.

 

The carrying value of the Company’s financial assets and liabilities, such as cash, accounts receivable and accounts payable are estimated by management to approximate fair value primarily due to the short-term nature of the instruments. The Company’s advances from related party approximates the fair value of such instruments based upon management’s best estimate of interest rates that would be available to the Company for similar financial arrangements at March 31, 2024 and December 31, 2023.

 

Cash and Cash Equivalents

 

Cash equivalents include money market accounts which have maturities of three months or less when acquired. For the purpose of the statements of cash flows, all highly liquid investments with an original maturity of three months or less are considered to be cash equivalents. Cash equivalents are stated at cost plus accrued interest, which approximates market value. There were no cash equivalents on hand at March 31, 2024 and December 31, 2023.

 

Accounts Receivable

 

Accounts receivable is carried at their estimated collectible amounts. Accounts receivable is periodically evaluated for collectability based on past credit history with customers and their current financial condition. The Company had an allowance of $5,520 at March 31, 2024 and December 31, 2023.

 

Property and Equipment

 

Property and equipment is stated at cost, less accumulated depreciation. The cost of office equipment is depreciated using the straight-line method based on a five-year life expectancy.

 

Repairs and maintenance expenditures are charged to operations as incurred. Major improvements and replacements, which extend the useful life of an asset, are capitalized and depreciated over the remaining estimated useful life of the asset. When assets are retired or sold, the cost and related accumulated depreciation are eliminated and any resulting gain or loss is reflected in operations.

 

Impairment of Long-Lived Assets

 

In accordance with the provisions of ASC Topic 360, “Impairment or Disposal of Long-Lived Assets”, all long-lived assets such as property and equipment held and used by the Company are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is evaluated by a comparison of the carrying amount of an asset to its estimated future undiscounted cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amounts of the assets exceed the fair value of the assets.

 

F-6

 

 

SYRA HEALTH CORP.

NOTES TO CONDENSED FINANCIAL STATEMENTS

(Unaudited)

 

Leases

 

The Company accounts for its leases under ASC 842 - Leases. The Company determines if an arrangement is a lease at inception. Operating leases are included in operating lease right-of-use (“ROU”) assets, current portion of obligations under operating leases, and obligations under operating leases, non-current on the Company’s balance sheets.

 

Operating lease ROU assets and operating lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at commencement date, adjusted by the deferred rent liabilities at the adoption date. As the Company’s lease does not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at commencement date in determining the present value of future payments. The operating lease ROU asset also includes any lease payments made and excludes lease incentives and initial direct costs incurred. The Company’s terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Operating lease expense is recognized on a straight-line basis over the lease term.

 

Segment Reporting

 

ASC Topic 280, “Segment Reporting,” requires annual and interim reporting for an enterprise’s operating segments and related disclosures about its products, services, geographic areas and major customers. An operating segment is defined as a component of an enterprise that engages in business activities from which it may earn revenues and expenses, and about which separate financial information is regularly evaluated by the chief operating decision maker in deciding how to allocate resources. The Company operates as a single segment and will evaluate additional segment disclosure requirements as it expands its operations.

 

Revenue Recognition

 

The Company recognizes revenue in accordance with ASC 606, the core principle of which is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled to receive in exchange for those goods or services. To achieve this core principle, five basic criteria must be met before revenue can be recognized: (1) identify the contract with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to performance obligations in the contract; and (5) recognize revenue when or as the Company satisfies a performance obligation.

 

The Company accounts for revenues when both parties to the contract have approved the contract, the rights and obligations of the parties are identified, payment terms are identified, and collectability of consideration is probable. Payment terms vary by client and the services offered.

 

The Company has the following main forms of revenue:

 

  – Healthcare Workforce;
  – Population Health
  – Digital Health
  – Behavioral and Mental Health Services
  – Health Education

 

The Company primarily provides its services to state health and social service agencies and universities. Healthcare Workforce, Health Education and Behavioral Mental Health Service contracts are primarily accounted for as a single performance obligation satisfied over time because the customer simultaneously receives and consumes the benefits of our medical staffing on an hourly or daily basis. Population Health and Digital Health contracts generally consist of multiple performance obligations that are distinct, such as to provide data analytics and reporting, training, or develop technology for implementation and maintenance with the customer. The Company allocates the transaction price across the performance obligations based on the estimated fair value of the distinct performance obligations. Depending on the performance obligation, revenue is recognized at a point in time when the customer obtains the benefit of the services are provide, or over time in the case of digital health revenue where the customer simultaneously receives and consumes benefits of the contract, such as ongoing performance of our technology product.

 

F-7

 

 

The contracts generally stipulate bi-weekly or monthly billing, and the Company has elected the “as invoiced” practical expedient to recognize revenue based on the hours incurred at the contractual rate as the Company has the right to payment in an amount that corresponds directly with the value of performance completed to date. The Company may also be subject to penalties for violations of certain ethical standards and non-performance measures within these state contracts. The Company recognizes revenue net of penalties.

 

Disaggregated revenue data

 

The Company’s revenue consists of the following revenue services within its industry:

 

   Three Months Ended 
Net revenues:  March 31, 2024   March 31, 2023 
Healthcare workforce  $1,417,661   $1,110,840 
Population health   230,756    74,000 
Digital health   92,250    - 
Behavioral and mental services   1,673    1,730 
Health education   10,000    1,781 
Net revenues  $1,752,340   $1,188,351 

 

Cost of Services

 

The cost of services includes wages and related payroll taxes, employee benefits and certain other employee-related costs of the Company’s contract service employees, while the employees work on contract assignments.

 

Significant Concentrations

 

The majority of accounts receivable and revenue contracts are between the Company and different divisions within the Indiana Family and Social Services Administration (“FSSA”). Most contracts require monthly payments as the projects progress. The Company generally does not require collateral or advance payments. For the three months ended March 31, 2024 and 2023, FSSA accounted for approximately 67% and 99.6% of revenues, respectively, which was derived through a combination of divisions within the State of Indiana, including the FSSA-NeuroDiagnostic Institute, representing $1,108,230 and $1,109,960 of the Company’s Healthcare Workforce revenue for three months ended March 31, 2024 and 2023, respectively, and the FSSA-Division of Mental Health and Addiction, representing $71,000 and $74,000 of the Company’s Population Health revenues for the three months ended March 31, 2024 and 2023, respectively. In addition, the combined divisions of the FSSA (NeuroDiagnostic Institute and Division of Mental Health and Addiction), the Washington D.C. Department of Behavioral Health and Coordinated Care Corporation, doing business as Managed Health Services, owed 50% of the Company’s accounts receivable, respectively, at March 31, 2024, and FSSA represented 30% of outstanding accounts receivable as of December 31, 2023.

 

F-8

 

 

SYRA HEALTH CORP.

NOTES TO CONDENSED FINANCIAL STATEMENTS

(Unaudited)

 

Stock-Based Compensation

 

The Company accounts for equity instruments issued to employees and non-employees in accordance with the provisions of ASC 718 Stock Compensation (“ASC 718”). All transactions in which the consideration provided in exchange for the purchase of goods or services consists of the issuance of equity instruments are accounted for based on the fair value of the consideration received or the fair value of the equity instrument issued, whichever is more reliably measurable.

 

Basic and Diluted Loss Per Share

 

Basic earnings per share (“EPS”) are computed by dividing net income (the numerator) by the weighted average number of common shares outstanding for the period (the denominator). Weighted average shares for basic EPS are calculated based on weighted average Class B shares outstanding. Diluted EPS is computed by dividing net income by the weighted average number of common shares and potential common shares outstanding (if dilutive) during each period. Potential common shares include stock options, warrants, conversion of Class B shares and restricted stock. The number of potential common shares outstanding relating to stock options, warrants, conversion of Class B shares and restricted stock is computed using the treasury stock method. For the periods presented, potential dilutive securities had an anti-dilutive effect and were not included in the calculation of diluted net loss per common share.

 

Income Taxes

 

The Company accounts for income taxes under the Financial Accounting Standards Board (“FASB”) ASC 740 Income Taxes (“ASC 740”), which requires use of the liability method. FASB ASC 740-10-25 provides that deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. A valuation allowance is provided for significant deferred tax assets when it is more likely than not, that such asset will not be recovered through future operations.

 

Uncertain Tax Positions

 

In accordance with ASC 740, the Company recognizes the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be capable of withstanding examination by the taxing authorities based on the technical merits of the position. These standards prescribe a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. These standards also provide guidance on de-recognition, classification, interest and penalties, accounting in interim periods, disclosure, and transition.

 

Various taxing authorities may periodically audit the Company’s income tax returns. These audits include questions regarding the Company’s tax filing positions, including the timing and amount of deductions and the allocation of income to various tax jurisdictions. In evaluating the exposures connected with various tax filing positions, including state and local taxes, the Company records allowances for probable exposures. A number of years may elapse before a particular matter, for which an allowance has been established, is audited and fully resolved. The Company has not yet undergone an examination by any taxing authorities. The Company recognizes interest and penalties related to uncertain tax positions, if any, as an income tax expense.

 

The assessment of the Company’s tax position relies on the judgment of management to estimate the exposures associated with the Company’s various filing positions.

 

F-9

 

 

SYRA HEALTH CORP.

NOTES TO CONDENSED FINANCIAL STATEMENTS

(Unaudited)

 

Recent Accounting Standards

 

From time to time, new accounting pronouncements are issued by the FASB that are adopted by the Company as of the specified effective date.

 

Management does not believe that any recently issued, but not yet effective, accounting pronouncements, if currently adopted, would have a material effect on the Company’s financial statements.

 

Note 2 – Going Concern

 

As shown in the accompanying financial statements, as of March 31, 2024, the Company had a cash balance of $3,237,957, working capital of $3,345,431 and an accumulated deficit of $6,512,005 since inception. The Company is too early in its development stage to project revenue with a necessary level of certainty. Therefore, the Company may not have sufficient funds to sustain its operations for the next twelve months from the issuance date of these financial statements and may need to raise additional cash to fund its operations. These factors raise substantial doubt about the Company’s ability to continue as a going concern. The Company has commenced sales and continues to develop its operations. In the event sales do not materialize at the expected rates, management would seek additional financing or would attempt to conserve cash by further reducing expenses. There can be no assurance that the Company will be successful in achieving these objectives.

 

The Company continues to pursue sources of additional capital through debt and financing transactions or arrangements, including equity financing or other means. The Company may not be successful in identifying suitable funding transactions in a sufficient time period or at all, and may not obtain the required capital by other means. If the Company does not succeed in raising additional capital, resources may not be sufficient to fund its business. The Company’s ability to scale production and distribution capabilities and further increase the value of its brands, is largely dependent on its success in raising additional capital. From January through April of 2023, the Company raised a total of $1,455,000 of capital from the sale of convertible notes. On October 3, 2023 the Company completed IPO received net proceeds of approximately $5,332,283. In October 2023, the convertible notes were converted into Class A common stock in accordance with the terms of the convertible promissory notes as a result of the IPO.

 

The financial statements do not include any adjustments that might result from the outcome of any uncertainty as to the Company’s ability to continue as a going concern. These financial statements also do not include any adjustments relating to the recoverability and classification of recorded asset amounts, or amounts and classifications of liabilities that might be necessary should the Company be unable to continue as a going concern.

 

Note 3 – Related Party Transactions

 

The Company pays for payroll and related costs for its employees that provide services to Sahasra Technologies Corp., doing business as STLogics to service contracts of STLogics, which is an entity beneficially owned by the principal owners and management team of Syra. During the three months ended March 31, 2024, the Company paid $82,214 of payroll and related costs for these employees, and had a receivable from STLogics of $82,124 and $50,614 for additional costs incurred as of March 31, 2024 and December 31, 2023, respectively.

 

Office Lease

 

The Company leases its current corporate headquarters under a three-year lease from STVentures, LLC (“STVentures”), an entity beneficially owned by the principal owners and the management team of Syra and their affiliates. The lease commenced on July 1, 2021 and, as amended on May 1, 2022, provides for a base monthly rent of $10,711 over the three-year term of the lease. A total of $32,132 was included in selling, general and administrative expenses for the three months ended March 31, 2024 and 2023, respectively.

 

Information Technology (“IT”) Services

 

The Company incurred a total of $0 and $3,320 of services from RAD CUBE LLC, which is an entity beneficially owned by the principal owners and the management team of Syra and their affiliates, for outsourced IT services which have been presented within selling, general and administrative expenses in the statements of operations during the three months ended March 31, 2024 and 2023, respectively.

 

Recruitment and Human Resource Services

 

The Company paid a total of $145,318 and $66,713 for recruitment and human resource services from NLogix, which is an entity beneficially owned by the principal owners and the management team of Syra and their affiliates, which have been presented within cost of sales in the statements of operations during the three months ended March 31, 2024 and 2023, respectively.

 

F-10

 

 

SYRA HEALTH CORP.

NOTES TO CONDENSED FINANCIAL STATEMENTS

(Unaudited)

 

Note 4 – Basic and Diluted Earnings per Share

 

During the three months ended March 31, 2024, the Company used the two-class method to compute net loss per common share because it had issued securities, other than a single class of common stock, that contractually entitled the holders to participate in dividends and earnings. These participating securities included the Company’s Class A common stock, which was authorized pursuant to the Company’s amendment to its Certificate of Incorporation on May 2, 2022, and convertible Class B common stock which are entitled to share equally, on a per share basis, in all assets of the Company of whatever kind available for distribution to the holders of common stock. The two-class method requires earnings for the period to be allocated between common stock and participating securities based upon their respective rights to receive distributed and undistributed earnings.

 

Under the two-class method, for periods with net income, basic net income per common share is computed by dividing the net income attributable to common stockholders by the weighted average number of shares of common stock outstanding during the period. Net income attributable to common stockholders is computed by subtracting from net income the portion of current period earnings that the participating securities would have been entitled to receive pursuant to their dividend rights had all of the period’s earnings been distributed. No such adjustment to earnings is made during periods with a net loss, as the holders of the participating securities have no obligation to fund losses.

 

The Company reports the more dilutive of the approaches (two-class or “if-converted”) as its diluted net income per share during the period. For the periods presented, potential dilutive securities had an anti-dilutive effect and were not included in the calculation of diluted net loss per common share.

 

 

Common shares consisting of shares potentially dilutive that are excluded from the calculated of diluted earnings per share because they are anti-dilutive as of March 31, 2024 and 2023 are as follows:

 

   March 31, 2024   March 31, 2023 
Warrants   1,760,350    - 
Stock options   164,750    28,000 
Total   1,925,100    28,000 

 

Note 5 – Other Current Assets

 

Other current assets included the following as of March 31, 2024 and December 31, 2023:

 

   March 31,   December 31, 
   2024   2023 
Federal and state income tax receivable (1) (2)  $148,401   $73,069 
Prepaid expenses   233,486    316,718 
Total other current assets  $381,887   $389,787 

 

(1)Includes $50,000 for a federal refundable payroll tax credit, called the Employee Retention Tax Credit (“ERTC”) Tax Credit, which provides a credit to businesses who kept employees, or were negatively impacted, during the COVID-19 pandemic.

 

(2)Includes $75,332 for a refundable corporate income tax credit from the State of Indiana, called the Economic Development for a Growing Economy (“EDGE”) Tax Credit, which provides an incentive to businesses to support jobs creation, capital investment and to improve the standard of living for Indiana residents.

 

F-11

 

 

SYRA HEALTH CORP.

NOTES TO CONDENSED FINANCIAL STATEMENTS

(Unaudited)

 

Note 6 – Property and Equipment

 

Property and equipment at March 31, 2024 and December 31, 2023, consisted of the following:

 

   March 31,   December 31, 
   2024   2023 
Office equipment  $148,419   $142,800 
Less: Accumulated depreciation   (76,371)   (63,826)
Total property and equipment, net  $72,048   $78,974 

 

Depreciation of property and equipment was $12,545 and $11,763 for the three months ended March 31, 2024 and 2023, respectively.

 

Note 7 – Accrued Expenses

 

Accrued expenses at March 31, 2024 and December 31, 2023, consisted of the following:

 

   March 31,   December 31, 
   2024   2023 
Accrued payroll and taxes  $312,576   $148,924 
Accrued expenses   7,122    50,054 
Total accrued expenses  $319,698   $198,978 

 

The Company provides postretirement benefits pursuant to IRS code section 401(k) for employees meeting specified criteria. The Company matches 100% of the employees’ contributions that are not in excess of 4% of the employee’s contributions. These matching contributions are fully vested and paid pursuant to the employees’ bi-weekly or semi-monthly pay periods. The Company does not prefund these benefits and has the right to modify or terminate certain of these benefits in the future. For the three months ended March 31, 2024, the Company incurred $26,485 of IRA contribution expenses pursuant to the Company’s matching contributions, including $0, as accrued at March 31, 2024.

 

 

F-12

 

 

SYRA HEALTH CORP.

NOTES TO CONDENSED FINANCIAL STATEMENTS

(Unaudited)

 

Note 8 – Lease

 

The Company leases its current corporate headquarters under a three-year lease from STVentures, a related party. The lease, as amended on May 1, 2022 to expand its office space from 2,976 square feet to approximately 5,978 square feet, commenced on July 1, 2021, and provides for a base monthly rent of $10,711, as increased from $5,332 per month, over the three-year term of the lease. The Company is occupying the space for executive and administrative offices. Rent expense for the three months ended March 31, 2024 and 2023 was $32,132, which is included in selling, general and administrative expenses within the statements of operations.

 

The components of lease expense were as follows:

 

   2024   2023 
   For the Three Months Ended 
   March 31, 
   2024   2023 
Operating lease cost:          
Amortization of ROU asset  $31,373   $121,089 
Interest on lease liability   759    7,438 
Total operating lease cost  $32,132   $128,527 

 

Supplemental balance sheet information related to leases was as follows:

 

   March 31,   December 31, 
   2024   2023 
Operating lease:          
Operating lease assets  $31,826   $63,199 
           
Current portion of operating lease liability, related party  $31,826    63,199 
Noncurrent operating lease liability, related party   -    - 
Total operating lease liability  $31,826   $63,199 
           
Weighted average remaining lease term:          
Operating leases   0.25 years    0.5 years 
           
Weighted average discount rate:          
Operating lease   5.75%   5.75%

 

F-13

 

 

SYRA HEALTH CORP.

NOTES TO CONDENSED FINANCIAL STATEMENTS

(Unaudited)

Note 9 – Notes Payable

 

In 2023, the Company entered into three insurance policy financing arrangements to purchase various insurance policies. The total principal of these arrangements was $370,596 with interest rates ranging from 10.38% through 14.05% and monthly payments totaling $32,328 are due through July 2024. The Company made principal repayments of $85,883 and incurred interest expense of $4,077 during the three months ended March 31, 2024. As of March 31, 2024 and December 31, 2023, the remaining balance was $99,021 and $184,904, respectively.

 

Note 10 – Commitments and Contingencies

 

Legal Contingencies

 

From time to time, we may be involved in various disputes and litigation matters that arise in the ordinary course of business. The Company is currently not a party to any material legal proceedings.

 

In January 2024, a former employee filed a wrongful termination lawsuit against the Company in the U.S. District Court, Southern District of Indiana. The Company plans to vigorously defend itself against the claims, which it believes are without merit.

 

Note 11 – Changes in Stockholders’ Equity (Deficit)

 

Class A Common Stock

 

The Company has 100,000,000 authorized shares of $0.001 par value Class A common stock, and 5,769,087 shares were issued and outstanding as of March 31, 2024.

 

During the three months ended March 31, 2024, two investors exercised 130,789 warrants to purchase Class A Common stock pursuant to which the Company received cash proceeds of $850,129.

 

During the three months ended March 31, 2024, the Company issued 50,000 shares pursuant to the restricted stock award from November 2023. These shares vest quarterly over a one-year period. The Company recognized expense of $18,875 for these awards and expects to recognize an additional $48,503 through the end of the vesting period.

 

Convertible Class B Common Stock

 

The Company has 5,000,000 authorized shares of $0.001 par value convertible Class B common stock, and had 833,334 shares issued and outstanding as of March 31, 2024, as retrospectively applied, pursuant to the Company’s subsequent recapitalization in 2022 and effective as of May 3, 2022, whereby the founders exchanged their 83,334 Founders Shares for 833,334 shares of convertible Class B common stock.

 

F-14

 

 

SYRA HEALTH CORP.

NOTES TO CONDENSED FINANCIAL STATEMENTS

(Unaudited)

 

Note 12 – Common Stock Options

 

Omnibus Equity Incentive Plan

 

On April 11, 2022, the Company’s board of directors adopted, and the Company’s stockholders approved, the Syra Health Corp. 2022 Omnibus Equity Incentive Plan, as amended on April 19, 2023 (as amended, the “2022 Plan”). No more than 1,041,667 shares of the Company’s Class A common stock shall be issued pursuant to the exercise of incentive stock options under the 2022 Plan.

 

Class A Common Stock Option Awards

 

During the three months ended March 31, 2024, the Company granted options to purchase an aggregate 24,000 shares of the Company’s Class A common stock at an exercise price of $1.88 per share for a term of 10 years under the 2022 Plan. These options will vest 25% on each anniversary until fully vested. The options had no intrinsic value. The aggregate estimated value using the Black-Scholes Pricing Model, based on an expected term of 6.25 years, a weighted average volatility rate of 110%, a weighted average risk-free interest rate of 4.16%, and a weighted average call option value of $1.498, was $35,945. During the three months ended March 31, 2024 and 2023, the Company recognized expense of $14,140 and $1,367 related to common stock options. As of March 31, 2024, a total of $218,760 of unamortized expenses are expected to be expensed over the vesting period.

 

The following is a summary of activity of outstanding stock options:

 

       Weighted 
       Average 
   Number   Exercise 
   of Shares   Prices 
Balance, December 31, 2023   140,750   $1.82 
Options granted   24,000    1.88 
Options cancelled   -    - 
Balance, March 31, 2024   164,750   $1.83 
Exercisable, March 31, 2024   -   $- 

 

The options had a weighted average remaining life of 9.42 years and no intrinsic value as of March 31, 2024.

 

Note 13 – Subsequent Events

 

The Company evaluates events that have occurred after the balance sheet date through the date these financial statements were issued.

 

F-15

 

 

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.

 

You should read the following discussion and analysis of our financial condition and results of operations together with our unaudited interim condensed financial statements and the related notes appearing elsewhere in this Quarterly Report on Form 10-Q. In addition to historical information, this discussion and analysis contains forward-looking statements that involve risks, uncertainties and assumptions. Our actual results may differ materially from those discussed below. Factors that could cause or contribute to such differences include, but are not limited to, those identified below, and those discussed in the section titled “Risk Factors” included in this Quarterly Report on Form 10-Q, as may be amended, supplemented or superseded from time to time by other reports we file with the SEC. All amounts in this report are in U.S. dollars, unless otherwise noted.

 

Throughout this Quarterly Report on Form 10-Q, references to “we,” “our,” “us,” the “Company,” or “Syra,” refer to Syra Health Corp.

 

Overview

 

We are a healthcare services company promoting preventative health, holistic wellness, health education, and equitable healthcare for all patient demographics. We leverage deep scientific and healthcare expertise to create strategic frameworks and develop patient-centric solutions for the betterment of patient lives and health outcome linked to developing a healthier population. We are developing comprehensive end-to-end solutions in health education services, population health, behavioral and mental health, healthcare workforce and digital health.

 

Results of Operations for the Three Months Ended March 31, 2024 and 2022

 

The following table summarizes selected items from the statements of operations for the three months ended March 31, 2024 and 2023.

 

   For the Three Months     
   Ended     
   March 31,   March 31,   Increase / 
   2024   2023   (Decrease) 
             
Net revenues               
Healthcare workforce  $1,417,661   $1,110,840   $306,821 
Population health   230,756    74,000    156,756 
Digital health   92,250    -    92,250 
Behavioral and mental health   1,673    1,730    (57)
Health education   10,000    1,781    8,219 
Net revenues   1,752,340    1,188,351    563,989 
Cost of services   1,573,053    1,041,195    531,858 
Gross profit   179,287    147,156    31,1312 
                
Operating expenses:               
Salaries and benefits   736,303    457,745    278,558 
Professional fees   194,580    236,660    (42,080)
Research and development expenses   277,548    -    277,548 
Selling, general and administrative expenses   402,265    215,463    186,802 
Depreciation   12,545    11,763    782 
Total operating expenses:   1,623,241    921,631    701,610 
                
Operating loss   (1,443,954)   (774,475)   (669,479)
                
Total other income (expense)   (3,096)   (11,417)   8,321 
                
Net loss  $(1,447,050)  $(785,892)  $(661,158)

 

-4-

 

 

Net Revenues

 

Net revenue during the three months ended March 31, 2024 was comprised of $1,417,661 of healthcare staffing services revenue, $230,756 of population health revenue, $1,673 of behavioral and mental health revenue and $92,250 of digital health services revenue and $10,000 of health education revenue, compared to net revenue during the three months ended March 31, 2023 of $1,110,840 of healthcare workforce revenue, $74,000 of population health revenue, $1,730 of behavioral and mental health revenue and $1,781 of health education revenue, an overall revenue increase of $563,989, or 47%. The increase in healthcare workforce revenue was driven by new customer acquisitions and additions to existing contracts. Population health revenues and digital health services increased in 2024 due to additional services provided to state departments and other customers.

 

Cost of Services

 

Our cost of services included wages and related payroll taxes, employee benefits and certain other employee-related costs of our contract service employees while they worked on contract assignments. We incurred $1,573,053 of cost of services for the three months ended March 31, 2024, compared to $1,041,195 for the three months ended March 31, 2023, an increase of $531,858, or 51%. Our gross profit was approximately 10% for the three months ended March 31, 2024, compared to approximately 12% for the three months ended March 31, 2023, a decrease of approximately 2%. Our cost of services increased primarily due to an increase in labor costs, and increased consulting costs associated with a slight change in service mix from healthcare workforce services to project-based population health and digital health services that carry better margins.

 

Operating Expenses

 

Salaries and Benefits

 

Our salaries and benefits include wages and related payroll taxes, employee benefits and certain other employee-related costs of our management and office personnel. We incurred $736,303 of salaries and benefits during the three months ended March 31, 2024, compared to $457,745 for the three months ended March 31, 2023, an increase of $278,558, or 61%. Salaries and benefits increased in 2024 as we supported our increased operations and added office personnel following our IPO process.

 

Professional Fees

 

Professional fees primarily consisted of expenses incurred from business development, accounting, legal fees, and consulting activities. We incurred $194,580 of professional fees for the three months ended March 31, 2024, compared to $236,660 for the three months ended March 31, 2023, a decrease of $42,080, or 18%. Professional fees decreased in 2024 due to decreased legal and other professional costs as the Company completed its IPO process in the fourth quarter of 2024.

 

Research and Development Expenses

 

Research and development expenses primarily consist of consulting expenses incurred to develop our technology-based solutions. We incurred $277,548 and $0 of research and development expenses for the three months ended March 31, 2024 and 2023, respectively.

 

Selling, General and Administrative Expenses

 

SG&A primarily consisted of marketing, rent, office, insurance, travel and repair and maintenance expenses incurred. We incurred $402,266 of SG&A expenses during the three months ended March 31, 2024, compared to $215,463 for the three months ended March 31, 2024, an increase of $186,802, or 87%. Our SG&A expenses increased primarily due to our increased operations in 2024. SG&A included $32,132 of rent incurred in both periods from STVentures, LLC, an entity beneficially owned by our principal owners, our management team and their affiliates, $10,783 and $20,435 of office and computer supplies, $133,148 and $47,441 of insurance, $15,376 and $869 of advertising, and $37,746 and $13,971 of subscription and membership fees for the three months ended March 31, 2024 and 2023, respectively.

 

Depreciation

 

We incurred $12,545 of depreciation expense for the three months ended March 31, 2024, compared to $11,763 of depreciation expense for the three months ended March 31, 2024, an increase of $782, or 7%. Depreciation expense increased as we expanded our office space and placed additional office equipment into service during 2023.

 

-5-

 

 

Other Income (Expense)

 

Other expense, on a net basis, consisted of $4,077 of interest incurred on insurance finance charges, as partially offset by $981 of interest income, for the three months ended March 31, 2024. Other expense, on a net basis, consisted of $11,419 of interest incurred on a line of credit and convertible notes, as partially offset by $2 of interest income, for the three months ended March 31, 2023. Other expense, on a net basis, decreased by $8,321, or 73%, primarily due to decreased debt financing compared to the prior period.

 

Net Loss

 

Our net loss for the three months ended March 31, 2024 was $1,447,050, compared to a net loss of $785,892 for the three months ended March 31, 2023, an increase of $661,158.

 

Liquidity and Capital Resources

 

We believe that our existing sources of liquidity, along with cash expected to be generated from sales and services, will not be sufficient to fund our operations, anticipated capital expenditures, working capital and other financing requirements for at least the next twelve months from the issuance of the financial statements included elsewhere in this annual report. In the event we are unable to achieve profitable operations in the near term, we may require additional equity and/or debt financing; however, we cannot provide assurance that such financing will be available to us on favorable terms, or at all. We will continue to monitor our expenditures and cash flow position.

 

The following table summarizes total current assets, liabilities, accumulated deficit and working capital (deficit) at March 31, 2024 and December 31, 2023.

 

   March 31,   December 31, 
   2024   2023 
Current Assets  $4,447,651   $4,781,110 
           
Current Liabilities  $1,102,220   $910,072 
           
Accumulated Deficit  $(6,512,005)  $(2,912,305)
           
Working Capital  $3,345,431   $3,871,038 

 

Liquidity is the ability of a company to generate funds to support its current and future operations, satisfy its obligations, and otherwise operate on an ongoing basis. To date, we have funded our operations through equity and debt financings. Our primary uses of cash have been for the development of operations, compensation, and professional fees. All funds received have been expended in the furtherance of growing our business and establishing our services and solutions. The following trends are reasonably likely to result in a material decrease in our liquidity over the near to long term:

 

  ● A substantial increase in working capital requirements to finance our operations;
  ● Addition of administrative and professional personnel as our business continues to grow;
  ● The cost of being a public company; and
  ● Payments for seeking and securing quality staffing personnel.

 

Cash Flow Activities for the Three Months Ended March 31, 2024 and 2023

 

Net Cash Used in Operating Activities

 

Cash used in operating activities for the three months ended March 31, 2024 and 2023 was $800,745 and $45,062, respectively, which was primarily attributable to our net loss for the periods.

 

Net Cash Used in Investing Activities

 

Cash used in investing activities for the three months ended March 31, 2024 and 2023 was $5,619 and $9,659, respectively, which related entirely to the purchase of property and equipment during both periods.

 

-6-

 

 

Net Cash Provided by Financing Activities

 

Cash provided by financing activities for the three months ended March 31, 2024 was $764,246, which consisted of $850,129 of proceeds received from the exercise of Class A common stock warrants, partially offset by $85,883 of repayments on notes payable. Cash provided by financing activities for the three months ended March 31, 2023 was $647,788, which consisted of $300,000 of proceeds received from a line of credit, and $1,255,000 of proceeds received from the sale of convertible notes payable, as partially offset by $751,952 of repayments on the line of credit and payment off deferred financing costs of $155,260.

 

Critical Accounting Policies and Estimates

 

The preparation of the financial statements included elsewhere in this Quarterly Report on Form 10-Q requires us to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, expenses, and related disclosures. We evaluate our estimates and assumptions on an ongoing basis. Our estimates are based on historical experience and various other assumptions that we believe to be reasonable under the circumstances. Our actual results could differ from these estimates.

 

The critical accounting estimates, assumptions and judgments that we believe have the most significant impact on our financial statements are described below.

 

Reverse Stock Split

 

On August 28, 2023, we effectuated a 1-for-1.2 reverse stock split of our issued and outstanding common stock and common stock equivalents. All issued and outstanding shares of common stock and common stock equivalents and per share data have been adjusted in this Quarterly Report on Form 10-Q, on a retrospective basis, to reflect the reverse stock split for all periods presented. Neither the authorized shares of common stock, nor the par value of the common stock were adjusted as a result of the reverse stock split.

 

Accounts Receivable

 

Accounts receivable is carried at their estimated collectible amounts. Accounts receivable is periodically evaluated for collectability based on past credit history with customers and their current financial condition. We had an allowance of $5,520 at March 31, 2024 and December 31, 2023, respectively.

 

Impairment of Long-Lived Assets

 

In accordance with the provisions of Accounting Standards Codification (“ASC”) Topic 360, “Impairment or Disposal of Long-Lived Assets,” all long-lived assets such as property and equipment held and used by us are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is evaluated by a comparison of the carrying amount of an asset to its estimated future undiscounted cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amounts of the assets exceed the fair value of the assets.

 

Leases

 

We account for our leases under ASC 842 - Leases. We determine if an arrangement is a lease at inception. Operating leases are included in operating lease right-of-use (“ROU”) assets, current portion of obligations under operating leases, and obligations under operating leases, non-current on our balance sheets.

 

Operating lease ROU assets and operating lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at commencement date, adjusted by the deferred rent liabilities at the adoption date. As our lease does not provide an implicit rate, we use our incremental borrowing rate based on the information available at commencement date in determining the present value of future payments. The operating lease ROU asset also includes any lease payments made and excludes lease incentives and initial direct costs incurred. Our terms may include options to extend or terminate the lease when it is reasonably certain that we will exercise that option. Operating lease expense is recognized on a straight-line basis over the lease term.

 

Revenue Recognition

 

We recognize revenue in accordance with ASC 606, the core principle of which is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled to receive in exchange for those goods or services. To achieve this core principle, five basic criteria must be met before revenue can be recognized: (1) identify the contract with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to performance obligations in the contract; and (5) recognize revenue when or as we satisfy a performance obligation.

 

-7-

 

 

We account for revenues when both parties to the contract have approved the contract, the rights and obligations of the parties are identified, payment terms are identified, and collectability of consideration is probable. Payment terms vary by client and the services offered.

 

We have the following main forms of revenue:

 

  – Healthcare Workforce Services
  – Behavioral and Mental Health Services
  – Digital Health
  – Population Health
  – Health Education

 

We primarily provide our services to state and local government health agencies, payers, and other private health organizations. Healthcare Workforce, Behavioral and Mental Health and Health Education contracts are accounted for as a single performance obligation satisfied over time because the customer simultaneously receives and consumes the benefits of our medical staffing on an hourly or daily basis. Population Health and Digital Health contracts generally consist of multiple performance obligations that are distinct, such as to provide data analytics and reporting, training, or develop technology for implementation and maintenance with the customer. We allocate the transaction price across the performance obligations based on the estimated fair value of the distinct performance obligations. Depending on the performance obligation, revenue is recognized at a point in time when the customer obtains the benefit of the services are provide, or over time in the case of digital health revenue where the customer simultaneously receives and consumes benefits of the contract, such as ongoing performance of our technology product.

 

The contracts generally stipulate bi-weekly or monthly billing, and we have elected the “as invoiced” practical expedient to recognize revenue based on the hours incurred at the contractual rate as we have the right to payment in an amount that corresponds directly with the value of performance completed to date. We may also be subject to penalties for violations of certain ethical standards and non-performance measures within these state contracts. We recognize revenue net of penalties.

 

Significant Concentrations

 

The majority of accounts receivable and revenue contracts are between our Company and different divisions within the FSSA. Most contracts require monthly payments as the projects progress. We generally do not require collateral or advance payments. For the three months ended March 31, 2024 and 2023, Indiana Family and Social Services Administration (“FSSA”) accounted for approximately 67% and 99.6% of our revenues, respectively. In addition, the combined divisions of the FSSA (NeuroDiagnostic Institute and Division of Mental Health and Addiction), the Washington D.C. Department of Behavioral Health and Coordinated Care Corporation, doing business as Managed Health Services, owed 50% and 30% of our accounts receivable, respectively, at March 31, 2024 and December 31, 2023, respectively.

 

JOBS Act

 

On April 5, 2012, the Jumpstart Our Business Startups Act (the “JOBS Act”) was enacted. Section 107 of the JOBS Act provides that an “emerging growth company” can take advantage of the extended transition period provided in Section 7(a)(2)(B) of the Securities Act for complying with new or revised accounting standards. In other words, an “emerging growth company” can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies.

 

We have chosen to take advantage of the extended transition periods available to emerging growth companies under the JOBS Act for complying with new or revised accounting standards until those standards would otherwise apply to private companies provided under the JOBS Act. As a result, our financial statements may not be comparable to those of companies that comply with public company effective dates for complying with new or revised accounting standards.

 

Subject to certain conditions set forth in the JOBS Act, as an “emerging growth company,” we intend to rely on certain of these exemptions, including, without limitation, (i) providing an auditor’s attestation report on our internal controls over financial reporting pursuant to Section 404(b) of the Sarbanes-Oxley Act of 2002, as amended, and (ii) complying with the requirement adopted by the Public Company Accounting Oversight Board regarding the communication of critical audit matters in the auditor’s report on financial statements. We will remain an “emerging growth company” until the earliest of (i) the last day of the fiscal year in which we have total annual gross revenues of $1.235 billion or more; (ii) the last day of our fiscal year following the fifth anniversary of the date of the completion of our IPO; (iii) the date on which we have issued more than $1 billion in nonconvertible debt during the previous three years; or (iv) the date on which we are deemed to be a large accelerated filer under the rules of the SEC.

 

-8-

 

 

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.

 

The Company is not required to provide the information required by this Item as it is a “smaller reporting company,” as defined in Rule 12b-2 of the Exchange Act.

 

ITEM 4. CONTROLS AND PROCEDURES.

 

Our principal executive officer and principal financial officer evaluated the effectiveness of our “disclosure controls and procedures” as of March 31, 2024 the end of the period covered by this Quarterly Report on Form 10-Q. The term “disclosure controls and procedures” as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files under the Exchange Act is accumulated and communicated to a company’s management, including its principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure. In designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, cannot provide absolute assurance that the objectives of the controls system are met, and no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within a company have been detected. Based on the evaluation of our disclosure controls and procedures as of March 31, 2024, our Chief Executive Officer and our Chief Financial Officer concluded that, as of such date, our disclosure controls and procedures were effective. Effective internal control contemplates an appropriate level of review to ensure timely preparation and completeness and accuracy of the financial statements and disclosures.

 

Remediation Plans

 

We intend to work to strengthen internal control over financial reporting and management is committed to ensuring that such controls are designed and operating effectively. We are implementing processing and control improvements to address the above material weaknesses as follows:

 

●we intend to adopt a formal policy or written procedures for the approval, identification and reporting of related-party transactions;
●we intend to provide written documentation of our internal control policies and procedures; and
●we intend to add staff members with requisite accounting experience at such time that adequate resources are available to us to remediate such weakness.

 

Changes in Internal Control

 

Except as set forth above, there were no changes in our internal control over financial reporting that occurred during the three months ended March 31, 2024 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

 

-9-

 

 

PART II — OTHER INFORMATION

 

ITEM 1. LEGAL PROCEEDINGS.

 

From time to time, we may become involved in various lawsuits and legal proceedings, which arise in the ordinary course of business. Litigation is subject to inherent uncertainties and an adverse result in these or other matters may arise from time to time that may harm our business. We are currently not aware of any such legal proceedings or claims that will have, individually or in the aggregate, a material adverse effect on our business, financial condition or operating results.

 

In January 2024, a former employee filed a wrongful termination lawsuit against the Company in the U.S. District Court, Southern District of Indiana. The Company plans to vigorously defend itself against the claims, which it believes are without merit.

 

ITEM 1A. RISK FACTORS.

 

In addition to other information set forth in this report, readers should carefully consider the risk factors discussed in the Prospectus. Any of the risk factors disclosed in the Prospectus or our reports could materially affect our business, financial condition or future results. The risks described in the Prospectus are not the only risks we face. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially and adversely affect our business, financial condition and/or operating results.

 

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS.

 

None.

 

ITEM 3. DEFAULTS UPON SENIOR SECURITIES.

 

None.

 

ITEM 4. MINE SAFETY DISCLOSURES

 

Not applicable.

 

ITEM 5. OTHER INFORMATION.

 

None.

 

-10-

 

 

ITEM 6. EXHIBITS.

 

Exhibit

No.

   Description
     
31.1*   Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
     
31.2*   Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
     
32.1**   Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
     
32.2**   Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
     
101.INS*   Inline XBRL Instance Document
     
101.SCH*   Inline XBRL Taxonomy Extension Schema Document
     
101.CAL*   Inline XBRL Taxonomy Extension Calculation Linkbase Document
     
101.DEF*   Inline XBRL Taxonomy Extension Definition Linkbase Document
     
101.LAB*   Inline XBRL Taxonomy Extension Label Linkbase Document
     
101.PRE*   Inline XBRL Taxonomy Extension Presentation Linkbase Document
     
104*   Cover Page Interactive Data File - the cover page from the Registrant’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2023 is formatted in Inline XBRL included in the Exhibit 101 Inline XBRL Document Set

 

* Filed herewith.
** Furnished herewith.

 

-11-

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

  SYRA HEALTH CORP.
     
Date: May 9, 2024 By: /s/ Deepika Vuppalanchi
    Deepika Vuppalanchi
    Chief Executive Officer
    (Principal Executive Officer)
     
Date: May 9, 2024 By: /s/ Priya Prasad
    Priya Prasad
    Chief Financial Officer
    (Principal Financial and Accounting Officer)

 

-12-

 EX-31.1 2 ex31-1.htm

 

Exhibit 31.1

 

Certification of Chief Executive Officer of Syra Health Corp.

Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

 

I, Deepika Vuppalanchi, certify that:

 

1. I have reviewed this Quarterly Report on Form 10-Q of Syra Health Corp.;
   
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
   
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
   
4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15(d)-15(f)) for the registrant and have:

 

  a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
     
  b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
     
  c. Evaluated the effectiveness of the registrant’s disclosure controls and procedures, and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
     
  d. Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

  a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
     
  b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: May 9, 2024 /s/ Deepika Vuppalanchi
  Deepika Vuppalanchi
  Chief Executive Officer (Principal Executive Officer)

 

 

 EX-31.2 3 ex31-2.htm

 

Exhibit 31.2

 

Certification of Chief Financial Officer of Syra Health Corp.

Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

 

I, Priya Prasad, certify that:

 

1. I have reviewed this Quarterly Report on Form 10-Q of Syra Health Corp;
   
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
   
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
   
4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15(d)-15(f)) for the registrant and have:

 

  a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
     
  b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
     
  c. Evaluated the effectiveness of the registrant’s disclosure controls and procedures, and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
     
  d. Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

  a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
     
  b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: May 9, 2024 /s/ Priya Prasad
  Priya Prasad
  Chief Financial Officer
  (Principal Financial and Accounting Officer)

 

 


 EX-32.1 4 ex32-1.htm

 

Exhibit 32.1

 

Certification of Chief Executive Officer

Pursuant to 18 U.S.C. Section 1350 as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

 

Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned, Deepika Vuppalanchi, Chief Executive Officer of Syra Health Corp. (the “Company”), hereby certifies that based on the undersigned’s knowledge:

 

  1. The Company’s Quarterly Report on Form 10-Q for the period ended March 31, 2024 (the “Report”) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
     
  2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

Date: May 9, 2024 /s/ Deepika Vuppalanchi
  Deepika Vuppalanchi
  Chief Executive Officer
  (Principal Executive Officer)

 

 

 

 EX-32.2 5 ex32-2.htm

 

Exhibit 32.2

 

Certification of Chief Financial Officer

Pursuant to 18 U.S.C. Section 1350 as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

 

Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned, Priya Prasad, Chief Financial Officer of Syra Health Corp. (the “Company”), hereby certifies that based on the undersigned’s knowledge:

 

  1. The Company’s Quarterly Report on Form 10-Q for the period ended March 31, 2024 (the “Report”) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
     
  2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

Date: May 9, 2024 /s/ Priya Prasad
  Priya Prasad
  Chief Financial Officer
  (Principal Financial and Accounting Officer)

 

 

 EX-101.SCH 6 syra-20240331.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - Condensed Balance Sheets link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - Condensed Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - Condensed Statements of Operations (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - Statements of Changes in Stockholders' Equity (Deficit) (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - Condensed Statements of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000007 - Disclosure - Nature of Business and Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - Going Concern link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - Related Party Transactions link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - Basic and Diluted Earnings per Share link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - Other Current Assets link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - Other Current Assets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - Property and Equipment link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - Accrued Expenses link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - Lease link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - Notes Payable link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - Changes in Stockholders’ Equity (Deficit) link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - Common Stock Options link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - Nature of Business and Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - Nature of Business and Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - Basic and Diluted Earnings per Share (Tables) link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - Other Current Assets (Tables) link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - Property and Equipment (Tables) link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - Accrued Expenses (Tables) link:presentationLink link:calculationLink link:definitionLink 00000027 - Disclosure - Lease (Tables) link:presentationLink link:calculationLink link:definitionLink 00000028 - Disclosure - Common Stock Options (Tables) link:presentationLink link:calculationLink link:definitionLink 00000029 - Disclosure - Schedule of Disaggregation of Revenue (Details) link:presentationLink link:calculationLink link:definitionLink 00000030 - Disclosure - Nature of Business and Significant Accounting Policies (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000031 - Disclosure - Going Concern (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000032 - Disclosure - Related Party Transactions (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000033 - Disclosure - Schedule of Diluted Earnings Per Share (Details) link:presentationLink link:calculationLink link:definitionLink 00000034 - Disclosure - Schedule of Other Current Assets (Details) link:presentationLink link:calculationLink link:definitionLink 00000035 - Disclosure - Schedule of Property and Equipment (Details) link:presentationLink link:calculationLink link:definitionLink 00000036 - Disclosure - Property and Equipment (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000037 - Disclosure - Schedule of Accrued Expenses (Details) link:presentationLink link:calculationLink link:definitionLink 00000038 - Disclosure - Accrued Expenses (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000039 - Disclosure - Schedule of Lease Cost expenses (Details) link:presentationLink link:calculationLink link:definitionLink 00000040 - Disclosure - Schedule of Supplemental Balance Sheets Information (Details) link:presentationLink link:calculationLink link:definitionLink 00000041 - Disclosure - Lease (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000042 - Disclosure - Notes Payable (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000043 - Disclosure - Changes in Stockholders’ Equity (Deficit) (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000044 - Disclosure - Schedule of Share-Based Compensation, Stock Options Activity (Details) link:presentationLink link:calculationLink link:definitionLink 00000045 - Disclosure - Common Stock Options (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 syra-20240331_cal.xml XBRL CALCULATION FILE EX-101.DEF 8 syra-20240331_def.xml XBRL DEFINITION FILE EX-101.LAB 9 syra-20240331_lab.xml XBRL LABEL FILE Related and Nonrelated Parties [Axis] Nonrelated Party [Member] Related Party [Member] Class of Stock [Axis] Common Class A [Member] Convertible Class B Common Stock [Member] Equity Components [Axis] Preferred Stock [Member] Common Stock [Member] Additional Paid-in Capital [Member] Retained Earnings [Member] Concentration Risk Type [Axis] Customer Concentration Risk [Member] Concentration Risk Benchmark [Axis] Revenue Benchmark [Member] Customer [Axis] Family and Social Services Administration (FSSA) [Member] Product and Service [Axis] Healthcare Workforce [Member] FSSA – NeuroDiagnostic Institute [Member] Population Health [Member] FSSA – Division of Mental Health and Addiction [Member] Accounts Receivable [Member] Digital Health [Member] Behavioral and Mental Services [Member] Health Education [Member] Sahasra Technologies Corp [Member] ST Logics [Member] STVentures [Member] Information Technology Services [Member] RAD CUBE LLC [Member] Recruitment and Human Resource Services [Member] NLogix [Member] Antidilutive Securities [Axis] Warrant [Member] Share-Based Payment Arrangement, Option [Member] Tax Credit Carryforward [Axis] Employee Retention Tax Credit [Member] Economic Development Growing Economy [Member] Long-Lived Tangible Asset [Axis] Office Equipment [Member] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Insurance Policy Financing Arrangements [Member] Statistical Measurement [Axis] Minimum [Member] Maximum [Member] Two Investors [Member] Award Type [Axis] November 2023 [Member] Convertible Common Stock B [Member] Plan Name [Axis] Omnibus Equity Incentive Plan [Member] 2022 Plan [Member] Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] Entity Information, Former Legal or Registered Name Statement [Table] Statement [Line Items] ASSETS Current assets: Cash Accounts receivable Other current assets Total current assets Property and equipment, net Right-of-use asset Total assets LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT) Current liabilities: Accounts payable Accrued expenses Deferred revenue Current portion of operating lease liability, related party Notes payable Total current liabilities Total liabilities Commitments and contingencies Stockholders’ equity (deficit): Preferred stock, $0.001 par value, 10,000,000 shares authorized, no shares designated, issued and outstanding Common stock, value Additional paid-in capital Accumulated deficit Total stockholders’ equity (deficit) Total liabilities and stockholders’ equity (deficit) Preferred stock, par value Preferred stock, shares authorized Preferred stock, shares designated Preferred stock, shares issued Preferred stock, shares outstanding Common stock, par value Common stock, shares authorized Common stock, shares issued Common stock, shares outstanding Income Statement [Abstract] Net revenues Cost of services Gross profit Operating expenses: Salaries and benefits Professional services Research and development expenses Selling, general and administrative expenses Depreciation Total operating expenses Operating loss Other income (expense): Interest income Interest expense Total other income (expense) Net loss Weighted average common shares outstanding - basic Weighted average common shares outstanding - diluted Net loss per common share - basic Net loss per common share - diluted Balance Balance, shares Class A common stock options issued for services Net loss Warrants exercised for cash Warrants exercised for cash, shares Class A common stock awarded for services Class A common stock awarded for services, shares Balance Balance, shares Statement of Cash Flows [Abstract] CASH FLOWS FROM OPERATING ACTIVITIES Adjustments to reconcile net loss to net cash used in operating activities: Common stock issued for services Non-cash lease expense Stock-based compensation, stock options Changes in operating assets and liabilities: Accounts receivable Accounts receivable, related party Other current assets Accounts payable Accounts payable, related parties Deferred revenue Accrued expenses Operating lease liability Net cash used in operating activities CASH FLOWS FROM INVESTING ACTIVITIES Purchase of property and equipment Net cash used in investing activities CASH FLOWS FROM FINANCING ACTIVITIES Proceeds received on exercise of warrants Payment of deferred offering costs Proceeds received from line of credit Repayments on line of credit Repayments on notes payable Proceeds received from convertible notes payable Net cash provided by financing activities NET CHANGE IN CASH AND CASH EQUIVALENTS CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD CASH AND CASH EQUIVALENTS AT END OF PERIOD SUPPLEMENTAL INFORMATION: Interest paid Income taxes paid Accounting Policies [Abstract] Nature of Business and Significant Accounting Policies Organization, Consolidation and Presentation of Financial Statements [Abstract] Going Concern Related Party Transactions [Abstract] Related Party Transactions Earnings Per Share [Abstract] Basic and Diluted Earnings per Share Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract] Other Current Assets Tax Credit Carryforward [Table] Tax Credit Carryforward [Line Items] Tax credits Property, Plant and Equipment [Abstract] Property and Equipment Payables and Accruals [Abstract] Accrued Expenses Leases [Abstract] Lease Debt Disclosure [Abstract] Notes Payable Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Equity [Abstract] Changes in Stockholders’ Equity (Deficit) Common Stock Options Subsequent Events [Abstract] Subsequent Events Basis of Presentation Use of Estimates Concentrations of Credit Risk Fair Value of Financial Instruments Cash and Cash Equivalents Accounts Receivable Property and Equipment Impairment of Long-Lived Assets Leases Segment Reporting Revenue Recognition Cost of Services Significant Concentrations Stock-Based Compensation Basic and Diluted Loss Per Share Income Taxes Uncertain Tax Positions Recent Accounting Standards Schedule of Disaggregation of Revenue Schedule of Diluted Earnings Per Share Schedule of Other Current Assets Schedule of Property and Equipment Schedule of Accrued Expenses Schedule of Lease Cost expenses Schedule of Supplemental Balance Sheets Information Schedule of Share-Based Compensation, Stock Options Activity Nature of Operation, Product Information, Concentration of Risk [Table] Product Information [Line Items] Net revenues FDIC insured amount Cash equivalents Accounts receivable Property and equipment useful life Risk percentage Revenues Cash Working capital Accumulated deficit Convertible notes payable Proceeds from commnon stock Related Party Transaction [Table] Related Party Transaction [Line Items] Advanced balance of loan Receivable from related party Lease term Base monthly rent Lease expense Service cost Antidilutive Security, Excluded EPS Calculation [Table] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Total Federal and state income tax receivable Prepaid expenses Total other current assets Property, Plant and Equipment [Table] Property, Plant and Equipment [Line Items] Office equipment Less: Accumulated depreciation Total property and equipment, net Accrued payroll and taxes Accrued expenses Total accrued expenses Employers contribution percentage match Employees contribution percentage Investment retirement account contribution expenses Accrued retirement contributions Amortization of ROU asset Interest on lease liability Total operating lease cost Operating lease assets Noncurrent operating lease liability, related party Total operating lease liability Weighted-average remaining lease term (in years) (Year) Weighted-average discount rate (Rate) Defined Benefit Plan [Table] Defined Benefit Plan Disclosure [Line Items] Office space Increased base monthly rent Lease rent expense Schedule of Long-Term Debt Instruments [Table] Debt Instrument [Line Items] Principal amount Interest rate percentage Periodic interest payment Principal repayments Interest expense Stock, Class of Stock [Table] Class of Stock [Line Items] Warrants to purchase Proceeds from issuance of warrants Restricted stock awarded Recognized expense Additional recognized expense at vesting period Conversion of stock, shares converted Number of options, beginning balance Weighted average exercise prices, ending balance Options granted Weighted average exercise price, granted Options cancelled Weighted average exercise price, cancelled Number of options, ending balance Weighted average exercise prices, ending balance Exercisable ending balance Weighted average exercise price, exercisable Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Shares issued Granted options Exercise price Granted options term Number of options vested Expected term Weighted average volatility rate Weighted average risk free interest rate Weighted average call option value Aggregate intrinsic value Unamortized expenses Remaining contractual life Healthcare Workforce [Member] Population Health [Member] Digital Health [Member] Behavioral and Mental Services [Member] Health Education [Member] Significant Concentrations [Policy Text Block] Family and Social Services Administration (FSSA) [Member] FSSA – NeuroDiagnostic Institute [Member] FSSA – Division of Mental Health and Addiction [Member] Preferred stock, shares designated. Convertible Class B Common Stock [Member] Working capital. Sahasra Technologies Corp [Member] ST Logics [Member] STVentures [Member] Information Technology Services [Member] RAD CUBE LLC [Member] Value of stock awarded issued in lieu of cash for services contributed to the entity. Value of the stock awarded issued includes, but is not limited to, services contributed by vendors and founders. Common stock awarded for services, shares Recruitment and Human Resource Services [Member] NLogix [Member] Employee retention tax credit receivables. Investment retirement account contribution expenses. Accrued retirement contributions. Number of warrants exercised for cash value. Number of warrants exercised for cash shares. Operating lease interest expense. Supplemental balance sheets information table text block. Insurance Policy Financing Arrangements [Member] Remaining balance payments. Two Investors [Member] November 2023 [Member] Recognized expense. Additional recognized expense at vesting period. Convertible Common Stock B [Member] Omnibus Equity Incentive Plan [Member] Ten Employees [Member] Number of options vested. Weighted average risk free interest rate. Weighted average exercise price. Employee Retention Tax Credit [Member] Economic Development Growing Economy [Member] 2022 Plan [Member] Increase decrease in payments for rent. Assets, Current Assets Liabilities, Current Liabilities Equity, Attributable to Parent Liabilities and Equity Gross Profit Operating Expenses Operating Income (Loss) Nonoperating Income (Expense) Shares, Outstanding Increase (Decrease) in Accounts Receivable Increase (Decrease) in Accounts Receivable, Related Parties Increase (Decrease) in Other Current Assets Increase (Decrease) in Accounts Payable, Trade Increase (Decrease) in Deferred Revenue Increase (Decrease) in Accrued Liabilities Net Cash Provided by (Used in) Operating Activities Payments to Acquire Property, Plant, and Equipment Net Cash Provided by (Used in) Investing Activities Payments of Debt Issuance Costs Repayments of Lines of Credit Repayments of Notes Payable Net Cash Provided by (Used in) Financing Activities Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Property, Plant and Equipment, Policy [Policy Text Block] Revenues Accounts Receivable, after Allowance for Credit Loss Cash and Cash Equivalents, at Carrying Value Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Accrued Employee Benefits, Current Operating Lease, Liability Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number EX-101.PRE 10 syra-20240331_pre.xml XBRL PRESENTATION FILE XML 12 R1.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Cover - shares
 3 Months Ended
Mar. 31, 2024
May 06, 2024
Cover [Abstract]    
Document Type 10-Q  
Amendment Flag false  
Document Quarterly Report true  
Document Transition Report false  
Document Period End Date Mar. 31, 2024  
Document Fiscal Period Focus Q1  
Document Fiscal Year Focus 2024  
Current Fiscal Year End Date --12-31  
Entity File Number 001-41822  
Entity Registrant Name SYRA HEALTH CORP.  
Entity Central Index Key 0001922335  
Entity Tax Identification Number 85-4027995  
Entity Incorporation, State or Country Code DE  
Entity Address, Address Line One 1119 Keystone Way N. #201  
Entity Address, City or Town Carmel  
Entity Address, State or Province IN  
Entity Address, Postal Zip Code 46032  
City Area Code (463)  
Local Phone Number 345-8950  
Title of 12(b) Security Class A Common Stock, $0.001 par value  
Trading Symbol SYRA  
Security Exchange Name NASDAQ  
Entity Current Reporting Status No  
Entity Interactive Data Current Yes  
Entity Filer Category Non-accelerated Filer  
Entity Small Business true  
Entity Emerging Growth Company true  
Elected Not To Use the Extended Transition Period false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   6,421,632
Entity Information, Former Legal or Registered Name Not applicable  
XML 13 R2.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Condensed Balance Sheets - USD ($)
Mar. 31, 2024
Dec. 31, 2023
Current assets:    
Cash $ 3,237,957 $ 3,280,075
Other current assets 381,887 389,787
Total current assets 4,447,651 4,781,110
Property and equipment, net 72,048 78,974
Right-of-use asset 31,826 63,199
Total assets 4,551,525 4,923,283
Current liabilities:    
Accounts payable 645,567 462,991
Accrued expenses 319,698 198,978
Deferred revenue 6,108
Current portion of operating lease liability, related party 31,826 63,199
Notes payable 99,021 184,904
Total current liabilities 1,102,220 910,072
Total liabilities 1,102,220 910,072
Commitments and contingencies
Stockholders’ equity (deficit):    
Preferred stock, $0.001 par value, 10,000,000 shares authorized, no shares designated, issued and outstanding
Additional paid-in capital 9,954,708 9,071,745
Accumulated deficit (6,512,005) (5,064,955)
Total stockholders’ equity (deficit) 3,449,305 4,013,211
Total liabilities and stockholders’ equity (deficit) 4,551,525 4,923,283
Common Class A [Member]    
Stockholders’ equity (deficit):    
Common stock, value 5,769 5,588
Convertible Class B Common Stock [Member]    
Stockholders’ equity (deficit):    
Common stock, value 833 833
Nonrelated Party [Member]    
Current assets:    
Accounts receivable 745,683 1,060,634
Related Party [Member]    
Current assets:    
Accounts receivable $ 82,124 $ 50,614
XML 14 R3.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Condensed Balance Sheets (Parenthetical) - $ / shares
Mar. 31, 2024
Dec. 31, 2023
Preferred stock, par value $ 0.001 $ 0.001
Preferred stock, shares authorized 10,000,000 10,000,000
Preferred stock, shares designated 0 0
Preferred stock, shares issued 0 0
Preferred stock, shares outstanding 0 0
Common Class A [Member]    
Common stock, par value $ 0.001 $ 0.001
Common stock, shares authorized 100,000,000 100,000,000
Common stock, shares issued 5,769,087 5,588,298
Common stock, shares outstanding 5,769,087 5,588,298
Convertible Class B Common Stock [Member]    
Common stock, par value $ 0.001 $ 0.001
Common stock, shares authorized 5,000,000 5,000,000
Common stock, shares issued 833,334 833,334
Common stock, shares outstanding 833,334 833,334
XML 15 R4.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Condensed Statements of Operations (Unaudited) - USD ($)
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Income Statement [Abstract]    
Net revenues $ 1,752,340 $ 1,188,351
Cost of services 1,573,053 1,041,195
Gross profit 179,287 147,156
Operating expenses:    
Salaries and benefits 736,303 457,745
Professional services 194,580 236,660
Research and development expenses 277,548
Selling, general and administrative expenses 402,265 215,463
Depreciation 12,545 11,763
Total operating expenses 1,623,241 921,631
Operating loss (1,443,954) (774,475)
Other income (expense):    
Interest income 981 2
Interest expense (4,077) (11,419)
Total other income (expense) (3,096) (11,417)
Net loss $ (1,447,050) $ (785,892)
Weighted average common shares outstanding - basic 6,495,213 4,353,717
Weighted average common shares outstanding - diluted 6,495,213 4,353,717
Net loss per common share - basic $ (0.22) $ (0.18)
Net loss per common share - diluted $ (0.22) $ (0.18)
XML 16 R5.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Statements of Changes in Stockholders' Equity (Deficit) (Unaudited) - USD ($)
Preferred Stock [Member]
Common Stock [Member]
Common Class A [Member]
Common Stock [Member]
Convertible Class B Common Stock [Member]
Additional Paid-in Capital [Member]
Retained Earnings [Member]
Total
Balance at Dec. 31, 2022 $ 3,569 $ 833 $ 2,832,308 $ (2,126,612) $ 710,198
Balance, shares at Dec. 31, 2022 3,568,758 833,334      
Class A common stock options issued for services 18,246 18,246
Net loss (785,892) (785,892)
Balance at Mar. 31, 2023 $ 3,569 $ 833 2,850,554 (2,912,504) (57,249)
Balance, shares at Mar. 31, 2023 3,568,758 833,334      
Balance at Dec. 31, 2023 $ 5,588 $ 833 9,071,745 (5,064,955) 4,013,211
Balance, shares at Dec. 31, 2023 5,588,298 833,334      
Class A common stock options issued for services 14,140 14,140
Net loss (1,447,050) (1,447,050)
Warrants exercised for cash $ 131 849,998 850,129
Warrants exercised for cash, shares   130,789        
Class A common stock awarded for services $ 50 18,825 18,875
Class A common stock awarded for services, shares   50,000        
Balance at Mar. 31, 2024 $ 5,769 $ 833 $ 9,954,708 $ (6,512,005) $ 3,449,305
Balance, shares at Mar. 31, 2024 5,769,087 833,334      
XML 17 R6.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Condensed Statements of Cash Flows (Unaudited) - USD ($)
 3 Months Ended 4 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Apr. 30, 2023
CASH FLOWS FROM OPERATING ACTIVITIES      
Net loss $ (1,447,050) $ (785,892)  
Adjustments to reconcile net loss to net cash used in operating activities:      
Depreciation 12,545 11,763  
Common stock issued for services 18,875  
Non-cash lease expense 31,373 29,624  
Stock-based compensation, stock options 14,140 1,367  
Changes in operating assets and liabilities:      
Accounts receivable 314,951 835,456  
Accounts receivable, related party (31,510)  
Other current assets 7,900 (103,025)  
Accounts payable 182,576 31,775  
Accounts payable, related parties (1,600)  
Deferred revenue 6,108  
Accrued expenses 120,720 (34,906)  
Operating lease liability (31,373) (29,624)  
Net cash used in operating activities (800,745) (45,062)  
CASH FLOWS FROM INVESTING ACTIVITIES      
Purchase of property and equipment (5,619) (9,659)  
Net cash used in investing activities (5,619) (9,659)  
CASH FLOWS FROM FINANCING ACTIVITIES      
Proceeds received on exercise of warrants 850,129  
Payment of deferred offering costs (155,260)  
Proceeds received from line of credit 300,000  
Repayments on line of credit (751,952)  
Repayments on notes payable (85,883)  
Proceeds received from convertible notes payable 1,255,000 $ 1,455,000
Net cash provided by financing activities 764,246 647,788  
NET CHANGE IN CASH AND CASH EQUIVALENTS (42,118) 593,067  
CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD 3,280,075 3,344 $ 3,344
CASH AND CASH EQUIVALENTS AT END OF PERIOD 3,237,957 596,411  
SUPPLEMENTAL INFORMATION:      
Interest paid 4,077 9,850  
Income taxes paid  
XML 18 R7.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Nature of Business and Significant Accounting Policies
 3 Months Ended
Mar. 31, 2024
Accounting Policies [Abstract]  
Nature of Business and Significant Accounting Policies

Note 1 – Nature of Business and Significant Accounting Policies

 

Nature of Business

 

Syra Health Corp. (“Syra” or the “Company”) was incorporated in the state of Indiana on November 20, 2020 to provide workforce staffing solutions, health education and healthcare research consulting services to mental health hospitals and organizations, including government agencies, integrated health networks, managed care entities and pharmaceutical manufacturers. On March 11, 2022, the Company redomiciled to Delaware. The Company’s corporate office is located in Carmel, Indiana.

 

Basis of Presentation

 

The accompanying interim consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) and should be read in conjunction with the financial statements and notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2023, which was filed with the Securities and Exchange Commission (“SEC”) on March 25, 2024. Certain information and footnote disclosures normally included in the financial statements prepared in accordance with U.S. GAAP have been omitted from this report on Form 10-Q pursuant to the rules and regulations of the SEC.

 

Results for the interim periods in this report are not necessarily indicative of future financial results and have not been audited by our independent registered public accounting firm. In the opinion of management, the accompanying unaudited consolidated financial statements include all adjustments necessary to present fairly our interim financial statements as of March 31, 2024, and for the three ended March 31, 2024 and 2023. These adjustments are of a normal recurring nature and consistent with the adjustments recorded to prepare the annual audited financial statements as of December 31, 2023.

 

Use of Estimates

 

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that may affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates.

 

 

SYRA HEALTH CORP.

NOTES TO CONDENSED FINANCIAL STATEMENTS

(Unaudited)

 

Concentrations of Credit Risk

 

The Company maintains cash in bank deposit accounts, the balances of which at times may exceed federally insured limits. Accounts are guaranteed by the Federal Deposit Insurance Corporation (“FDIC”) up to $250,000 under current regulations. The Company did not have any cash in excess of FDIC insured limits at March 31, 2024. The Company has not experienced any losses in such accounts.

 

Fair Value of Financial Instruments

 

Accounting Standards Codification (“ASC”) 820 defines fair value, establishes a three-level valuation hierarchy for disclosures of fair value measurement and enhances disclosure requirements for fair value measures. The three levels are defined as follows:

 

  - Level 1 inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets.
  - Level 2 inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the financial instrument.
  - Level 3 inputs to valuation methodology are unobservable and significant to the fair measurement.

 

The carrying value of the Company’s financial assets and liabilities, such as cash, accounts receivable and accounts payable are estimated by management to approximate fair value primarily due to the short-term nature of the instruments. The Company’s advances from related party approximates the fair value of such instruments based upon management’s best estimate of interest rates that would be available to the Company for similar financial arrangements at March 31, 2024 and December 31, 2023.

 

Cash and Cash Equivalents

 

Cash equivalents include money market accounts which have maturities of three months or less when acquired. For the purpose of the statements of cash flows, all highly liquid investments with an original maturity of three months or less are considered to be cash equivalents. Cash equivalents are stated at cost plus accrued interest, which approximates market value. There were no cash equivalents on hand at March 31, 2024 and December 31, 2023.

 

Accounts Receivable

 

Accounts receivable is carried at their estimated collectible amounts. Accounts receivable is periodically evaluated for collectability based on past credit history with customers and their current financial condition. The Company had an allowance of $5,520 at March 31, 2024 and December 31, 2023.

 

Property and Equipment

 

Property and equipment is stated at cost, less accumulated depreciation. The cost of office equipment is depreciated using the straight-line method based on a five-year life expectancy.

 

Repairs and maintenance expenditures are charged to operations as incurred. Major improvements and replacements, which extend the useful life of an asset, are capitalized and depreciated over the remaining estimated useful life of the asset. When assets are retired or sold, the cost and related accumulated depreciation are eliminated and any resulting gain or loss is reflected in operations.

 

Impairment of Long-Lived Assets

 

In accordance with the provisions of ASC Topic 360, “Impairment or Disposal of Long-Lived Assets”, all long-lived assets such as property and equipment held and used by the Company are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is evaluated by a comparison of the carrying amount of an asset to its estimated future undiscounted cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amounts of the assets exceed the fair value of the assets.

 

 

SYRA HEALTH CORP.

NOTES TO CONDENSED FINANCIAL STATEMENTS

(Unaudited)

 

Leases

 

The Company accounts for its leases under ASC 842 - Leases. The Company determines if an arrangement is a lease at inception. Operating leases are included in operating lease right-of-use (“ROU”) assets, current portion of obligations under operating leases, and obligations under operating leases, non-current on the Company’s balance sheets.

 

Operating lease ROU assets and operating lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at commencement date, adjusted by the deferred rent liabilities at the adoption date. As the Company’s lease does not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at commencement date in determining the present value of future payments. The operating lease ROU asset also includes any lease payments made and excludes lease incentives and initial direct costs incurred. The Company’s terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Operating lease expense is recognized on a straight-line basis over the lease term.

 

Segment Reporting

 

ASC Topic 280, “Segment Reporting,” requires annual and interim reporting for an enterprise’s operating segments and related disclosures about its products, services, geographic areas and major customers. An operating segment is defined as a component of an enterprise that engages in business activities from which it may earn revenues and expenses, and about which separate financial information is regularly evaluated by the chief operating decision maker in deciding how to allocate resources. The Company operates as a single segment and will evaluate additional segment disclosure requirements as it expands its operations.

 

Revenue Recognition

 

The Company recognizes revenue in accordance with ASC 606, the core principle of which is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled to receive in exchange for those goods or services. To achieve this core principle, five basic criteria must be met before revenue can be recognized: (1) identify the contract with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to performance obligations in the contract; and (5) recognize revenue when or as the Company satisfies a performance obligation.

 

The Company accounts for revenues when both parties to the contract have approved the contract, the rights and obligations of the parties are identified, payment terms are identified, and collectability of consideration is probable. Payment terms vary by client and the services offered.

 

The Company has the following main forms of revenue:

 

  – Healthcare Workforce;
  – Population Health
  – Digital Health
  – Behavioral and Mental Health Services
  – Health Education

 

The Company primarily provides its services to state health and social service agencies and universities. Healthcare Workforce, Health Education and Behavioral Mental Health Service contracts are primarily accounted for as a single performance obligation satisfied over time because the customer simultaneously receives and consumes the benefits of our medical staffing on an hourly or daily basis. Population Health and Digital Health contracts generally consist of multiple performance obligations that are distinct, such as to provide data analytics and reporting, training, or develop technology for implementation and maintenance with the customer. The Company allocates the transaction price across the performance obligations based on the estimated fair value of the distinct performance obligations. Depending on the performance obligation, revenue is recognized at a point in time when the customer obtains the benefit of the services are provide, or over time in the case of digital health revenue where the customer simultaneously receives and consumes benefits of the contract, such as ongoing performance of our technology product.

 

 

The contracts generally stipulate bi-weekly or monthly billing, and the Company has elected the “as invoiced” practical expedient to recognize revenue based on the hours incurred at the contractual rate as the Company has the right to payment in an amount that corresponds directly with the value of performance completed to date. The Company may also be subject to penalties for violations of certain ethical standards and non-performance measures within these state contracts. The Company recognizes revenue net of penalties.

 

Disaggregated revenue data

 

The Company’s revenue consists of the following revenue services within its industry:

 

   Three Months Ended 
Net revenues:  March 31, 2024   March 31, 2023 
Healthcare workforce  $1,417,661   $1,110,840 
Population health   230,756    74,000 
Digital health   92,250    - 
Behavioral and mental services   1,673    1,730 
Health education   10,000    1,781 
Net revenues  $1,752,340   $1,188,351 

 

Cost of Services

 

The cost of services includes wages and related payroll taxes, employee benefits and certain other employee-related costs of the Company’s contract service employees, while the employees work on contract assignments.

 

Significant Concentrations

 

The majority of accounts receivable and revenue contracts are between the Company and different divisions within the Indiana Family and Social Services Administration (“FSSA”). Most contracts require monthly payments as the projects progress. The Company generally does not require collateral or advance payments. For the three months ended March 31, 2024 and 2023, FSSA accounted for approximately 67% and 99.6% of revenues, respectively, which was derived through a combination of divisions within the State of Indiana, including the FSSA-NeuroDiagnostic Institute, representing $1,108,230 and $1,109,960 of the Company’s Healthcare Workforce revenue for three months ended March 31, 2024 and 2023, respectively, and the FSSA-Division of Mental Health and Addiction, representing $71,000 and $74,000 of the Company’s Population Health revenues for the three months ended March 31, 2024 and 2023, respectively. In addition, the combined divisions of the FSSA (NeuroDiagnostic Institute and Division of Mental Health and Addiction), the Washington D.C. Department of Behavioral Health and Coordinated Care Corporation, doing business as Managed Health Services, owed 50% of the Company’s accounts receivable, respectively, at March 31, 2024, and FSSA represented 30% of outstanding accounts receivable as of December 31, 2023.

 

 

SYRA HEALTH CORP.

NOTES TO CONDENSED FINANCIAL STATEMENTS

(Unaudited)

 

Stock-Based Compensation

 

The Company accounts for equity instruments issued to employees and non-employees in accordance with the provisions of ASC 718 Stock Compensation (“ASC 718”). All transactions in which the consideration provided in exchange for the purchase of goods or services consists of the issuance of equity instruments are accounted for based on the fair value of the consideration received or the fair value of the equity instrument issued, whichever is more reliably measurable.

 

Basic and Diluted Loss Per Share

 

Basic earnings per share (“EPS”) are computed by dividing net income (the numerator) by the weighted average number of common shares outstanding for the period (the denominator). Weighted average shares for basic EPS are calculated based on weighted average Class B shares outstanding. Diluted EPS is computed by dividing net income by the weighted average number of common shares and potential common shares outstanding (if dilutive) during each period. Potential common shares include stock options, warrants, conversion of Class B shares and restricted stock. The number of potential common shares outstanding relating to stock options, warrants, conversion of Class B shares and restricted stock is computed using the treasury stock method. For the periods presented, potential dilutive securities had an anti-dilutive effect and were not included in the calculation of diluted net loss per common share.

 

Income Taxes

 

The Company accounts for income taxes under the Financial Accounting Standards Board (“FASB”) ASC 740 Income Taxes (“ASC 740”), which requires use of the liability method. FASB ASC 740-10-25 provides that deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. A valuation allowance is provided for significant deferred tax assets when it is more likely than not, that such asset will not be recovered through future operations.

 

Uncertain Tax Positions

 

In accordance with ASC 740, the Company recognizes the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be capable of withstanding examination by the taxing authorities based on the technical merits of the position. These standards prescribe a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. These standards also provide guidance on de-recognition, classification, interest and penalties, accounting in interim periods, disclosure, and transition.

 

Various taxing authorities may periodically audit the Company’s income tax returns. These audits include questions regarding the Company’s tax filing positions, including the timing and amount of deductions and the allocation of income to various tax jurisdictions. In evaluating the exposures connected with various tax filing positions, including state and local taxes, the Company records allowances for probable exposures. A number of years may elapse before a particular matter, for which an allowance has been established, is audited and fully resolved. The Company has not yet undergone an examination by any taxing authorities. The Company recognizes interest and penalties related to uncertain tax positions, if any, as an income tax expense.

 

The assessment of the Company’s tax position relies on the judgment of management to estimate the exposures associated with the Company’s various filing positions.

 

 

SYRA HEALTH CORP.

NOTES TO CONDENSED FINANCIAL STATEMENTS

(Unaudited)

 

Recent Accounting Standards

 

From time to time, new accounting pronouncements are issued by the FASB that are adopted by the Company as of the specified effective date.

 

Management does not believe that any recently issued, but not yet effective, accounting pronouncements, if currently adopted, would have a material effect on the Company’s financial statements.

 
XML 19 R8.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Going Concern
 3 Months Ended
Mar. 31, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Going Concern

Note 2 – Going Concern

 

As shown in the accompanying financial statements, as of March 31, 2024, the Company had a cash balance of $3,237,957, working capital of $3,345,431 and an accumulated deficit of $6,512,005 since inception. The Company is too early in its development stage to project revenue with a necessary level of certainty. Therefore, the Company may not have sufficient funds to sustain its operations for the next twelve months from the issuance date of these financial statements and may need to raise additional cash to fund its operations. These factors raise substantial doubt about the Company’s ability to continue as a going concern. The Company has commenced sales and continues to develop its operations. In the event sales do not materialize at the expected rates, management would seek additional financing or would attempt to conserve cash by further reducing expenses. There can be no assurance that the Company will be successful in achieving these objectives.

 

The Company continues to pursue sources of additional capital through debt and financing transactions or arrangements, including equity financing or other means. The Company may not be successful in identifying suitable funding transactions in a sufficient time period or at all, and may not obtain the required capital by other means. If the Company does not succeed in raising additional capital, resources may not be sufficient to fund its business. The Company’s ability to scale production and distribution capabilities and further increase the value of its brands, is largely dependent on its success in raising additional capital. From January through April of 2023, the Company raised a total of $1,455,000 of capital from the sale of convertible notes. On October 3, 2023 the Company completed IPO received net proceeds of approximately $5,332,283. In October 2023, the convertible notes were converted into Class A common stock in accordance with the terms of the convertible promissory notes as a result of the IPO.

 

The financial statements do not include any adjustments that might result from the outcome of any uncertainty as to the Company’s ability to continue as a going concern. These financial statements also do not include any adjustments relating to the recoverability and classification of recorded asset amounts, or amounts and classifications of liabilities that might be necessary should the Company be unable to continue as a going concern.

 
XML 20 R9.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Related Party Transactions
 3 Months Ended
Mar. 31, 2024
Related Party Transactions [Abstract]  
Related Party Transactions

Note 3 – Related Party Transactions

 

The Company pays for payroll and related costs for its employees that provide services to Sahasra Technologies Corp., doing business as STLogics to service contracts of STLogics, which is an entity beneficially owned by the principal owners and management team of Syra. During the three months ended March 31, 2024, the Company paid $82,214 of payroll and related costs for these employees, and had a receivable from STLogics of $82,124 and $50,614 for additional costs incurred as of March 31, 2024 and December 31, 2023, respectively.

 

Office Lease

 

The Company leases its current corporate headquarters under a three-year lease from STVentures, LLC (“STVentures”), an entity beneficially owned by the principal owners and the management team of Syra and their affiliates. The lease commenced on July 1, 2021 and, as amended on May 1, 2022, provides for a base monthly rent of $10,711 over the three-year term of the lease. A total of $32,132 was included in selling, general and administrative expenses for the three months ended March 31, 2024 and 2023, respectively.

 

Information Technology (“IT”) Services

 

The Company incurred a total of $0 and $3,320 of services from RAD CUBE LLC, which is an entity beneficially owned by the principal owners and the management team of Syra and their affiliates, for outsourced IT services which have been presented within selling, general and administrative expenses in the statements of operations during the three months ended March 31, 2024 and 2023, respectively.

 

Recruitment and Human Resource Services

 

The Company paid a total of $145,318 and $66,713 for recruitment and human resource services from NLogix, which is an entity beneficially owned by the principal owners and the management team of Syra and their affiliates, which have been presented within cost of sales in the statements of operations during the three months ended March 31, 2024 and 2023, respectively.

 

 

SYRA HEALTH CORP.

NOTES TO CONDENSED FINANCIAL STATEMENTS

(Unaudited)

 
XML 21 R10.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Basic and Diluted Earnings per Share
 3 Months Ended
Mar. 31, 2024
Earnings Per Share [Abstract]  
Basic and Diluted Earnings per Share

Note 4 – Basic and Diluted Earnings per Share

 

During the three months ended March 31, 2024, the Company used the two-class method to compute net loss per common share because it had issued securities, other than a single class of common stock, that contractually entitled the holders to participate in dividends and earnings. These participating securities included the Company’s Class A common stock, which was authorized pursuant to the Company’s amendment to its Certificate of Incorporation on May 2, 2022, and convertible Class B common stock which are entitled to share equally, on a per share basis, in all assets of the Company of whatever kind available for distribution to the holders of common stock. The two-class method requires earnings for the period to be allocated between common stock and participating securities based upon their respective rights to receive distributed and undistributed earnings.

 

Under the two-class method, for periods with net income, basic net income per common share is computed by dividing the net income attributable to common stockholders by the weighted average number of shares of common stock outstanding during the period. Net income attributable to common stockholders is computed by subtracting from net income the portion of current period earnings that the participating securities would have been entitled to receive pursuant to their dividend rights had all of the period’s earnings been distributed. No such adjustment to earnings is made during periods with a net loss, as the holders of the participating securities have no obligation to fund losses.

 

The Company reports the more dilutive of the approaches (two-class or “if-converted”) as its diluted net income per share during the period. For the periods presented, potential dilutive securities had an anti-dilutive effect and were not included in the calculation of diluted net loss per common share.

 

 

Common shares consisting of shares potentially dilutive that are excluded from the calculated of diluted earnings per share because they are anti-dilutive as of March 31, 2024 and 2023 are as follows:

 

   March 31, 2024   March 31, 2023 
Warrants   1,760,350    - 
Stock options   164,750    28,000 
Total   1,925,100    28,000 

 
XML 22 R11.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Other Current Assets
 3 Months Ended
Mar. 31, 2024
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]  
Other Current Assets

Note 5 – Other Current Assets

 

Other current assets included the following as of March 31, 2024 and December 31, 2023:

 

   March 31,   December 31, 
   2024   2023 
Federal and state income tax receivable (1) (2)  $148,401   $73,069 
Prepaid expenses   233,486    316,718 
Total other current assets  $381,887   $389,787 

 

(1)Includes $50,000 for a federal refundable payroll tax credit, called the Employee Retention Tax Credit (“ERTC”) Tax Credit, which provides a credit to businesses who kept employees, or were negatively impacted, during the COVID-19 pandemic.

 

(2)Includes $75,332 for a refundable corporate income tax credit from the State of Indiana, called the Economic Development for a Growing Economy (“EDGE”) Tax Credit, which provides an incentive to businesses to support jobs creation, capital investment and to improve the standard of living for Indiana residents.

 

 

SYRA HEALTH CORP.

NOTES TO CONDENSED FINANCIAL STATEMENTS

(Unaudited)

 
XML 23 R12.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Other Current Assets (Parenthetical)
 3 Months Ended
Mar. 31, 2024
USD ($)
Employee Retention Tax Credit [Member]  
Tax Credit Carryforward [Line Items]  
Tax credits $ 50,000
Economic Development Growing Economy [Member]  
Tax Credit Carryforward [Line Items]  
Tax credits $ 75,332
XML 24 R13.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Property and Equipment
 3 Months Ended
Mar. 31, 2024
Property, Plant and Equipment [Abstract]  
Property and Equipment

Note 6 – Property and Equipment

 

Property and equipment at March 31, 2024 and December 31, 2023, consisted of the following:

 

   March 31,   December 31, 
   2024   2023 
Office equipment  $148,419   $142,800 
Less: Accumulated depreciation   (76,371)   (63,826)
Total property and equipment, net  $72,048   $78,974 

 

Depreciation of property and equipment was $12,545 and $11,763 for the three months ended March 31, 2024 and 2023, respectively.

 
XML 25 R14.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Accrued Expenses
 3 Months Ended
Mar. 31, 2024
Payables and Accruals [Abstract]  
Accrued Expenses

Note 7 – Accrued Expenses

 

Accrued expenses at March 31, 2024 and December 31, 2023, consisted of the following:

 

   March 31,   December 31, 
   2024   2023 
Accrued payroll and taxes  $312,576   $148,924 
Accrued expenses   7,122    50,054 
Total accrued expenses  $319,698   $198,978 

 

The Company provides postretirement benefits pursuant to IRS code section 401(k) for employees meeting specified criteria. The Company matches 100% of the employees’ contributions that are not in excess of 4% of the employee’s contributions. These matching contributions are fully vested and paid pursuant to the employees’ bi-weekly or semi-monthly pay periods. The Company does not prefund these benefits and has the right to modify or terminate certain of these benefits in the future. For the three months ended March 31, 2024, the Company incurred $26,485 of IRA contribution expenses pursuant to the Company’s matching contributions, including $0, as accrued at March 31, 2024.

 

 

 

SYRA HEALTH CORP.

NOTES TO CONDENSED FINANCIAL STATEMENTS

(Unaudited)

 
XML 26 R15.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Lease
 3 Months Ended
Mar. 31, 2024
Leases [Abstract]  
Lease

Note 8 – Lease

 

The Company leases its current corporate headquarters under a three-year lease from STVentures, a related party. The lease, as amended on May 1, 2022 to expand its office space from 2,976 square feet to approximately 5,978 square feet, commenced on July 1, 2021, and provides for a base monthly rent of $10,711, as increased from $5,332 per month, over the three-year term of the lease. The Company is occupying the space for executive and administrative offices. Rent expense for the three months ended March 31, 2024 and 2023 was $32,132, which is included in selling, general and administrative expenses within the statements of operations.

 

The components of lease expense were as follows:

 

   2024   2023 
   For the Three Months Ended 
   March 31, 
   2024   2023 
Operating lease cost:          
Amortization of ROU asset  $31,373   $121,089 
Interest on lease liability   759    7,438 
Total operating lease cost  $32,132   $128,527 

 

Supplemental balance sheet information related to leases was as follows:

 

   March 31,   December 31, 
   2024   2023 
Operating lease:          
Operating lease assets  $31,826   $63,199 
           
Current portion of operating lease liability, related party  $31,826    63,199 
Noncurrent operating lease liability, related party   -    - 
Total operating lease liability  $31,826   $63,199 
           
Weighted average remaining lease term:          
Operating leases   0.25 years    0.5 years 
           
Weighted average discount rate:          
Operating lease   5.75%   5.75%

 

 

SYRA HEALTH CORP.

NOTES TO CONDENSED FINANCIAL STATEMENTS

(Unaudited)
XML 27 R16.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Notes Payable
 3 Months Ended
Mar. 31, 2024
Debt Disclosure [Abstract]  
Notes Payable

Note 9 – Notes Payable

 

In 2023, the Company entered into three insurance policy financing arrangements to purchase various insurance policies. The total principal of these arrangements was $370,596 with interest rates ranging from 10.38% through 14.05% and monthly payments totaling $32,328 are due through July 2024. The Company made principal repayments of $85,883 and incurred interest expense of $4,077 during the three months ended March 31, 2024. As of March 31, 2024 and December 31, 2023, the remaining balance was $99,021 and $184,904, respectively.

 
XML 28 R17.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Commitments and Contingencies
 3 Months Ended
Mar. 31, 2024
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies

Note 10 – Commitments and Contingencies

 

Legal Contingencies

 

From time to time, we may be involved in various disputes and litigation matters that arise in the ordinary course of business. The Company is currently not a party to any material legal proceedings.

 

In January 2024, a former employee filed a wrongful termination lawsuit against the Company in the U.S. District Court, Southern District of Indiana. The Company plans to vigorously defend itself against the claims, which it believes are without merit.

 
XML 29 R18.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Changes in Stockholders’ Equity (Deficit)
 3 Months Ended
Mar. 31, 2024
Equity [Abstract]  
Changes in Stockholders’ Equity (Deficit)

Note 11 – Changes in Stockholders’ Equity (Deficit)

 

Class A Common Stock

 

The Company has 100,000,000 authorized shares of $0.001 par value Class A common stock, and 5,769,087 shares were issued and outstanding as of March 31, 2024.

 

During the three months ended March 31, 2024, two investors exercised 130,789 warrants to purchase Class A Common stock pursuant to which the Company received cash proceeds of $850,129.

 

During the three months ended March 31, 2024, the Company issued 50,000 shares pursuant to the restricted stock award from November 2023. These shares vest quarterly over a one-year period. The Company recognized expense of $18,875 for these awards and expects to recognize an additional $48,503 through the end of the vesting period.

 

Convertible Class B Common Stock

 

The Company has 5,000,000 authorized shares of $0.001 par value convertible Class B common stock, and had 833,334 shares issued and outstanding as of March 31, 2024, as retrospectively applied, pursuant to the Company’s subsequent recapitalization in 2022 and effective as of May 3, 2022, whereby the founders exchanged their 83,334 Founders Shares for 833,334 shares of convertible Class B common stock.

 

 

SYRA HEALTH CORP.

NOTES TO CONDENSED FINANCIAL STATEMENTS

(Unaudited)

 
XML 30 R19.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Common Stock Options
 3 Months Ended
Mar. 31, 2024
Equity [Abstract]  
Common Stock Options

Note 12 – Common Stock Options

 

Omnibus Equity Incentive Plan

 

On April 11, 2022, the Company’s board of directors adopted, and the Company’s stockholders approved, the Syra Health Corp. 2022 Omnibus Equity Incentive Plan, as amended on April 19, 2023 (as amended, the “2022 Plan”). No more than 1,041,667 shares of the Company’s Class A common stock shall be issued pursuant to the exercise of incentive stock options under the 2022 Plan.

 

Class A Common Stock Option Awards

 

During the three months ended March 31, 2024, the Company granted options to purchase an aggregate 24,000 shares of the Company’s Class A common stock at an exercise price of $1.88 per share for a term of 10 years under the 2022 Plan. These options will vest 25% on each anniversary until fully vested. The options had no intrinsic value. The aggregate estimated value using the Black-Scholes Pricing Model, based on an expected term of 6.25 years, a weighted average volatility rate of 110%, a weighted average risk-free interest rate of 4.16%, and a weighted average call option value of $1.498, was $35,945. During the three months ended March 31, 2024 and 2023, the Company recognized expense of $14,140 and $1,367 related to common stock options. As of March 31, 2024, a total of $218,760 of unamortized expenses are expected to be expensed over the vesting period.

 

The following is a summary of activity of outstanding stock options:

 

       Weighted 
       Average 
   Number   Exercise 
   of Shares   Prices 
Balance, December 31, 2023   140,750   $1.82 
Options granted   24,000    1.88 
Options cancelled   -    - 
Balance, March 31, 2024   164,750   $1.83 
Exercisable, March 31, 2024   -   $- 

 

The options had a weighted average remaining life of 9.42 years and no intrinsic value as of March 31, 2024.

 
XML 31 R20.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Subsequent Events
 3 Months Ended
Mar. 31, 2024
Subsequent Events [Abstract]  
Subsequent Events

Note 13 – Subsequent Events

 

The Company evaluates events that have occurred after the balance sheet date through the date these financial statements were issued.
XML 32 R21.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Nature of Business and Significant Accounting Policies (Policies)
 3 Months Ended
Mar. 31, 2024
Accounting Policies [Abstract]  
Basis of Presentation

Basis of Presentation

 

The accompanying interim consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) and should be read in conjunction with the financial statements and notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2023, which was filed with the Securities and Exchange Commission (“SEC”) on March 25, 2024. Certain information and footnote disclosures normally included in the financial statements prepared in accordance with U.S. GAAP have been omitted from this report on Form 10-Q pursuant to the rules and regulations of the SEC.

 

Results for the interim periods in this report are not necessarily indicative of future financial results and have not been audited by our independent registered public accounting firm. In the opinion of management, the accompanying unaudited consolidated financial statements include all adjustments necessary to present fairly our interim financial statements as of March 31, 2024, and for the three ended March 31, 2024 and 2023. These adjustments are of a normal recurring nature and consistent with the adjustments recorded to prepare the annual audited financial statements as of December 31, 2023.

 
Use of Estimates

Use of Estimates

 

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that may affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates.

 

 

SYRA HEALTH CORP.

NOTES TO CONDENSED FINANCIAL STATEMENTS

(Unaudited)

 
Concentrations of Credit Risk

Concentrations of Credit Risk

 

The Company maintains cash in bank deposit accounts, the balances of which at times may exceed federally insured limits. Accounts are guaranteed by the Federal Deposit Insurance Corporation (“FDIC”) up to $250,000 under current regulations. The Company did not have any cash in excess of FDIC insured limits at March 31, 2024. The Company has not experienced any losses in such accounts.

 
Fair Value of Financial Instruments

Fair Value of Financial Instruments

 

Accounting Standards Codification (“ASC”) 820 defines fair value, establishes a three-level valuation hierarchy for disclosures of fair value measurement and enhances disclosure requirements for fair value measures. The three levels are defined as follows:

 

  - Level 1 inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets.
  - Level 2 inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the financial instrument.
  - Level 3 inputs to valuation methodology are unobservable and significant to the fair measurement.

 

The carrying value of the Company’s financial assets and liabilities, such as cash, accounts receivable and accounts payable are estimated by management to approximate fair value primarily due to the short-term nature of the instruments. The Company’s advances from related party approximates the fair value of such instruments based upon management’s best estimate of interest rates that would be available to the Company for similar financial arrangements at March 31, 2024 and December 31, 2023.

 
Cash and Cash Equivalents

Cash and Cash Equivalents

 

Cash equivalents include money market accounts which have maturities of three months or less when acquired. For the purpose of the statements of cash flows, all highly liquid investments with an original maturity of three months or less are considered to be cash equivalents. Cash equivalents are stated at cost plus accrued interest, which approximates market value. There were no cash equivalents on hand at March 31, 2024 and December 31, 2023.

 
Accounts Receivable

Accounts Receivable

 

Accounts receivable is carried at their estimated collectible amounts. Accounts receivable is periodically evaluated for collectability based on past credit history with customers and their current financial condition. The Company had an allowance of $5,520 at March 31, 2024 and December 31, 2023.

 
Property and Equipment

Property and Equipment

 

Property and equipment is stated at cost, less accumulated depreciation. The cost of office equipment is depreciated using the straight-line method based on a five-year life expectancy.

 

Repairs and maintenance expenditures are charged to operations as incurred. Major improvements and replacements, which extend the useful life of an asset, are capitalized and depreciated over the remaining estimated useful life of the asset. When assets are retired or sold, the cost and related accumulated depreciation are eliminated and any resulting gain or loss is reflected in operations.

 
Impairment of Long-Lived Assets

Impairment of Long-Lived Assets

 

In accordance with the provisions of ASC Topic 360, “Impairment or Disposal of Long-Lived Assets”, all long-lived assets such as property and equipment held and used by the Company are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is evaluated by a comparison of the carrying amount of an asset to its estimated future undiscounted cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amounts of the assets exceed the fair value of the assets.

 

 

SYRA HEALTH CORP.

NOTES TO CONDENSED FINANCIAL STATEMENTS

(Unaudited)

 
Leases

Leases

 

The Company accounts for its leases under ASC 842 - Leases. The Company determines if an arrangement is a lease at inception. Operating leases are included in operating lease right-of-use (“ROU”) assets, current portion of obligations under operating leases, and obligations under operating leases, non-current on the Company’s balance sheets.

 

Operating lease ROU assets and operating lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at commencement date, adjusted by the deferred rent liabilities at the adoption date. As the Company’s lease does not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at commencement date in determining the present value of future payments. The operating lease ROU asset also includes any lease payments made and excludes lease incentives and initial direct costs incurred. The Company’s terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Operating lease expense is recognized on a straight-line basis over the lease term.

 
Segment Reporting

Segment Reporting

 

ASC Topic 280, “Segment Reporting,” requires annual and interim reporting for an enterprise’s operating segments and related disclosures about its products, services, geographic areas and major customers. An operating segment is defined as a component of an enterprise that engages in business activities from which it may earn revenues and expenses, and about which separate financial information is regularly evaluated by the chief operating decision maker in deciding how to allocate resources. The Company operates as a single segment and will evaluate additional segment disclosure requirements as it expands its operations.

 
Revenue Recognition

Revenue Recognition

 

The Company recognizes revenue in accordance with ASC 606, the core principle of which is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled to receive in exchange for those goods or services. To achieve this core principle, five basic criteria must be met before revenue can be recognized: (1) identify the contract with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to performance obligations in the contract; and (5) recognize revenue when or as the Company satisfies a performance obligation.

 

The Company accounts for revenues when both parties to the contract have approved the contract, the rights and obligations of the parties are identified, payment terms are identified, and collectability of consideration is probable. Payment terms vary by client and the services offered.

 

The Company has the following main forms of revenue:

 

  – Healthcare Workforce;
  – Population Health
  – Digital Health
  – Behavioral and Mental Health Services
  – Health Education

 

The Company primarily provides its services to state health and social service agencies and universities. Healthcare Workforce, Health Education and Behavioral Mental Health Service contracts are primarily accounted for as a single performance obligation satisfied over time because the customer simultaneously receives and consumes the benefits of our medical staffing on an hourly or daily basis. Population Health and Digital Health contracts generally consist of multiple performance obligations that are distinct, such as to provide data analytics and reporting, training, or develop technology for implementation and maintenance with the customer. The Company allocates the transaction price across the performance obligations based on the estimated fair value of the distinct performance obligations. Depending on the performance obligation, revenue is recognized at a point in time when the customer obtains the benefit of the services are provide, or over time in the case of digital health revenue where the customer simultaneously receives and consumes benefits of the contract, such as ongoing performance of our technology product.

 

 

The contracts generally stipulate bi-weekly or monthly billing, and the Company has elected the “as invoiced” practical expedient to recognize revenue based on the hours incurred at the contractual rate as the Company has the right to payment in an amount that corresponds directly with the value of performance completed to date. The Company may also be subject to penalties for violations of certain ethical standards and non-performance measures within these state contracts. The Company recognizes revenue net of penalties.

 

Disaggregated revenue data

 

The Company’s revenue consists of the following revenue services within its industry:

 

   Three Months Ended 
Net revenues:  March 31, 2024   March 31, 2023 
Healthcare workforce  $1,417,661   $1,110,840 
Population health   230,756    74,000 
Digital health   92,250    - 
Behavioral and mental services   1,673    1,730 
Health education   10,000    1,781 
Net revenues  $1,752,340   $1,188,351 

 
Cost of Services

Cost of Services

 

The cost of services includes wages and related payroll taxes, employee benefits and certain other employee-related costs of the Company’s contract service employees, while the employees work on contract assignments.

 
Significant Concentrations

Significant Concentrations

 

The majority of accounts receivable and revenue contracts are between the Company and different divisions within the Indiana Family and Social Services Administration (“FSSA”). Most contracts require monthly payments as the projects progress. The Company generally does not require collateral or advance payments. For the three months ended March 31, 2024 and 2023, FSSA accounted for approximately 67% and 99.6% of revenues, respectively, which was derived through a combination of divisions within the State of Indiana, including the FSSA-NeuroDiagnostic Institute, representing $1,108,230 and $1,109,960 of the Company’s Healthcare Workforce revenue for three months ended March 31, 2024 and 2023, respectively, and the FSSA-Division of Mental Health and Addiction, representing $71,000 and $74,000 of the Company’s Population Health revenues for the three months ended March 31, 2024 and 2023, respectively. In addition, the combined divisions of the FSSA (NeuroDiagnostic Institute and Division of Mental Health and Addiction), the Washington D.C. Department of Behavioral Health and Coordinated Care Corporation, doing business as Managed Health Services, owed 50% of the Company’s accounts receivable, respectively, at March 31, 2024, and FSSA represented 30% of outstanding accounts receivable as of December 31, 2023.

 

 

SYRA HEALTH CORP.

NOTES TO CONDENSED FINANCIAL STATEMENTS

(Unaudited)

 
Stock-Based Compensation

Stock-Based Compensation

 

The Company accounts for equity instruments issued to employees and non-employees in accordance with the provisions of ASC 718 Stock Compensation (“ASC 718”). All transactions in which the consideration provided in exchange for the purchase of goods or services consists of the issuance of equity instruments are accounted for based on the fair value of the consideration received or the fair value of the equity instrument issued, whichever is more reliably measurable.

 
Basic and Diluted Loss Per Share

Basic and Diluted Loss Per Share

 

Basic earnings per share (“EPS”) are computed by dividing net income (the numerator) by the weighted average number of common shares outstanding for the period (the denominator). Weighted average shares for basic EPS are calculated based on weighted average Class B shares outstanding. Diluted EPS is computed by dividing net income by the weighted average number of common shares and potential common shares outstanding (if dilutive) during each period. Potential common shares include stock options, warrants, conversion of Class B shares and restricted stock. The number of potential common shares outstanding relating to stock options, warrants, conversion of Class B shares and restricted stock is computed using the treasury stock method. For the periods presented, potential dilutive securities had an anti-dilutive effect and were not included in the calculation of diluted net loss per common share.

 
Income Taxes

Income Taxes

 

The Company accounts for income taxes under the Financial Accounting Standards Board (“FASB”) ASC 740 Income Taxes (“ASC 740”), which requires use of the liability method. FASB ASC 740-10-25 provides that deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. A valuation allowance is provided for significant deferred tax assets when it is more likely than not, that such asset will not be recovered through future operations.

 
Uncertain Tax Positions

Uncertain Tax Positions

 

In accordance with ASC 740, the Company recognizes the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be capable of withstanding examination by the taxing authorities based on the technical merits of the position. These standards prescribe a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. These standards also provide guidance on de-recognition, classification, interest and penalties, accounting in interim periods, disclosure, and transition.

 

Various taxing authorities may periodically audit the Company’s income tax returns. These audits include questions regarding the Company’s tax filing positions, including the timing and amount of deductions and the allocation of income to various tax jurisdictions. In evaluating the exposures connected with various tax filing positions, including state and local taxes, the Company records allowances for probable exposures. A number of years may elapse before a particular matter, for which an allowance has been established, is audited and fully resolved. The Company has not yet undergone an examination by any taxing authorities. The Company recognizes interest and penalties related to uncertain tax positions, if any, as an income tax expense.

 

The assessment of the Company’s tax position relies on the judgment of management to estimate the exposures associated with the Company’s various filing positions.

 

 

SYRA HEALTH CORP.

NOTES TO CONDENSED FINANCIAL STATEMENTS

(Unaudited)

 
Recent Accounting Standards

Recent Accounting Standards

 

From time to time, new accounting pronouncements are issued by the FASB that are adopted by the Company as of the specified effective date.

 

Management does not believe that any recently issued, but not yet effective, accounting pronouncements, if currently adopted, would have a material effect on the Company’s financial statements.
XML 33 R22.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Nature of Business and Significant Accounting Policies (Tables)
 3 Months Ended
Mar. 31, 2024
Accounting Policies [Abstract]  
Schedule of Disaggregation of Revenue

The Company’s revenue consists of the following revenue services within its industry:

 

   Three Months Ended 
Net revenues:  March 31, 2024   March 31, 2023 
Healthcare workforce  $1,417,661   $1,110,840 
Population health   230,756    74,000 
Digital health   92,250    - 
Behavioral and mental services   1,673    1,730 
Health education   10,000    1,781 
Net revenues  $1,752,340   $1,188,351 
XML 34 R23.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Basic and Diluted Earnings per Share (Tables)
 3 Months Ended
Mar. 31, 2024
Earnings Per Share [Abstract]  
Schedule of Diluted Earnings Per Share

Common shares consisting of shares potentially dilutive that are excluded from the calculated of diluted earnings per share because they are anti-dilutive as of March 31, 2024 and 2023 are as follows:

 

   March 31, 2024   March 31, 2023 
Warrants   1,760,350    - 
Stock options   164,750    28,000 
Total   1,925,100    28,000 
XML 35 R24.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Other Current Assets (Tables)
 3 Months Ended
Mar. 31, 2024
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]  
Schedule of Other Current Assets

Other current assets included the following as of March 31, 2024 and December 31, 2023:

 

   March 31,   December 31, 
   2024   2023 
Federal and state income tax receivable (1) (2)  $148,401   $73,069 
Prepaid expenses   233,486    316,718 
Total other current assets  $381,887   $389,787 

 

(1)Includes $50,000 for a federal refundable payroll tax credit, called the Employee Retention Tax Credit (“ERTC”) Tax Credit, which provides a credit to businesses who kept employees, or were negatively impacted, during the COVID-19 pandemic.

 

(2)Includes $75,332 for a refundable corporate income tax credit from the State of Indiana, called the Economic Development for a Growing Economy (“EDGE”) Tax Credit, which provides an incentive to businesses to support jobs creation, capital investment and to improve the standard of living for Indiana residents.
XML 36 R25.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Property and Equipment (Tables)
 3 Months Ended
Mar. 31, 2024
Property, Plant and Equipment [Abstract]  
Schedule of Property and Equipment

Property and equipment at March 31, 2024 and December 31, 2023, consisted of the following:

 

   March 31,   December 31, 
   2024   2023 
Office equipment  $148,419   $142,800 
Less: Accumulated depreciation   (76,371)   (63,826)
Total property and equipment, net  $72,048   $78,974 
XML 37 R26.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Accrued Expenses (Tables)
 3 Months Ended
Mar. 31, 2024
Payables and Accruals [Abstract]  
Schedule of Accrued Expenses

Accrued expenses at March 31, 2024 and December 31, 2023, consisted of the following:

 

   March 31,   December 31, 
   2024   2023 
Accrued payroll and taxes  $312,576   $148,924 
Accrued expenses   7,122    50,054 
Total accrued expenses  $319,698   $198,978 
XML 38 R27.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Lease (Tables)
 3 Months Ended
Mar. 31, 2024
Leases [Abstract]  
Schedule of Lease Cost expenses

The components of lease expense were as follows:

 

   2024   2023 
   For the Three Months Ended 
   March 31, 
   2024   2023 
Operating lease cost:          
Amortization of ROU asset  $31,373   $121,089 
Interest on lease liability   759    7,438 
Total operating lease cost  $32,132   $128,527 
Schedule of Supplemental Balance Sheets Information

Supplemental balance sheet information related to leases was as follows:

 

   March 31,   December 31, 
   2024   2023 
Operating lease:          
Operating lease assets  $31,826   $63,199 
           
Current portion of operating lease liability, related party  $31,826    63,199 
Noncurrent operating lease liability, related party   -    - 
Total operating lease liability  $31,826   $63,199 
           
Weighted average remaining lease term:          
Operating leases   0.25 years    0.5 years 
           
Weighted average discount rate:          
Operating lease   5.75%   5.75%
XML 39 R28.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Common Stock Options (Tables)
 3 Months Ended
Mar. 31, 2024
Equity [Abstract]  
Schedule of Share-Based Compensation, Stock Options Activity

The following is a summary of activity of outstanding stock options:

 

       Weighted 
       Average 
   Number   Exercise 
   of Shares   Prices 
Balance, December 31, 2023   140,750   $1.82 
Options granted   24,000    1.88 
Options cancelled   -    - 
Balance, March 31, 2024   164,750   $1.83 
Exercisable, March 31, 2024   -   $- 
XML 40 R29.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Schedule of Disaggregation of Revenue (Details) - USD ($)
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Product Information [Line Items]    
Net revenues $ 1,752,340 $ 1,188,351
Healthcare Workforce [Member]    
Product Information [Line Items]    
Net revenues 1,417,661 1,110,840
Population Health [Member]    
Product Information [Line Items]    
Net revenues 230,756 74,000
Digital Health [Member]    
Product Information [Line Items]    
Net revenues 92,250
Behavioral and Mental Services [Member]    
Product Information [Line Items]    
Net revenues 1,673 1,730
Health Education [Member]    
Product Information [Line Items]    
Net revenues $ 10,000 $ 1,781
XML 41 R30.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Nature of Business and Significant Accounting Policies (Details Narrative) - USD ($)
 3 Months Ended 12 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Dec. 31, 2023
Product Information [Line Items]      
FDIC insured amount $ 250,000    
Cash equivalents 0   $ 0
Accounts receivable $ 5,520   $ 5,520
Property and equipment useful life 5 years    
Revenues $ 1,752,340 $ 1,188,351  
FSSA – NeuroDiagnostic Institute [Member] | Healthcare Workforce [Member]      
Product Information [Line Items]      
Revenues 1,108,230 1,109,960  
FSSA – Division of Mental Health and Addiction [Member] | Population Health [Member]      
Product Information [Line Items]      
Revenues $ 71,000 $ 74,000  
Customer Concentration Risk [Member] | Revenue Benchmark [Member] | Family and Social Services Administration (FSSA) [Member]      
Product Information [Line Items]      
Risk percentage 67.00% 99.60%  
Customer Concentration Risk [Member] | Accounts Receivable [Member] | Family and Social Services Administration (FSSA) [Member]      
Product Information [Line Items]      
Risk percentage 50.00%   30.00%
XML 42 R31.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Going Concern (Details Narrative) - USD ($)
 3 Months Ended 4 Months Ended
Oct. 03, 2023
Mar. 31, 2024
Mar. 31, 2023
Apr. 30, 2023
Dec. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]          
Cash   $ 3,237,957      
Working capital   3,345,431      
Accumulated deficit   6,512,005     $ 5,064,955
Convertible notes payable   $ 1,255,000 $ 1,455,000  
Proceeds from commnon stock $ 5,332,283        
XML 43 R32.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Related Party Transactions (Details Narrative) - USD ($)
 3 Months Ended
Jul. 01, 2022
May 01, 2022
Mar. 31, 2024
Mar. 31, 2023
Dec. 31, 2023
Jul. 01, 2021
Related Party Transaction [Line Items]            
Lease expense     $ 32,132 $ 128,527    
Service cost     1,573,053 1,041,195    
Sahasra Technologies Corp [Member]            
Related Party Transaction [Line Items]            
Advanced balance of loan     82,214      
ST Logics [Member]            
Related Party Transaction [Line Items]            
Receivable from related party     $ 82,124   $ 50,614  
STVentures [Member]            
Related Party Transaction [Line Items]            
Lease term 3 years   3 years     3 years
Base monthly rent $ 10,711 $ 10,711        
Lease expense     $ 32,132 32,132    
RAD CUBE LLC [Member] | Information Technology Services [Member]            
Related Party Transaction [Line Items]            
Service cost     0 3,320    
NLogix [Member] | Recruitment and Human Resource Services [Member]            
Related Party Transaction [Line Items]            
Service cost     $ 145,318 $ 66,713    
XML 44 R33.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Schedule of Diluted Earnings Per Share (Details) - shares
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Total 1,925,100 28,000
Warrant [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Total 1,760,350
Share-Based Payment Arrangement, Option [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Total 164,750 28,000
XML 45 R34.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Schedule of Other Current Assets (Details) - USD ($)
Mar. 31, 2024
Dec. 31, 2023
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]    
Federal and state income tax receivable [1],[2] $ 148,401 $ 73,069
Prepaid expenses 233,486 316,718
Total other current assets $ 381,887 $ 389,787
[1] Includes $50,000 for a federal refundable payroll tax credit, called the Employee Retention Tax Credit (“ERTC”) Tax Credit, which provides a credit to businesses who kept employees, or were negatively impacted, during the COVID-19 pandemic.
[2] Includes $75,332 for a refundable corporate income tax credit from the State of Indiana, called the Economic Development for a Growing Economy (“EDGE”) Tax Credit, which provides an incentive to businesses to support jobs creation, capital investment and to improve the standard of living for Indiana residents.
XML 46 R35.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Schedule of Property and Equipment (Details) - USD ($)
Mar. 31, 2024
Dec. 31, 2023
Property, Plant and Equipment [Line Items]    
Less: Accumulated depreciation $ (76,371) $ (63,826)
Total property and equipment, net 72,048 78,974
Office Equipment [Member]    
Property, Plant and Equipment [Line Items]    
Office equipment $ 148,419 $ 142,800
XML 47 R36.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Property and Equipment (Details Narrative) - USD ($)
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Property, Plant and Equipment [Abstract]    
Depreciation $ 12,545 $ 11,763
XML 48 R37.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Schedule of Accrued Expenses (Details) - USD ($)
Mar. 31, 2024
Dec. 31, 2023
Payables and Accruals [Abstract]    
Accrued payroll and taxes $ 312,576 $ 148,924
Accrued expenses 7,122 50,054
Total accrued expenses $ 319,698 $ 198,978
XML 49 R38.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Accrued Expenses (Details Narrative)
 3 Months Ended
Mar. 31, 2024
USD ($)
Payables and Accruals [Abstract]  
Employers contribution percentage match 100.00%
Employees contribution percentage 4.00%
Investment retirement account contribution expenses $ 26,485
Accrued retirement contributions $ 0
XML 50 R39.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Schedule of Lease Cost expenses (Details) - USD ($)
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Leases [Abstract]    
Amortization of ROU asset $ 31,373 $ 121,089
Interest on lease liability 759 7,438
Total operating lease cost $ 32,132 $ 128,527
XML 51 R40.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Schedule of Supplemental Balance Sheets Information (Details) - USD ($)
Mar. 31, 2024
Dec. 31, 2023
Leases [Abstract]    
Operating lease assets $ 31,826 $ 63,199
Current portion of operating lease liability, related party 31,826 63,199
Noncurrent operating lease liability, related party
Total operating lease liability $ 31,826 $ 63,199
Weighted-average remaining lease term (in years) (Year) 3 months 6 months
Weighted-average discount rate (Rate) 5.75% 5.75%
XML 52 R41.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Lease (Details Narrative)
 3 Months Ended
Jul. 01, 2022
USD ($)
May 01, 2022
USD ($)
ft²
Jul. 01, 2021
USD ($)
ft²
Mar. 31, 2024
USD ($)
Mar. 31, 2023
USD ($)
Defined Benefit Plan Disclosure [Line Items]          
Lease rent expense       $ 32,132 $ 128,527
STVentures [Member]          
Defined Benefit Plan Disclosure [Line Items]          
Lease term 3 years   3 years 3 years  
Office space | ft²   2,976 5,978    
Base monthly rent $ 10,711 $ 10,711      
Increased base monthly rent     $ 5,332    
Lease rent expense       $ 32,132 $ 32,132
XML 53 R42.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Notes Payable (Details Narrative) - USD ($)
 3 Months Ended 12 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Dec. 31, 2023
Debt Instrument [Line Items]      
Principal repayments $ 85,883    
Interest expense 4,077 $ 11,419  
Notes payable $ 99,021   $ 184,904
Insurance Policy Financing Arrangements [Member]      
Debt Instrument [Line Items]      
Principal amount     370,596
Periodic interest payment     $ 32,328
Insurance Policy Financing Arrangements [Member] | Minimum [Member]      
Debt Instrument [Line Items]      
Interest rate percentage     10.38%
Insurance Policy Financing Arrangements [Member] | Maximum [Member]      
Debt Instrument [Line Items]      
Interest rate percentage     14.05%
XML 54 R43.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Changes in Stockholders’ Equity (Deficit) (Details Narrative) - USD ($)
 3 Months Ended
May 03, 2022
Mar. 31, 2024
Dec. 31, 2023
Class of Stock [Line Items]      
Recognized expense   $ 18,875  
Additional recognized expense at vesting period   $ 48,503  
November 2023 [Member]      
Class of Stock [Line Items]      
Restricted stock awarded   50,000  
Common Class A [Member]      
Class of Stock [Line Items]      
Common stock, shares authorized   100,000,000 100,000,000
Common stock, par value   $ 0.001 $ 0.001
Common stock, shares issued   5,769,087 5,588,298
Common stock, shares outstanding   5,769,087 5,588,298
Common Class A [Member] | Two Investors [Member]      
Class of Stock [Line Items]      
Warrants to purchase   130,789  
Proceeds from issuance of warrants   $ 850,129  
Convertible Common Stock B [Member]      
Class of Stock [Line Items]      
Common stock, shares authorized   5,000,000  
Common stock, par value   $ 0.001  
Common stock, shares issued   833,334  
Common stock, shares outstanding   833,334  
Convertible Class B Common Stock [Member]      
Class of Stock [Line Items]      
Common stock, shares authorized   5,000,000 5,000,000
Common stock, par value   $ 0.001 $ 0.001
Common stock, shares issued 83,334 833,334 833,334
Common stock, shares outstanding   833,334 833,334
Conversion of stock, shares converted 833,334    
XML 55 R44.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Schedule of Share-Based Compensation, Stock Options Activity (Details)
 3 Months Ended
Mar. 31, 2024
$ / shares
shares
Equity [Abstract]  
Number of options, beginning balance | shares 140,750
Weighted average exercise prices, ending balance | $ / shares $ 1.82
Options granted | shares 24,000
Weighted average exercise price, granted | $ / shares $ 1.88
Options cancelled | shares
Weighted average exercise price, cancelled | $ / shares
Number of options, ending balance | shares 164,750
Weighted average exercise prices, ending balance | $ / shares $ 1.83
Exercisable ending balance | shares
Weighted average exercise price, exercisable | $ / shares
XML 56 R45.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Common Stock Options (Details Narrative) - USD ($)
 3 Months Ended
Apr. 11, 2022
Mar. 31, 2024
Mar. 31, 2023
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]      
Shares issued   $ 850,129  
Number of options vested   25.00%  
Expected term   6 years 3 months  
Weighted average volatility rate   110.00%  
Weighted average risk free interest rate   4.16%  
Weighted average call option value   $ 1.498  
Aggregate intrinsic value   $ 35,945  
Stock-based compensation, stock options   14,140 $ 1,367
Unamortized expenses   $ 218,760  
Remaining contractual life   9 years 5 months 1 day  
Omnibus Equity Incentive Plan [Member] | Maximum [Member]      
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]      
Shares issued $ 1,041,667    
2022 Plan [Member]      
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]      
Granted options   24,000  
Exercise price   $ 1.88  
Granted options term   10 years  
EXCEL 57 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 58 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 59 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 61 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1.u1 html 102 211 1 true 39 0 false 5 false false R1.htm 00000001 - Document - Cover Sheet http://syrahealth.com/role/Cover Cover Cover 1 false false R2.htm 00000002 - Statement - Condensed Balance Sheets Sheet http://syrahealth.com/role/BalanceSheets Condensed Balance Sheets Statements 2 false false R3.htm 00000003 - Statement - Condensed Balance Sheets (Parenthetical) Sheet http://syrahealth.com/role/BalanceSheetsParenthetical Condensed Balance Sheets (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - Condensed Statements of Operations (Unaudited) Sheet http://syrahealth.com/role/StatementsOfOperations Condensed Statements of Operations (Unaudited) Statements 4 false false R5.htm 00000005 - Statement - Statements of Changes in Stockholders' Equity (Deficit) (Unaudited) Sheet http://syrahealth.com/role/StatementsOfChangesInStockholdersEquityDeficit Statements of Changes in Stockholders' Equity (Deficit) (Unaudited) Statements 5 false false R6.htm 00000006 - Statement - Condensed Statements of Cash Flows (Unaudited) Sheet http://syrahealth.com/role/StatementsOfCashFlows Condensed Statements of Cash Flows (Unaudited) Statements 6 false false R7.htm 00000007 - Disclosure - Nature of Business and Significant Accounting Policies Sheet http://syrahealth.com/role/NatureOfBusinessAndSignificantAccountingPolicies Nature of Business and Significant Accounting Policies Notes 7 false false R8.htm 00000008 - Disclosure - Going Concern Sheet http://syrahealth.com/role/GoingConcern Going Concern Notes 8 false false R9.htm 00000009 - Disclosure - Related Party Transactions Sheet http://syrahealth.com/role/RelatedPartyTransactions Related Party Transactions Notes 9 false false R10.htm 00000010 - Disclosure - Basic and Diluted Earnings per Share Sheet http://syrahealth.com/role/BasicAndDilutedEarningsPerShare Basic and Diluted Earnings per Share Notes 10 false false R11.htm 00000011 - Disclosure - Other Current Assets Sheet http://syrahealth.com/role/OtherCurrentAssets Other Current Assets Notes 11 false false R12.htm 00000012 - Disclosure - Other Current Assets (Parenthetical) Sheet http://syrahealth.com/role/OtherCurrentAssetsParenthetical Other Current Assets (Parenthetical) Notes 12 false false R13.htm 00000013 - Disclosure - Property and Equipment Sheet http://syrahealth.com/role/PropertyAndEquipment Property and Equipment Notes 13 false false R14.htm 00000014 - Disclosure - Accrued Expenses Sheet http://syrahealth.com/role/AccruedExpenses Accrued Expenses Notes 14 false false R15.htm 00000015 - Disclosure - Lease Sheet http://syrahealth.com/role/Lease Lease Notes 15 false false R16.htm 00000016 - Disclosure - Notes Payable Notes http://syrahealth.com/role/NotesPayable Notes Payable Notes 16 false false R17.htm 00000017 - Disclosure - Commitments and Contingencies Sheet http://syrahealth.com/role/CommitmentsAndContingencies Commitments and Contingencies Notes 17 false false R18.htm 00000018 - Disclosure - Changes in Stockholders??? Equity (Deficit) Sheet http://syrahealth.com/role/ChangesInStockholdersEquityDeficit Changes in Stockholders??? Equity (Deficit) Notes 18 false false R19.htm 00000019 - Disclosure - Common Stock Options Sheet http://syrahealth.com/role/CommonStockOptions Common Stock Options Notes 19 false false R20.htm 00000020 - Disclosure - Subsequent Events Sheet http://syrahealth.com/role/SubsequentEvents Subsequent Events Notes 20 false false R21.htm 00000021 - Disclosure - Nature of Business and Significant Accounting Policies (Policies) Sheet http://syrahealth.com/role/NatureOfBusinessAndSignificantAccountingPoliciesPolicies Nature of Business and Significant Accounting Policies (Policies) Policies http://syrahealth.com/role/NatureOfBusinessAndSignificantAccountingPolicies 21 false false R22.htm 00000022 - Disclosure - Nature of Business and Significant Accounting Policies (Tables) Sheet http://syrahealth.com/role/NatureOfBusinessAndSignificantAccountingPoliciesTables Nature of Business and Significant Accounting Policies (Tables) Tables http://syrahealth.com/role/NatureOfBusinessAndSignificantAccountingPolicies 22 false false R23.htm 00000023 - Disclosure - Basic and Diluted Earnings per Share (Tables) Sheet http://syrahealth.com/role/BasicAndDilutedEarningsPerShareTables Basic and Diluted Earnings per Share (Tables) Tables http://syrahealth.com/role/BasicAndDilutedEarningsPerShare 23 false false R24.htm 00000024 - Disclosure - Other Current Assets (Tables) Sheet http://syrahealth.com/role/OtherCurrentAssetsTables Other Current Assets (Tables) Tables http://syrahealth.com/role/OtherCurrentAssets 24 false false R25.htm 00000025 - Disclosure - Property and Equipment (Tables) Sheet http://syrahealth.com/role/PropertyAndEquipmentTables Property and Equipment (Tables) Tables http://syrahealth.com/role/PropertyAndEquipment 25 false false R26.htm 00000026 - Disclosure - Accrued Expenses (Tables) Sheet http://syrahealth.com/role/AccruedExpensesTables Accrued Expenses (Tables) Tables http://syrahealth.com/role/AccruedExpenses 26 false false R27.htm 00000027 - Disclosure - Lease (Tables) Sheet http://syrahealth.com/role/LeaseTables Lease (Tables) Tables http://syrahealth.com/role/Lease 27 false false R28.htm 00000028 - Disclosure - Common Stock Options (Tables) Sheet http://syrahealth.com/role/CommonStockOptionsTables Common Stock Options (Tables) Tables http://syrahealth.com/role/CommonStockOptions 28 false false R29.htm 00000029 - Disclosure - Schedule of Disaggregation of Revenue (Details) Sheet http://syrahealth.com/role/ScheduleOfDisaggregationOfRevenueDetails Schedule of Disaggregation of Revenue (Details) Details 29 false false R30.htm 00000030 - Disclosure - Nature of Business and Significant Accounting Policies (Details Narrative) Sheet http://syrahealth.com/role/NatureOfBusinessAndSignificantAccountingPoliciesDetailsNarrative Nature of Business and Significant Accounting Policies (Details Narrative) Details http://syrahealth.com/role/NatureOfBusinessAndSignificantAccountingPoliciesTables 30 false false R31.htm 00000031 - Disclosure - Going Concern (Details Narrative) Sheet http://syrahealth.com/role/GoingConcernDetailsNarrative Going Concern (Details Narrative) Details http://syrahealth.com/role/GoingConcern 31 false false R32.htm 00000032 - Disclosure - Related Party Transactions (Details Narrative) Sheet http://syrahealth.com/role/RelatedPartyTransactionsDetailsNarrative Related Party Transactions (Details Narrative) Details http://syrahealth.com/role/RelatedPartyTransactions 32 false false R33.htm 00000033 - Disclosure - Schedule of Diluted Earnings Per Share (Details) Sheet http://syrahealth.com/role/ScheduleOfDilutedEarningsPerShareDetails Schedule of Diluted Earnings Per Share (Details) Details 33 false false R34.htm 00000034 - Disclosure - Schedule of Other Current Assets (Details) Sheet http://syrahealth.com/role/ScheduleOfOtherCurrentAssetsDetails Schedule of Other Current Assets (Details) Details 34 false false R35.htm 00000035 - Disclosure - Schedule of Property and Equipment (Details) Sheet http://syrahealth.com/role/ScheduleOfPropertyAndEquipmentDetails Schedule of Property and Equipment (Details) Details 35 false false R36.htm 00000036 - Disclosure - Property and Equipment (Details Narrative) Sheet http://syrahealth.com/role/PropertyAndEquipmentDetailsNarrative Property and Equipment (Details Narrative) Details http://syrahealth.com/role/PropertyAndEquipmentTables 36 false false R37.htm 00000037 - Disclosure - Schedule of Accrued Expenses (Details) Sheet http://syrahealth.com/role/ScheduleOfAccruedExpensesDetails Schedule of Accrued Expenses (Details) Details 37 false false R38.htm 00000038 - Disclosure - Accrued Expenses (Details Narrative) Sheet http://syrahealth.com/role/AccruedExpensesDetailsNarrative Accrued Expenses (Details Narrative) Details http://syrahealth.com/role/AccruedExpensesTables 38 false false R39.htm 00000039 - Disclosure - Schedule of Lease Cost expenses (Details) Sheet http://syrahealth.com/role/ScheduleOfLeaseCostExpensesDetails Schedule of Lease Cost expenses (Details) Details 39 false false R40.htm 00000040 - Disclosure - Schedule of Supplemental Balance Sheets Information (Details) Sheet http://syrahealth.com/role/ScheduleOfSupplementalBalanceSheetsInformationDetails Schedule of Supplemental Balance Sheets Information (Details) Details 40 false false R41.htm 00000041 - Disclosure - Lease (Details Narrative) Sheet http://syrahealth.com/role/LeaseDetailsNarrative Lease (Details Narrative) Details http://syrahealth.com/role/LeaseTables 41 false false R42.htm 00000042 - Disclosure - Notes Payable (Details Narrative) Notes http://syrahealth.com/role/NotesPayableDetailsNarrative Notes Payable (Details Narrative) Details http://syrahealth.com/role/NotesPayable 42 false false R43.htm 00000043 - Disclosure - Changes in Stockholders??? Equity (Deficit) (Details Narrative) Sheet http://syrahealth.com/role/ChangesInStockholdersEquityDeficitDetailsNarrative Changes in Stockholders??? Equity (Deficit) (Details Narrative) Details http://syrahealth.com/role/ChangesInStockholdersEquityDeficit 43 false false R44.htm 00000044 - Disclosure - Schedule of Share-Based Compensation, Stock Options Activity (Details) Sheet http://syrahealth.com/role/ScheduleOfShare-basedCompensationStockOptionsActivityDetails Schedule of Share-Based Compensation, Stock Options Activity (Details) Details 44 false false R45.htm 00000045 - Disclosure - Common Stock Options (Details Narrative) Sheet http://syrahealth.com/role/CommonStockOptionsDetailsNarrative Common Stock Options (Details Narrative) Details http://syrahealth.com/role/CommonStockOptionsTables 45 false false All Reports Book All Reports [ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 4 fact(s) appearing in ix:hidden were eligible for transformation: us-gaap:LesseeOperatingLeaseTermOfContract, us-gaap:PropertyPlantAndEquipmentUsefulLife - form10-q.htm 81, 83, 85, 86 form10-q.htm syra-20240331.xsd syra-20240331_cal.xml syra-20240331_def.xml syra-20240331_lab.xml syra-20240331_pre.xml http://fasb.org/us-gaap/2024 http://xbrl.sec.gov/dei/2024 true true JSON 64 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "form10-q.htm": { "nsprefix": "SYRA", "nsuri": "http://syrahealth.com/20240331", "dts": { "inline": { "local": [ "form10-q.htm" ] }, "schema": { "local": [ "syra-20240331.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd", "https://xbrl.sec.gov/country/2024/country-2024.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd", "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd" ] }, "calculationLink": { "local": [ "syra-20240331_cal.xml" ] }, "definitionLink": { "local": [ "syra-20240331_def.xml" ] }, "labelLink": { "local": [ "syra-20240331_lab.xml" ] }, "presentationLink": { "local": [ "syra-20240331_pre.xml" ] } }, "keyStandard": 199, "keyCustom": 12, "axisStandard": 14, "axisCustom": 0, "memberStandard": 15, "memberCustom": 24, "hidden": { "total": 68, "http://fasb.org/us-gaap/2024": 64, "http://xbrl.sec.gov/dei/2024": 4 }, "contextCount": 102, "entityCount": 1, "segmentCount": 39, "elementCount": 357, "unitCount": 5, "baseTaxonomies": { "http://fasb.org/us-gaap/2024": 432, "http://xbrl.sec.gov/dei/2024": 31 }, "report": { "R1": { "role": "http://syrahealth.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "From2024-01-01to2024-03-31", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-03-31", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R2": { "role": "http://syrahealth.com/role/BalanceSheets", "longName": "00000002 - Statement - Condensed Balance Sheets", "shortName": "Condensed Balance Sheets", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "AsOf2024-03-31", "name": "us-gaap:Cash", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-03-31", "name": "us-gaap:Cash", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R3": { "role": "http://syrahealth.com/role/BalanceSheetsParenthetical", "longName": "00000003 - Statement - Condensed Balance Sheets (Parenthetical)", "shortName": "Condensed Balance Sheets (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "AsOf2024-03-31", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "unitRef": "USDPShares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-03-31", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "unitRef": "USDPShares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R4": { "role": "http://syrahealth.com/role/StatementsOfOperations", "longName": "00000004 - Statement - Condensed Statements of Operations (Unaudited)", "shortName": "Condensed Statements of Operations (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "From2024-01-01to2024-03-31", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-03-31", "name": "us-gaap:GrossProfit", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "unique": true } }, "R5": { "role": "http://syrahealth.com/role/StatementsOfChangesInStockholdersEquityDeficit", "longName": "00000005 - Statement - Statements of Changes in Stockholders' Equity (Deficit) (Unaudited)", "shortName": "Statements of Changes in Stockholders' Equity (Deficit) (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "AsOf2022-12-31_us-gaap_CommonStockMember_us-gaap_CommonClassAMember", "name": "us-gaap:StockholdersEquity", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2022-12-31_us-gaap_CommonStockMember_us-gaap_CommonClassAMember", "name": "us-gaap:StockholdersEquity", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R6": { "role": "http://syrahealth.com/role/StatementsOfCashFlows", "longName": "00000006 - Statement - Condensed Statements of Cash Flows (Unaudited)", "shortName": "Condensed Statements of Cash Flows (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "From2024-01-01to2024-03-31", "name": "us-gaap:NetIncomeLoss", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-03-31", "name": "us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "unique": true } }, "R7": { "role": "http://syrahealth.com/role/NatureOfBusinessAndSignificantAccountingPolicies", "longName": "00000007 - Disclosure - Nature of Business and Significant Accounting Policies", "shortName": "Nature of Business and Significant Accounting Policies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "7", "firstAnchor": { "contextRef": "From2024-01-01to2024-03-31", "name": "us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-03-31", "name": "us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R8": { "role": "http://syrahealth.com/role/GoingConcern", "longName": "00000008 - Disclosure - Going Concern", "shortName": "Going Concern", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "From2024-01-01to2024-03-31", "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-03-31", "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R9": { "role": "http://syrahealth.com/role/RelatedPartyTransactions", "longName": "00000009 - Disclosure - Related Party Transactions", "shortName": "Related Party Transactions", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "From2024-01-01to2024-03-31", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-03-31", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R10": { "role": "http://syrahealth.com/role/BasicAndDilutedEarningsPerShare", "longName": "00000010 - Disclosure - Basic and Diluted Earnings per Share", "shortName": "Basic and Diluted Earnings per Share", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "From2024-01-01to2024-03-31", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-03-31", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R11": { "role": "http://syrahealth.com/role/OtherCurrentAssets", "longName": "00000011 - Disclosure - Other Current Assets", "shortName": "Other Current Assets", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "From2024-01-01to2024-03-31", "name": "us-gaap:OtherCurrentAssetsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-03-31", "name": "us-gaap:OtherCurrentAssetsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R12": { "role": "http://syrahealth.com/role/OtherCurrentAssetsParenthetical", "longName": "00000012 - Disclosure - Other Current Assets (Parenthetical)", "shortName": "Other Current Assets (Parenthetical)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "parenthetical", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "From2024-01-012024-03-31_custom_EmployeeRetentionTaxCreditMember", "name": "us-gaap:IncomeTaxReconciliationTaxCredits", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "link:footnote", "span", "td", "tr", "table", "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock", "us-gaap:OtherCurrentAssetsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-012024-03-31_custom_EmployeeRetentionTaxCreditMember", "name": "us-gaap:IncomeTaxReconciliationTaxCredits", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "link:footnote", "span", "td", "tr", "table", "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock", "us-gaap:OtherCurrentAssetsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R13": { "role": "http://syrahealth.com/role/PropertyAndEquipment", "longName": "00000013 - Disclosure - Property and Equipment", "shortName": "Property and Equipment", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "From2024-01-01to2024-03-31", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-03-31", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R14": { "role": "http://syrahealth.com/role/AccruedExpenses", "longName": "00000014 - Disclosure - Accrued Expenses", "shortName": "Accrued Expenses", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "From2024-01-01to2024-03-31", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-03-31", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R15": { "role": "http://syrahealth.com/role/Lease", "longName": "00000015 - Disclosure - Lease", "shortName": "Lease", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "From2024-01-01to2024-03-31", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-03-31", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R16": { "role": "http://syrahealth.com/role/NotesPayable", "longName": "00000016 - Disclosure - Notes Payable", "shortName": "Notes Payable", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "From2024-01-01to2024-03-31", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-03-31", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R17": { "role": "http://syrahealth.com/role/CommitmentsAndContingencies", "longName": "00000017 - Disclosure - Commitments and Contingencies", "shortName": "Commitments and Contingencies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "From2024-01-01to2024-03-31", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-03-31", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R18": { "role": "http://syrahealth.com/role/ChangesInStockholdersEquityDeficit", "longName": "00000018 - Disclosure - Changes in Stockholders\u2019 Equity (Deficit)", "shortName": "Changes in Stockholders\u2019 Equity (Deficit)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "From2024-01-01to2024-03-31", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-03-31", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R19": { "role": "http://syrahealth.com/role/CommonStockOptions", "longName": "00000019 - Disclosure - Common Stock Options", "shortName": "Common Stock Options", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "From2024-01-01to2024-03-31", "name": "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-03-31", "name": "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R20": { "role": "http://syrahealth.com/role/SubsequentEvents", "longName": "00000020 - Disclosure - Subsequent Events", "shortName": "Subsequent Events", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "From2024-01-01to2024-03-31", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-03-31", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R21": { "role": "http://syrahealth.com/role/NatureOfBusinessAndSignificantAccountingPoliciesPolicies", "longName": "00000021 - Disclosure - Nature of Business and Significant Accounting Policies (Policies)", "shortName": "Nature of Business and Significant Accounting Policies (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "21", "firstAnchor": { "contextRef": "From2024-01-01to2024-03-31", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-03-31", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R22": { "role": "http://syrahealth.com/role/NatureOfBusinessAndSignificantAccountingPoliciesTables", "longName": "00000022 - Disclosure - Nature of Business and Significant Accounting Policies (Tables)", "shortName": "Nature of Business and Significant Accounting Policies (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "22", "firstAnchor": { "contextRef": "From2024-01-01to2024-03-31", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:RevenueFromContractWithCustomerPolicyTextBlock", "us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-03-31", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:RevenueFromContractWithCustomerPolicyTextBlock", "us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R23": { "role": "http://syrahealth.com/role/BasicAndDilutedEarningsPerShareTables", "longName": "00000023 - Disclosure - Basic and Diluted Earnings per Share (Tables)", "shortName": "Basic and Diluted Earnings per Share (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "23", "firstAnchor": { "contextRef": "From2024-01-01to2024-03-31", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-03-31", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R24": { "role": "http://syrahealth.com/role/OtherCurrentAssetsTables", "longName": "00000024 - Disclosure - Other Current Assets (Tables)", "shortName": "Other Current Assets (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "24", "firstAnchor": { "contextRef": "From2024-01-01to2024-03-31", "name": "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:OtherCurrentAssetsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-03-31", "name": "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:OtherCurrentAssetsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R25": { "role": "http://syrahealth.com/role/PropertyAndEquipmentTables", "longName": "00000025 - Disclosure - Property and Equipment (Tables)", "shortName": "Property and Equipment (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "25", "firstAnchor": { "contextRef": "From2024-01-01to2024-03-31", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-03-31", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R26": { "role": "http://syrahealth.com/role/AccruedExpensesTables", "longName": "00000026 - Disclosure - Accrued Expenses (Tables)", "shortName": "Accrued Expenses (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "26", "firstAnchor": { "contextRef": "From2024-01-01to2024-03-31", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-03-31", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R27": { "role": "http://syrahealth.com/role/LeaseTables", "longName": "00000027 - Disclosure - Lease (Tables)", "shortName": "Lease (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "27", "firstAnchor": { "contextRef": "From2024-01-01to2024-03-31", "name": "us-gaap:LeaseCostTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-03-31", "name": "us-gaap:LeaseCostTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R28": { "role": "http://syrahealth.com/role/CommonStockOptionsTables", "longName": "00000028 - Disclosure - Common Stock Options (Tables)", "shortName": "Common Stock Options (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "28", "firstAnchor": { "contextRef": "From2024-01-01to2024-03-31", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-03-31", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R29": { "role": "http://syrahealth.com/role/ScheduleOfDisaggregationOfRevenueDetails", "longName": "00000029 - Disclosure - Schedule of Disaggregation of Revenue (Details)", "shortName": "Schedule of Disaggregation of Revenue (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "29", "firstAnchor": { "contextRef": "From2024-01-01to2024-03-31", "name": "us-gaap:Revenues", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "us-gaap:DisaggregationOfRevenueTableTextBlock", "us-gaap:RevenueFromContractWithCustomerPolicyTextBlock", "us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-03-31", "name": "us-gaap:Revenues", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "us-gaap:DisaggregationOfRevenueTableTextBlock", "us-gaap:RevenueFromContractWithCustomerPolicyTextBlock", "us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R30": { "role": "http://syrahealth.com/role/NatureOfBusinessAndSignificantAccountingPoliciesDetailsNarrative", "longName": "00000030 - Disclosure - Nature of Business and Significant Accounting Policies (Details Narrative)", "shortName": "Nature of Business and Significant Accounting Policies (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "30", "firstAnchor": { "contextRef": "AsOf2024-03-31", "name": "us-gaap:CashFDICInsuredAmount", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "span", "p", "us-gaap:ConcentrationRiskCreditRisk", "us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-03-31", "name": "us-gaap:CashFDICInsuredAmount", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "span", "p", "us-gaap:ConcentrationRiskCreditRisk", "us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R31": { "role": "http://syrahealth.com/role/GoingConcernDetailsNarrative", "longName": "00000031 - Disclosure - Going Concern (Details Narrative)", "shortName": "Going Concern (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "31", "firstAnchor": { "contextRef": "AsOf2024-03-31", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "span", "p", "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-03-31", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "span", "p", "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R32": { "role": "http://syrahealth.com/role/RelatedPartyTransactionsDetailsNarrative", "longName": "00000032 - Disclosure - Related Party Transactions (Details Narrative)", "shortName": "Related Party Transactions (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "32", "firstAnchor": { "contextRef": "From2024-01-01to2024-03-31", "name": "us-gaap:OperatingLeaseExpense", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "us-gaap:LeaseCostTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2024-01-012024-03-31_custom_SahasraTechnologiesCorpMember", "name": "us-gaap:LoansAssumed1", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "span", "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "unique": true } }, "R33": { "role": "http://syrahealth.com/role/ScheduleOfDilutedEarningsPerShareDetails", "longName": "00000033 - Disclosure - Schedule of Diluted Earnings Per Share (Details)", "shortName": "Schedule of Diluted Earnings Per Share (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "33", "firstAnchor": { "contextRef": "From2024-01-01to2024-03-31", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-03-31", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R34": { "role": "http://syrahealth.com/role/ScheduleOfOtherCurrentAssetsDetails", "longName": "00000034 - Disclosure - Schedule of Other Current Assets (Details)", "shortName": "Schedule of Other Current Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "34", "firstAnchor": { "contextRef": "AsOf2024-03-31", "name": "us-gaap:PrepaidTaxes", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock", "us-gaap:OtherCurrentAssetsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-03-31", "name": "us-gaap:PrepaidTaxes", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock", "us-gaap:OtherCurrentAssetsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R35": { "role": "http://syrahealth.com/role/ScheduleOfPropertyAndEquipmentDetails", "longName": "00000035 - Disclosure - Schedule of Property and Equipment (Details)", "shortName": "Schedule of Property and Equipment (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "35", "firstAnchor": { "contextRef": "AsOf2024-03-31", "name": "us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-03-31", "name": "us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R36": { "role": "http://syrahealth.com/role/PropertyAndEquipmentDetailsNarrative", "longName": "00000036 - Disclosure - Property and Equipment (Details Narrative)", "shortName": "Property and Equipment (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "36", "firstAnchor": { "contextRef": "From2024-01-01to2024-03-31", "name": "us-gaap:Depreciation", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true }, "uniqueAnchor": null }, "R37": { "role": "http://syrahealth.com/role/ScheduleOfAccruedExpensesDetails", "longName": "00000037 - Disclosure - Schedule of Accrued Expenses (Details)", "shortName": "Schedule of Accrued Expenses (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "37", "firstAnchor": { "contextRef": "AsOf2024-03-31", "name": "us-gaap:AccruedPayrollTaxesCurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-03-31", "name": "us-gaap:AccruedPayrollTaxesCurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R38": { "role": "http://syrahealth.com/role/AccruedExpensesDetailsNarrative", "longName": "00000038 - Disclosure - Accrued Expenses (Details Narrative)", "shortName": "Accrued Expenses (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "38", "firstAnchor": { "contextRef": "From2024-01-01to2024-03-31", "name": "us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "p", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-03-31", "name": "us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "p", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R39": { "role": "http://syrahealth.com/role/ScheduleOfLeaseCostExpensesDetails", "longName": "00000039 - Disclosure - Schedule of Lease Cost expenses (Details)", "shortName": "Schedule of Lease Cost expenses (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "39", "firstAnchor": { "contextRef": "From2024-01-01to2024-03-31", "name": "us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "us-gaap:LeaseCostTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-03-31", "name": "us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "us-gaap:LeaseCostTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R40": { "role": "http://syrahealth.com/role/ScheduleOfSupplementalBalanceSheetsInformationDetails", "longName": "00000040 - Disclosure - Schedule of Supplemental Balance Sheets Information (Details)", "shortName": "Schedule of Supplemental Balance Sheets Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "40", "firstAnchor": { "contextRef": "AsOf2024-03-31", "name": "us-gaap:OperatingLeaseRightOfUseAsset", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2024-03-31", "name": "us-gaap:OperatingLeaseLiability", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "SYRA:SupplementalBalanceSheetsInformationTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "unique": true } }, "R41": { "role": "http://syrahealth.com/role/LeaseDetailsNarrative", "longName": "00000041 - Disclosure - Lease (Details Narrative)", "shortName": "Lease (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "41", "firstAnchor": { "contextRef": "From2024-01-01to2024-03-31", "name": "us-gaap:OperatingLeaseExpense", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "us-gaap:LeaseCostTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2022-05-01_custom_STVenturesMember", "name": "us-gaap:AreaOfLand", "unitRef": "Sqft", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "p", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "unique": true } }, "R42": { "role": "http://syrahealth.com/role/NotesPayableDetailsNarrative", "longName": "00000042 - Disclosure - Notes Payable (Details Narrative)", "shortName": "Notes Payable (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "42", "firstAnchor": { "contextRef": "From2024-01-01to2024-03-31", "name": "us-gaap:RepaymentsOfDebt", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "span", "p", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-03-31", "name": "us-gaap:RepaymentsOfDebt", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "span", "p", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R43": { "role": "http://syrahealth.com/role/ChangesInStockholdersEquityDeficitDetailsNarrative", "longName": "00000043 - Disclosure - Changes in Stockholders\u2019 Equity (Deficit) (Details Narrative)", "shortName": "Changes in Stockholders\u2019 Equity (Deficit) (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "43", "firstAnchor": { "contextRef": "From2024-01-01to2024-03-31", "name": "SYRA:RecognizedExpense", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-03-31", "name": "SYRA:RecognizedExpense", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R44": { "role": "http://syrahealth.com/role/ScheduleOfShare-basedCompensationStockOptionsActivityDetails", "longName": "00000044 - Disclosure - Schedule of Share-Based Compensation, Stock Options Activity (Details)", "shortName": "Schedule of Share-Based Compensation, Stock Options Activity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "44", "firstAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R45": { "role": "http://syrahealth.com/role/CommonStockOptionsDetailsNarrative", "longName": "00000045 - Disclosure - Common Stock Options (Details Narrative)", "shortName": "Common Stock Options (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "45", "firstAnchor": { "contextRef": "From2024-01-01to2024-03-31", "name": "us-gaap:StockIssuedDuringPeriodValueNewIssues", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-03-31", "name": "SYRA:NumberOfOptionsVested", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "p", "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "unique": true } } }, "tag": { "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountingPoliciesAbstract", "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "presentation": [ "http://syrahealth.com/role/AccruedExpenses" ], "lang": { "en-us": { "role": { "label": "Accrued Expenses", "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period." } } }, "auth_ref": [ "r47", "r49", "r53", "r672" ] }, "us-gaap_AccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableCurrent", "crdr": "credit", "calculation": { "http://syrahealth.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://syrahealth.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Accounts payable", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r47", "r564" ] }, "us-gaap_AccountsReceivableMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsReceivableMember", "presentation": [ "http://syrahealth.com/role/NatureOfBusinessAndSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Accounts Receivable [Member]", "documentation": "Due from customers or clients for goods or services that have been delivered or sold." } } }, "auth_ref": [ "r528" ] }, "us-gaap_AccountsReceivableNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsReceivableNet", "crdr": "debit", "presentation": [ "http://syrahealth.com/role/NatureOfBusinessAndSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "verboseLabel": "Accounts receivable", "label": "Accounts Receivable, after Allowance for Credit Loss", "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business." } } }, "auth_ref": [ "r472", "r527", "r575", "r695", "r696" ] }, "us-gaap_AccountsReceivableNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsReceivableNetCurrent", "crdr": "debit", "calculation": { "http://syrahealth.com/role/BalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://syrahealth.com/role/BalanceSheets", "http://syrahealth.com/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Accounts receivable", "verboseLabel": "Receivable from related party", "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current." } } }, "auth_ref": [ "r631" ] }, "us-gaap_AccruedEmployeeBenefitsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedEmployeeBenefitsCurrent", "crdr": "credit", "calculation": { "http://syrahealth.com/role/ScheduleOfAccruedExpensesDetails": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://syrahealth.com/role/ScheduleOfAccruedExpensesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Accrued expenses", "label": "Accrued Employee Benefits, Current", "documentation": "Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r49" ] }, "us-gaap_AccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://syrahealth.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 2.0 }, "http://syrahealth.com/role/ScheduleOfAccruedExpensesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://syrahealth.com/role/BalanceSheets", "http://syrahealth.com/role/ScheduleOfAccruedExpensesDetails" ], "lang": { "en-us": { "role": { "label": "Accrued expenses", "totalLabel": "Total accrued expenses", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r49" ] }, "us-gaap_AccruedPayrollTaxesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedPayrollTaxesCurrent", "crdr": "credit", "calculation": { "http://syrahealth.com/role/ScheduleOfAccruedExpensesDetails": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://syrahealth.com/role/ScheduleOfAccruedExpensesDetails" ], "lang": { "en-us": { "role": { "label": "Accrued payroll and taxes", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory payroll taxes incurred through that date and withheld from employees pertaining to services received from them, including entity's matching share of the employees FICA taxes and contributions to the state and federal unemployment insurance programs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r49" ] }, "SYRA_AccruedRetirementContributions": { "xbrltype": "monetaryItemType", "nsuri": "http://syrahealth.com/20240331", "localname": "AccruedRetirementContributions", "crdr": "credit", "presentation": [ "http://syrahealth.com/role/AccruedExpensesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Accrued retirement contributions", "documentation": "Accrued retirement contributions." } } }, "auth_ref": [] }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "crdr": "credit", "presentation": [ "http://syrahealth.com/role/ScheduleOfPropertyAndEquipmentDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Less: Accumulated depreciation", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services." } } }, "auth_ref": [ "r29", "r122", "r409" ] }, "us-gaap_AdditionalPaidInCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapital", "crdr": "credit", "calculation": { "http://syrahealth.com/role/BalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://syrahealth.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Additional paid-in capital", "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock." } } }, "auth_ref": [ "r58", "r564", "r727" ] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapitalMember", "presentation": [ "http://syrahealth.com/role/StatementsOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Additional Paid-in Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": [ "r440", "r621", "r622", "r623", "r624", "r674", "r730" ] }, "SYRA_AdditionalRecognizedExpenseAtVestingPeriod": { "xbrltype": "monetaryItemType", "nsuri": "http://syrahealth.com/20240331", "localname": "AdditionalRecognizedExpenseAtVestingPeriod", "crdr": "debit", "presentation": [ "http://syrahealth.com/role/ChangesInStockholdersEquityDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Additional recognized expense at vesting period", "documentation": "Additional recognized expense at vesting period." } } }, "auth_ref": [] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition", "crdr": "credit", "presentation": [ "http://syrahealth.com/role/StatementsOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Class A common stock options issued for services", "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement." } } }, "auth_ref": [] }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://syrahealth.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Adjustments to reconcile net loss to net cash used in operating activities:" } } }, "auth_ref": [] }, "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentDescription", "presentation": [ "http://syrahealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": [ "http://syrahealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AnnualInformationForm", "presentation": [ "http://syrahealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r597" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": [ "http://syrahealth.com/role/ScheduleOfDilutedEarningsPerShareDetails" ], "lang": { "en-us": { "role": { "label": "Total", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": [ "r173" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "presentation": [ "http://syrahealth.com/role/ScheduleOfDilutedEarningsPerShareDetails" ], "lang": { "en-us": { "role": { "label": "Antidilutive Securities [Axis]", "documentation": "Information by type of antidilutive security." } } }, "auth_ref": [ "r21" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "presentation": [ "http://syrahealth.com/role/ScheduleOfDilutedEarningsPerShareDetails" ], "lang": { "en-us": { "role": { "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesNameDomain", "presentation": [ "http://syrahealth.com/role/ScheduleOfDilutedEarningsPerShareDetails" ], "lang": { "en-us": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } }, "auth_ref": [ "r21" ] }, "us-gaap_AreaOfLand": { "xbrltype": "areaItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AreaOfLand", "presentation": [ "http://syrahealth.com/role/LeaseDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Office space", "documentation": "Area of land held." } } }, "auth_ref": [] }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ArrangementsAndNonarrangementTransactionsMember", "presentation": [ "http://syrahealth.com/role/NotesPayableDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": [ "r347" ] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Assets", "crdr": "debit", "calculation": { "http://syrahealth.com/role/BalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://syrahealth.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total assets", "label": "Assets", "documentation": "Amount of asset recognized for present right to economic benefit." } } }, "auth_ref": [ "r92", "r101", "r123", "r146", "r178", "r182", "r196", "r197", "r203", "r222", "r223", "r224", "r225", "r226", "r227", "r228", "r229", "r230", "r348", "r350", "r363", "r399", "r477", "r544", "r545", "r564", "r582", "r642", "r643", "r683" ] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsAbstract", "presentation": [ "http://syrahealth.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "ASSETS" } } }, "auth_ref": [] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrent", "crdr": "debit", "calculation": { "http://syrahealth.com/role/BalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://syrahealth.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total current assets", "label": "Assets, Current", "documentation": "Amount of asset recognized for present right to economic benefit, classified as current." } } }, "auth_ref": [ "r118", "r129", "r146", "r203", "r222", "r223", "r224", "r225", "r226", "r227", "r228", "r229", "r230", "r348", "r350", "r363", "r564", "r642", "r643", "r683" ] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrentAbstract", "presentation": [ "http://syrahealth.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Current assets:" } } }, "auth_ref": [] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://syrahealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r597" ] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AwardTypeAxis", "presentation": [ "http://syrahealth.com/role/ChangesInStockholdersEquityDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Award Type [Axis]", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": [ "r292", "r293", "r294", "r296", "r297", "r298", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r316", "r317", "r318", "r319", "r320" ] }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BasisOfAccountingPolicyPolicyTextBlock", "presentation": [ "http://syrahealth.com/role/NatureOfBusinessAndSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Basis of Presentation", "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } }, "auth_ref": [] }, "SYRA_BehavioralAndMentalServicesMember": { "xbrltype": "domainItemType", "nsuri": "http://syrahealth.com/20240331", "localname": "BehavioralAndMentalServicesMember", "presentation": [ "http://syrahealth.com/role/ScheduleOfDisaggregationOfRevenueDetails" ], "lang": { "en-us": { "role": { "label": "Behavioral and Mental Services [Member]", "documentation": "Behavioral and Mental Services [Member]" } } }, "auth_ref": [] }, "us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessDescriptionAndAccountingPoliciesTextBlock", "presentation": [ "http://syrahealth.com/role/NatureOfBusinessAndSignificantAccountingPolicies" ], "lang": { "en-us": { "role": { "label": "Nature of Business and Significant Accounting Policies", "documentation": "The entire disclosure for the business description and accounting policies concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Accounting policies describe all significant accounting policies of the reporting entity." } } }, "auth_ref": [ "r75", "r76" ] }, "us-gaap_Cash": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Cash", "crdr": "debit", "calculation": { "http://syrahealth.com/role/BalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://syrahealth.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Cash", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r105", "r402", "r451", "r471", "r564", "r582", "r608" ] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "presentation": [ "http://syrahealth.com/role/GoingConcernDetailsNarrative" ], "lang": { "en-us": { "role": { "verboseLabel": "Cash", "label": "Cash and Cash Equivalents, at Carrying Value", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r15", "r120", "r536" ] }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsPolicyTextBlock", "presentation": [ "http://syrahealth.com/role/NatureOfBusinessAndSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents", "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value." } } }, "auth_ref": [ "r16" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "presentation": [ "http://syrahealth.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "periodStartLabel": "CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD", "periodEndLabel": "CASH AND CASH EQUIVALENTS AT END OF PERIOD", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r15", "r72", "r143" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "calculation": { "http://syrahealth.com/role/StatementsOfCashFlows": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://syrahealth.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "NET CHANGE IN CASH AND CASH EQUIVALENTS", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r1", "r72" ] }, "us-gaap_CashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashEquivalentsAtCarryingValue", "crdr": "debit", "presentation": [ "http://syrahealth.com/role/NatureOfBusinessAndSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Cash equivalents", "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r608", "r694" ] }, "us-gaap_CashFDICInsuredAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashFDICInsuredAmount", "crdr": "debit", "presentation": [ "http://syrahealth.com/role/NatureOfBusinessAndSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "FDIC insured amount", "documentation": "The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": [ "http://syrahealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfStockDomain", "presentation": [ "http://syrahealth.com/role/BalanceSheets", "http://syrahealth.com/role/BalanceSheetsParenthetical", "http://syrahealth.com/role/ChangesInStockholdersEquityDeficitDetailsNarrative", "http://syrahealth.com/role/StatementsOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock." } } }, "auth_ref": [ "r115", "r124", "r125", "r126", "r146", "r167", "r168", "r170", "r172", "r180", "r181", "r203", "r222", "r224", "r225", "r226", "r229", "r230", "r259", "r260", "r263", "r266", "r273", "r363", "r432", "r433", "r434", "r435", "r440", "r441", "r442", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r452", "r463", "r486", "r508", "r521", "r522", "r523", "r524", "r525", "r603", "r616", "r625" ] }, "us-gaap_ClassOfStockLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfStockLineItems", "presentation": [ "http://syrahealth.com/role/ChangesInStockholdersEquityDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Class of Stock [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r124", "r125", "r126", "r180", "r259", "r260", "r261", "r263", "r266", "r271", "r273", "r432", "r433", "r434", "r435", "r554", "r603", "r616" ] }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "presentation": [ "http://syrahealth.com/role/CommonStockOptionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Exercise price", "documentation": "Exercise price per share or per unit of warrants or rights outstanding." } } }, "auth_ref": [ "r274" ] }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight", "presentation": [ "http://syrahealth.com/role/ChangesInStockholdersEquityDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Warrants to purchase", "documentation": "Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares." } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingencies", "crdr": "credit", "calculation": { "http://syrahealth.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://syrahealth.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Commitments and contingencies", "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur." } } }, "auth_ref": [ "r54", "r95", "r401", "r462" ] }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": [ "http://syrahealth.com/role/CommitmentsAndContingencies" ], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth_ref": [ "r82", "r214", "r215", "r529", "r637", "r639" ] }, "us-gaap_CommonClassAMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonClassAMember", "presentation": [ "http://syrahealth.com/role/BalanceSheets", "http://syrahealth.com/role/BalanceSheetsParenthetical", "http://syrahealth.com/role/ChangesInStockholdersEquityDeficitDetailsNarrative", "http://syrahealth.com/role/StatementsOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Common Class A [Member]", "documentation": "Classification of common stock representing ownership interest in a corporation." } } }, "auth_ref": [ "r730" ] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockMember", "presentation": [ "http://syrahealth.com/role/StatementsOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": [ "r572", "r573", "r574", "r576", "r577", "r578", "r579", "r621", "r622", "r624", "r674", "r726", "r730" ] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockParOrStatedValuePerShare", "presentation": [ "http://syrahealth.com/role/BalanceSheetsParenthetical", "http://syrahealth.com/role/ChangesInStockholdersEquityDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Common stock, par value", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": [ "r57" ] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesAuthorized", "presentation": [ "http://syrahealth.com/role/BalanceSheetsParenthetical", "http://syrahealth.com/role/ChangesInStockholdersEquityDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Common stock, shares authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r57", "r463" ] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesIssued", "presentation": [ "http://syrahealth.com/role/BalanceSheetsParenthetical", "http://syrahealth.com/role/ChangesInStockholdersEquityDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Common stock, shares issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": [ "r57" ] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesOutstanding", "presentation": [ "http://syrahealth.com/role/BalanceSheetsParenthetical", "http://syrahealth.com/role/ChangesInStockholdersEquityDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Common stock, shares outstanding", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": [ "r9", "r57", "r463", "r483", "r730", "r731" ] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockValue", "crdr": "credit", "calculation": { "http://syrahealth.com/role/BalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://syrahealth.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Common stock, value", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r57", "r404", "r564" ] }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskBenchmarkDomain", "presentation": [ "http://syrahealth.com/role/NatureOfBusinessAndSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "The denominator in a calculation of a disclosed concentration risk percentage." } } }, "auth_ref": [ "r23", "r24", "r40", "r41", "r201", "r528" ] }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskByBenchmarkAxis", "presentation": [ "http://syrahealth.com/role/NatureOfBusinessAndSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Concentration Risk Benchmark [Axis]", "documentation": "Information by benchmark of concentration risk." } } }, "auth_ref": [ "r23", "r24", "r40", "r41", "r201", "r429", "r528" ] }, "us-gaap_ConcentrationRiskByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskByTypeAxis", "presentation": [ "http://syrahealth.com/role/NatureOfBusinessAndSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Concentration Risk Type [Axis]", "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender." } } }, "auth_ref": [ "r23", "r24", "r40", "r41", "r201", "r528", "r605" ] }, "us-gaap_ConcentrationRiskCreditRisk": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskCreditRisk", "presentation": [ "http://syrahealth.com/role/NatureOfBusinessAndSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Concentrations of Credit Risk", "documentation": "Disclosure of accounting policy for credit risk." } } }, "auth_ref": [ "r45", "r108" ] }, "us-gaap_ConcentrationRiskPercentage1": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskPercentage1", "presentation": [ "http://syrahealth.com/role/NatureOfBusinessAndSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Risk percentage", "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division." } } }, "auth_ref": [ "r23", "r24", "r40", "r41", "r201" ] }, "us-gaap_ConcentrationRiskTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskTypeDomain", "presentation": [ "http://syrahealth.com/role/NatureOfBusinessAndSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration." } } }, "auth_ref": [ "r23", "r24", "r40", "r41", "r201", "r528" ] }, "us-gaap_ConversionOfStockSharesConverted1": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConversionOfStockSharesConverted1", "presentation": [ "http://syrahealth.com/role/ChangesInStockholdersEquityDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Conversion of stock, shares converted", "documentation": "The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period." } } }, "auth_ref": [ "r18", "r19", "r20" ] }, "SYRA_ConvertibleClassBCommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://syrahealth.com/20240331", "localname": "ConvertibleClassBCommonStockMember", "presentation": [ "http://syrahealth.com/role/BalanceSheets", "http://syrahealth.com/role/BalanceSheetsParenthetical", "http://syrahealth.com/role/ChangesInStockholdersEquityDeficitDetailsNarrative", "http://syrahealth.com/role/StatementsOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Convertible Class B Common Stock [Member]", "documentation": "Convertible Class B Common Stock [Member]" } } }, "auth_ref": [] }, "SYRA_ConvertibleCommonStockBMember": { "xbrltype": "domainItemType", "nsuri": "http://syrahealth.com/20240331", "localname": "ConvertibleCommonStockBMember", "presentation": [ "http://syrahealth.com/role/ChangesInStockholdersEquityDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Convertible Common Stock B [Member]", "documentation": "Convertible Common Stock B [Member]" } } }, "auth_ref": [] }, "us-gaap_CostOfGoodsAndServicesSold": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CostOfGoodsAndServicesSold", "crdr": "debit", "calculation": { "http://syrahealth.com/role/StatementsOfOperations": { "parentTag": "us-gaap_GrossProfit", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://syrahealth.com/role/RelatedPartyTransactionsDetailsNarrative", "http://syrahealth.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Cost of services", "verboseLabel": "Service cost", "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities." } } }, "auth_ref": [ "r64", "r65", "r395" ] }, "us-gaap_CostOfSalesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CostOfSalesPolicyTextBlock", "presentation": [ "http://syrahealth.com/role/NatureOfBusinessAndSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Cost of Services", "documentation": "Disclosure of accounting policy for cost of product sold and service rendered." } } }, "auth_ref": [ "r607" ] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CountryRegion", "presentation": [ "http://syrahealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://syrahealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "us-gaap_CustomerConcentrationRiskMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CustomerConcentrationRiskMember", "presentation": [ "http://syrahealth.com/role/NatureOfBusinessAndSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Customer Concentration Risk [Member]", "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer." } } }, "auth_ref": [ "r77", "r201" ] }, "us-gaap_DebtDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DebtDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtDisclosureTextBlock", "presentation": [ "http://syrahealth.com/role/NotesPayable" ], "lang": { "en-us": { "role": { "label": "Notes Payable", "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants." } } }, "auth_ref": [ "r83", "r144", "r209", "r210", "r211", "r212", "r213", "r220", "r221", "r231", "r237", "r238", "r239", "r240", "r241", "r242", "r247", "r254", "r255", "r257", "r371" ] }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentInterestRateStatedPercentage", "presentation": [ "http://syrahealth.com/role/NotesPayableDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Interest rate percentage", "documentation": "Contractual interest rate for funds borrowed, under the debt agreement." } } }, "auth_ref": [ "r51", "r233" ] }, "us-gaap_DebtInstrumentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentLineItems", "presentation": [ "http://syrahealth.com/role/NotesPayableDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Debt Instrument [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r149", "r232", "r233", "r234", "r235", "r236", "r238", "r243", "r244", "r245", "r246", "r248", "r249", "r250", "r251", "r252", "r253", "r256", "r549", "r550", "r551", "r552", "r553", "r562", "r617", "r677", "r678" ] }, "us-gaap_DebtInstrumentPeriodicPaymentInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentPeriodicPaymentInterest", "crdr": "debit", "presentation": [ "http://syrahealth.com/role/NotesPayableDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Periodic interest payment", "documentation": "Amount of the required periodic payments applied to interest." } } }, "auth_ref": [ "r12" ] }, "us-gaap_DebtInstrumentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentTable", "presentation": [ "http://syrahealth.com/role/NotesPayableDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Schedule of Long-Term Debt Instruments [Table]", "documentation": "Disclosure of information about long-term debt instrument or arrangement." } } }, "auth_ref": [ "r12", "r32", "r35", "r44", "r86", "r87", "r149", "r232", "r233", "r234", "r235", "r236", "r238", "r243", "r244", "r245", "r246", "r248", "r249", "r250", "r251", "r252", "r253", "r256", "r549", "r550", "r551", "r552", "r553", "r562", "r617", "r677", "r678" ] }, "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DeferredRevenueCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredRevenueCurrent", "crdr": "credit", "calculation": { "http://syrahealth.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://syrahealth.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Deferred revenue", "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current." } } }, "auth_ref": [ "r609" ] }, "us-gaap_DefinedBenefitPlanDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanDisclosureLineItems", "presentation": [ "http://syrahealth.com/role/LeaseDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Defined Benefit Plan Disclosure [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedContributionPlanEmployerMatchingContributionPercent", "presentation": [ "http://syrahealth.com/role/AccruedExpensesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Employees contribution percentage", "documentation": "Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan." } } }, "auth_ref": [] }, "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedContributionPlanEmployerMatchingContributionPercentOfMatch", "presentation": [ "http://syrahealth.com/role/AccruedExpensesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Employers contribution percentage match", "documentation": "Percentage employer matches of the employee's percentage contribution matched." } } }, "auth_ref": [] }, "us-gaap_Depreciation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Depreciation", "crdr": "debit", "calculation": { "http://syrahealth.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 2.0 }, "http://syrahealth.com/role/StatementsOfOperations": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://syrahealth.com/role/PropertyAndEquipmentDetailsNarrative", "http://syrahealth.com/role/StatementsOfCashFlows", "http://syrahealth.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Depreciation", "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation." } } }, "auth_ref": [ "r5", "r28" ] }, "SYRA_DigitalHealthMember": { "xbrltype": "domainItemType", "nsuri": "http://syrahealth.com/20240331", "localname": "DigitalHealthMember", "presentation": [ "http://syrahealth.com/role/ScheduleOfDisaggregationOfRevenueDetails" ], "lang": { "en-us": { "role": { "label": "Digital Health [Member]", "documentation": "Digital Health [Member]" } } }, "auth_ref": [] }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisaggregationOfRevenueTableTextBlock", "presentation": [ "http://syrahealth.com/role/NatureOfBusinessAndSignificantAccountingPoliciesTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Disaggregation of Revenue", "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor." } } }, "auth_ref": [ "r645" ] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentAccountingStandard", "presentation": [ "http://syrahealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r596" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentAnnualReport", "presentation": [ "http://syrahealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r594", "r596", "r597" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://syrahealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://syrahealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": [ "http://syrahealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodStartDate", "presentation": [ "http://syrahealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentQuarterlyReport", "presentation": [ "http://syrahealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r595" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentRegistrationStatement", "presentation": [ "http://syrahealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r583" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://syrahealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r596" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentShellCompanyReport", "presentation": [ "http://syrahealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r596" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentTransitionReport", "presentation": [ "http://syrahealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r598" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": [ "http://syrahealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://syrahealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r586" ] }, "us-gaap_EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareAbstract", "lang": { "en-us": { "role": { "label": "Earnings Per Share [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareBasic", "presentation": [ "http://syrahealth.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Net loss per common share - basic", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": [ "r137", "r155", "r156", "r157", "r158", "r159", "r160", "r165", "r167", "r170", "r171", "r172", "r177", "r343", "r346", "r360", "r361", "r396", "r413", "r539" ] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareDiluted", "presentation": [ "http://syrahealth.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Net loss per common share - diluted", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": [ "r137", "r155", "r156", "r157", "r158", "r159", "r160", "r167", "r170", "r171", "r172", "r177", "r343", "r346", "r360", "r361", "r396", "r413", "r539" ] }, "us-gaap_EarningsPerSharePolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerSharePolicyTextBlock", "presentation": [ "http://syrahealth.com/role/NatureOfBusinessAndSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Basic and Diluted Loss Per Share", "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements." } } }, "auth_ref": [ "r21", "r22", "r174" ] }, "us-gaap_EarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareTextBlock", "presentation": [ "http://syrahealth.com/role/BasicAndDilutedEarningsPerShare" ], "lang": { "en-us": { "role": { "label": "Basic and Diluted Earnings per Share", "documentation": "The entire disclosure for earnings per share." } } }, "auth_ref": [ "r164", "r173", "r175", "r176" ] }, "SYRA_EconomicDevelopmentGrowingEconomyMember": { "xbrltype": "domainItemType", "nsuri": "http://syrahealth.com/20240331", "localname": "EconomicDevelopmentGrowingEconomyMember", "presentation": [ "http://syrahealth.com/role/OtherCurrentAssetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Economic Development Growing Economy [Member]", "documentation": "Economic Development Growing Economy [Member]" } } }, "auth_ref": [] }, "SYRA_EmployeeRetentionTaxCreditMember": { "xbrltype": "domainItemType", "nsuri": "http://syrahealth.com/20240331", "localname": "EmployeeRetentionTaxCreditMember", "presentation": [ "http://syrahealth.com/role/OtherCurrentAssetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Employee Retention Tax Credit [Member]", "documentation": "Employee Retention Tax Credit [Member]" } } }, "auth_ref": [] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeStockOptionMember", "presentation": [ "http://syrahealth.com/role/ScheduleOfDilutedEarningsPerShareDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Option [Member]", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": [ "http://syrahealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine2", "presentation": [ "http://syrahealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine3", "presentation": [ "http://syrahealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": [ "http://syrahealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCountry", "presentation": [ "http://syrahealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://syrahealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://syrahealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://syrahealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r589" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": [ "http://syrahealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r585" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://syrahealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://syrahealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://syrahealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r585" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityExTransitionPeriod", "presentation": [ "http://syrahealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r602" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": [ "http://syrahealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFilerCategory", "presentation": [ "http://syrahealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r585" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://syrahealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInformationFormerLegalOrRegisteredName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityInformationFormerLegalOrRegisteredName", "presentation": [ "http://syrahealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Information, Former Legal or Registered Name", "documentation": "Former Legal or Registered Name of an entity" } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://syrahealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r599" ] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityPrimarySicNumber", "presentation": [ "http://syrahealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r597" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://syrahealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": [ "http://syrahealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r585" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityShellCompany", "presentation": [ "http://syrahealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r585" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntitySmallBusiness", "presentation": [ "http://syrahealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r585" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://syrahealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r585" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityVoluntaryFilers", "presentation": [ "http://syrahealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://syrahealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r600" ] }, "us-gaap_EquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityAbstract", "lang": { "en-us": { "role": { "label": "Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityComponentDomain", "presentation": [ "http://syrahealth.com/role/StatementsOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": [ "r9", "r116", "r133", "r134", "r135", "r150", "r151", "r152", "r154", "r159", "r161", "r163", "r179", "r204", "r205", "r208", "r275", "r338", "r339", "r340", "r341", "r342", "r344", "r345", "r346", "r352", "r353", "r354", "r355", "r356", "r357", "r359", "r364", "r365", "r366", "r367", "r368", "r369", "r372", "r374", "r381", "r412", "r423", "r424", "r425", "r440", "r508" ] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Extension", "presentation": [ "http://syrahealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "SYRA_FSSADivisionOfMentalHealthAndAddictionMember": { "xbrltype": "domainItemType", "nsuri": "http://syrahealth.com/20240331", "localname": "FSSADivisionOfMentalHealthAndAddictionMember", "presentation": [ "http://syrahealth.com/role/NatureOfBusinessAndSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "FSSA \u0096 Division of Mental Health and Addiction [Member]", "documentation": "FSSA \u2013 Division of Mental Health and Addiction [Member]" } } }, "auth_ref": [] }, "SYRA_FSSANeuroDiagnosticInstituteMember": { "xbrltype": "domainItemType", "nsuri": "http://syrahealth.com/20240331", "localname": "FSSANeuroDiagnosticInstituteMember", "presentation": [ "http://syrahealth.com/role/NatureOfBusinessAndSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "FSSA \u0096 NeuroDiagnostic Institute [Member]", "documentation": "FSSA \u2013 NeuroDiagnostic Institute [Member]" } } }, "auth_ref": [] }, "us-gaap_FairValueOfFinancialInstrumentsPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueOfFinancialInstrumentsPolicy", "presentation": [ "http://syrahealth.com/role/NatureOfBusinessAndSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Fair Value of Financial Instruments", "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments." } } }, "auth_ref": [ "r7" ] }, "SYRA_FamilyAndSocialServicesAdministrationMember": { "xbrltype": "domainItemType", "nsuri": "http://syrahealth.com/20240331", "localname": "FamilyAndSocialServicesAdministrationMember", "presentation": [ "http://syrahealth.com/role/NatureOfBusinessAndSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Family and Social Services Administration (FSSA) [Member]", "documentation": "Family and Social Services Administration (FSSA) [Member]" } } }, "auth_ref": [] }, "us-gaap_GrossProfit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GrossProfit", "crdr": "credit", "calculation": { "http://syrahealth.com/role/StatementsOfOperations": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://syrahealth.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "totalLabel": "Gross profit", "label": "Gross Profit", "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity." } } }, "auth_ref": [ "r63", "r66", "r100", "r146", "r203", "r222", "r223", "r224", "r225", "r226", "r227", "r228", "r229", "r230", "r363", "r541", "r544", "r626", "r627", "r628", "r629", "r630", "r642" ] }, "SYRA_HealthcareWorkforceMember": { "xbrltype": "domainItemType", "nsuri": "http://syrahealth.com/20240331", "localname": "HealthcareWorkforceMember", "presentation": [ "http://syrahealth.com/role/NatureOfBusinessAndSignificantAccountingPoliciesDetailsNarrative", "http://syrahealth.com/role/ScheduleOfDisaggregationOfRevenueDetails" ], "lang": { "en-us": { "role": { "label": "Healthcare Workforce [Member]", "documentation": "Healthcare Workforce [Member]" } } }, "auth_ref": [] }, "SYRA_HealtheducationMember": { "xbrltype": "domainItemType", "nsuri": "http://syrahealth.com/20240331", "localname": "HealtheducationMember", "presentation": [ "http://syrahealth.com/role/ScheduleOfDisaggregationOfRevenueDetails" ], "lang": { "en-us": { "role": { "label": "Health Education [Member]", "documentation": "Health Education [Member]" } } }, "auth_ref": [] }, "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock", "presentation": [ "http://syrahealth.com/role/NatureOfBusinessAndSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Impairment of Long-Lived Assets", "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets." } } }, "auth_ref": [ "r0", "r81" ] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxDisclosureAbstract", "auth_ref": [] }, "us-gaap_IncomeTaxPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxPolicyTextBlock", "presentation": [ "http://syrahealth.com/role/NatureOfBusinessAndSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Income Taxes", "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements." } } }, "auth_ref": [ "r132", "r327", "r328", "r331", "r332", "r333", "r337", "r431" ] }, "us-gaap_IncomeTaxReconciliationTaxCredits": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxReconciliationTaxCredits", "crdr": "credit", "presentation": [ "http://syrahealth.com/role/OtherCurrentAssetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Tax credits", "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits." } } }, "auth_ref": [ "r329", "r330", "r673" ] }, "us-gaap_IncomeTaxUncertaintiesPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxUncertaintiesPolicy", "presentation": [ "http://syrahealth.com/role/NatureOfBusinessAndSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Uncertain Tax Positions", "documentation": "Disclosure of accounting policy for tax positions taken in the tax return filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities and other types of contingencies related to income taxes." } } }, "auth_ref": [] }, "us-gaap_IncomeTaxesPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxesPaidNet", "crdr": "credit", "presentation": [ "http://syrahealth.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Income taxes paid", "documentation": "Amount, after refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax." } } }, "auth_ref": [ "r17", "r142", "r334", "r335" ] }, "us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsPayableRelatedParties", "crdr": "debit", "calculation": { "http://syrahealth.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://syrahealth.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Accounts payable, related parties", "documentation": "The increase (decrease) during the reporting period in the obligations due for goods and services provided by the following types of related parties: a parent company and its subsidiaries, subsidiaries of a common parent, an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entities' management, an entity and its principal owners, management, or member of their immediate families, affiliates, or other parties with the ability to exert significant influence." } } }, "auth_ref": [ "r4" ] }, "us-gaap_IncreaseDecreaseInAccountsPayableTrade": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsPayableTrade", "crdr": "debit", "calculation": { "http://syrahealth.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 9.0 } }, "presentation": [ "http://syrahealth.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "verboseLabel": "Accounts payable", "label": "Increase (Decrease) in Accounts Payable, Trade", "documentation": "Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services." } } }, "auth_ref": [ "r4" ] }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsReceivable", "crdr": "credit", "calculation": { "http://syrahealth.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 6.0 } }, "presentation": [ "http://syrahealth.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Accounts receivable", "label": "Increase (Decrease) in Accounts Receivable", "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services." } } }, "auth_ref": [ "r4" ] }, "us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsReceivableRelatedParties", "crdr": "credit", "calculation": { "http://syrahealth.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 7.0 } }, "presentation": [ "http://syrahealth.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Accounts receivable, related party", "label": "Increase (Decrease) in Accounts Receivable, Related Parties", "documentation": "The increase (decrease) during the reporting period in the amount due to the reporting entity for good and services provided to the following types of related parties: a parent company and its subsidiaries; subsidiaries of a common parent; an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management, an entity and its principal owners, management, member of their immediate families, affiliates, or other parties with the ability to exert significant influence." } } }, "auth_ref": [ "r4" ] }, "us-gaap_IncreaseDecreaseInAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccruedLiabilities", "crdr": "debit", "calculation": { "http://syrahealth.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 12.0 } }, "presentation": [ "http://syrahealth.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "verboseLabel": "Accrued expenses", "label": "Increase (Decrease) in Accrued Liabilities", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid." } } }, "auth_ref": [ "r4" ] }, "us-gaap_IncreaseDecreaseInDeferredRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInDeferredRevenue", "crdr": "debit", "calculation": { "http://syrahealth.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 11.0 } }, "presentation": [ "http://syrahealth.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "verboseLabel": "Deferred revenue", "label": "Increase (Decrease) in Deferred Revenue", "documentation": "Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable." } } }, "auth_ref": [ "r533" ] }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": [ "http://syrahealth.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Changes in operating assets and liabilities:" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOperatingLeaseLiability", "crdr": "debit", "calculation": { "http://syrahealth.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 13.0 } }, "presentation": [ "http://syrahealth.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Operating lease liability", "documentation": "Amount of increase (decrease) in obligation for operating lease." } } }, "auth_ref": [ "r606", "r614" ] }, "us-gaap_IncreaseDecreaseInOtherCurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOtherCurrentAssets", "crdr": "credit", "calculation": { "http://syrahealth.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 8.0 } }, "presentation": [ "http://syrahealth.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Other current assets", "label": "Increase (Decrease) in Other Current Assets", "documentation": "Amount of increase (decrease) in current assets classified as other." } } }, "auth_ref": [ "r614" ] }, "SYRA_IncreaseDecreaseInPaymentsForRent": { "xbrltype": "monetaryItemType", "nsuri": "http://syrahealth.com/20240331", "localname": "IncreaseDecreaseInPaymentsForRent", "crdr": "debit", "presentation": [ "http://syrahealth.com/role/LeaseDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Increased base monthly rent", "documentation": "Increase decrease in payments for rent." } } }, "auth_ref": [] }, "SYRA_InformationTechnologyServicesMember": { "xbrltype": "domainItemType", "nsuri": "http://syrahealth.com/20240331", "localname": "InformationTechnologyServicesMember", "presentation": [ "http://syrahealth.com/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Information Technology Services [Member]", "documentation": "Information Technology Services [Member]" } } }, "auth_ref": [] }, "SYRA_InsurancePolicyFinancingArrangementsMember": { "xbrltype": "domainItemType", "nsuri": "http://syrahealth.com/20240331", "localname": "InsurancePolicyFinancingArrangementsMember", "presentation": [ "http://syrahealth.com/role/NotesPayableDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Insurance Policy Financing Arrangements [Member]", "documentation": "Insurance Policy Financing Arrangements [Member]" } } }, "auth_ref": [] }, "us-gaap_InterestExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestExpense", "crdr": "debit", "calculation": { "http://syrahealth.com/role/StatementsOfOperations": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://syrahealth.com/role/NotesPayableDetailsNarrative", "http://syrahealth.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "negatedLabel": "Interest expense", "label": "Interest expense", "documentation": "Amount of interest expense classified as operating and nonoperating. Includes, but is not limited to, cost of borrowing accounted for as interest expense." } } }, "auth_ref": [ "r178", "r182", "r186", "r187", "r197", "r370", "r544", "r545" ] }, "us-gaap_InterestPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestPaidNet", "crdr": "credit", "presentation": [ "http://syrahealth.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Interest paid", "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount." } } }, "auth_ref": [ "r138", "r140", "r141" ] }, "us-gaap_InvestmentIncomeInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentIncomeInterest", "crdr": "credit", "calculation": { "http://syrahealth.com/role/StatementsOfOperations": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://syrahealth.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Interest income", "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities." } } }, "auth_ref": [ "r178", "r185", "r197", "r544", "r611" ] }, "SYRA_InvestmentRetirementAccountContributionExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://syrahealth.com/20240331", "localname": "InvestmentRetirementAccountContributionExpenses", "crdr": "debit", "presentation": [ "http://syrahealth.com/role/AccruedExpensesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Investment retirement account contribution expenses", "documentation": "Investment retirement account contribution expenses." } } }, "auth_ref": [] }, "us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IssuanceOfStockAndWarrantsForServicesOrClaims", "crdr": "debit", "calculation": { "http://syrahealth.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://syrahealth.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Common stock issued for services", "documentation": "Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims." } } }, "auth_ref": [ "r5" ] }, "us-gaap_LeaseCostTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseCostTableTextBlock", "presentation": [ "http://syrahealth.com/role/LeaseTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Lease Cost expenses", "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income." } } }, "auth_ref": [ "r681" ] }, "us-gaap_LeasesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeasesAbstract", "lang": { "en-us": { "role": { "label": "Leases [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LesseeLeasesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeLeasesPolicyTextBlock", "presentation": [ "http://syrahealth.com/role/NatureOfBusinessAndSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Leases", "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee." } } }, "auth_ref": [ "r377" ] }, "us-gaap_LesseeOperatingLeaseTermOfContract": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseTermOfContract", "presentation": [ "http://syrahealth.com/role/LeaseDetailsNarrative", "http://syrahealth.com/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Lease term", "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r680" ] }, "us-gaap_LesseeOperatingLeasesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeasesTextBlock", "presentation": [ "http://syrahealth.com/role/Lease" ], "lang": { "en-us": { "role": { "label": "Lease", "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability." } } }, "auth_ref": [ "r373" ] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Liabilities", "crdr": "credit", "calculation": { "http://syrahealth.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://syrahealth.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities", "label": "Liabilities", "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others." } } }, "auth_ref": [ "r12", "r48", "r49", "r50", "r52", "r53", "r54", "r55", "r146", "r203", "r222", "r223", "r224", "r225", "r226", "r227", "r228", "r229", "r230", "r349", "r350", "r351", "r363", "r461", "r540", "r582", "r642", "r683", "r684" ] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": { "http://syrahealth.com/role/BalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://syrahealth.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities and stockholders\u2019 equity (deficit)", "label": "Liabilities and Equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": [ "r62", "r96", "r406", "r564", "r618", "r635", "r676" ] }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": [ "http://syrahealth.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY (DEFICIT)" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrent", "crdr": "credit", "calculation": { "http://syrahealth.com/role/BalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://syrahealth.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total current liabilities", "label": "Liabilities, Current", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": [ "r50", "r119", "r146", "r203", "r222", "r223", "r224", "r225", "r226", "r227", "r228", "r229", "r230", "r349", "r350", "r351", "r363", "r564", "r642", "r683", "r684" ] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrentAbstract", "presentation": [ "http://syrahealth.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Current liabilities:" } } }, "auth_ref": [] }, "us-gaap_LoansAssumed1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LoansAssumed1", "crdr": "credit", "presentation": [ "http://syrahealth.com/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Advanced balance of loan", "documentation": "The fair value of loans assumed in noncash investing or financing activities." } } }, "auth_ref": [ "r18", "r19", "r20" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": [ "http://syrahealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "srt_MajorCustomersAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MajorCustomersAxis", "presentation": [ "http://syrahealth.com/role/NatureOfBusinessAndSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Customer [Axis]" } } }, "auth_ref": [ "r201", "r556", "r566", "r569", "r645", "r697", "r698", "r699", "r701", "r702", "r703", "r704", "r705", "r706", "r707", "r708", "r709", "r710", "r711", "r712", "r713", "r714", "r715", "r716", "r717", "r718", "r719", "r720", "r721", "r722", "r723", "r724", "r725" ] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MaximumMember", "presentation": [ "http://syrahealth.com/role/CommonStockOptionsDetailsNarrative", "http://syrahealth.com/role/NotesPayableDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]" } } }, "auth_ref": [ "r216", "r217", "r218", "r219", "r288", "r325", "r362", "r394", "r421", "r422", "r428", "r453", "r454", "r516", "r517", "r518", "r519", "r520", "r530", "r531", "r547", "r554", "r557", "r558", "r559", "r560", "r561", "r567", "r644", "r685", "r686", "r687", "r688", "r689", "r690" ] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MinimumMember", "presentation": [ "http://syrahealth.com/role/NotesPayableDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]" } } }, "auth_ref": [ "r216", "r217", "r218", "r219", "r288", "r325", "r362", "r394", "r421", "r422", "r428", "r453", "r454", "r516", "r517", "r518", "r519", "r520", "r530", "r531", "r547", "r554", "r557", "r558", "r559", "r560", "r567", "r644", "r685", "r686", "r687", "r688", "r689", "r690" ] }, "SYRA_NLogixMember": { "xbrltype": "domainItemType", "nsuri": "http://syrahealth.com/20240331", "localname": "NLogixMember", "presentation": [ "http://syrahealth.com/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "NLogix [Member]", "documentation": "NLogix [Member]" } } }, "auth_ref": [] }, "srt_NameOfMajorCustomerDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "NameOfMajorCustomerDomain", "presentation": [ "http://syrahealth.com/role/NatureOfBusinessAndSignificantAccountingPoliciesDetailsNarrative" ], "auth_ref": [ "r201", "r556", "r566", "r569", "r645", "r697", "r698", "r699", "r701", "r702", "r703", "r704", "r705", "r706", "r707", "r708", "r709", "r710", "r711", "r712", "r713", "r714", "r715", "r716", "r717", "r718", "r719", "r720", "r721", "r722", "r723", "r724", "r725" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://syrahealth.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://syrahealth.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash provided by financing activities", "label": "Net Cash Provided by (Used in) Financing Activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": [ "r139" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": [ "http://syrahealth.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "CASH FLOWS FROM FINANCING ACTIVITIES" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://syrahealth.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://syrahealth.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash used in investing activities", "label": "Net Cash Provided by (Used in) Investing Activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": [ "r139" ] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": [ "http://syrahealth.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "CASH FLOWS FROM INVESTING ACTIVITIES" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivities", "calculation": { "http://syrahealth.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://syrahealth.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash used in operating activities", "label": "Net Cash Provided by (Used in) Operating Activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": [ "r72", "r73", "r74" ] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://syrahealth.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "CASH FLOWS FROM OPERATING ACTIVITIES" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLoss", "crdr": "credit", "calculation": { "http://syrahealth.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 1.0 }, "http://syrahealth.com/role/StatementsOfOperations": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://syrahealth.com/role/StatementsOfCashFlows", "http://syrahealth.com/role/StatementsOfChangesInStockholdersEquityDeficit", "http://syrahealth.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "totalLabel": "Net loss", "label": "Net loss", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": [ "r67", "r74", "r97", "r117", "r130", "r131", "r135", "r146", "r153", "r155", "r156", "r157", "r158", "r159", "r162", "r163", "r169", "r203", "r222", "r223", "r224", "r225", "r226", "r227", "r228", "r229", "r230", "r343", "r346", "r361", "r363", "r411", "r485", "r506", "r507", "r580", "r642" ] }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": [ "http://syrahealth.com/role/NatureOfBusinessAndSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Recent Accounting Standards", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "NoTradingSymbolFlag", "presentation": [ "http://syrahealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "us-gaap_NonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://syrahealth.com/role/StatementsOfOperations": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://syrahealth.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "totalLabel": "Total other income (expense)", "label": "Nonoperating Income (Expense)", "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)." } } }, "auth_ref": [ "r69" ] }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NonoperatingIncomeExpenseAbstract", "presentation": [ "http://syrahealth.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Other income (expense):" } } }, "auth_ref": [] }, "us-gaap_NonrelatedPartyMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NonrelatedPartyMember", "presentation": [ "http://syrahealth.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Nonrelated Party [Member]", "documentation": "Party not related to reporting entity." } } }, "auth_ref": [ "r619", "r620" ] }, "us-gaap_NotesPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NotesPayable", "crdr": "credit", "presentation": [ "http://syrahealth.com/role/NotesPayableDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Principal amount", "documentation": "Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer." } } }, "auth_ref": [ "r12", "r94", "r692", "r693" ] }, "us-gaap_NotesPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NotesPayableCurrent", "crdr": "credit", "calculation": { "http://syrahealth.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://syrahealth.com/role/BalanceSheets", "http://syrahealth.com/role/NotesPayableDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Notes payable", "documentation": "Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer." } } }, "auth_ref": [ "r48", "r49" ] }, "SYRA_NovemberTwoThousandTwentyThreeMember": { "xbrltype": "domainItemType", "nsuri": "http://syrahealth.com/20240331", "localname": "NovemberTwoThousandTwentyThreeMember", "presentation": [ "http://syrahealth.com/role/ChangesInStockholdersEquityDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "November 2023 [Member]", "documentation": "November 2023 [Member]" } } }, "auth_ref": [] }, "SYRA_NumberOfOptionsVested": { "xbrltype": "percentItemType", "nsuri": "http://syrahealth.com/20240331", "localname": "NumberOfOptionsVested", "presentation": [ "http://syrahealth.com/role/CommonStockOptionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Number of options vested", "documentation": "Number of options vested." } } }, "auth_ref": [] }, "us-gaap_OfficeEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OfficeEquipmentMember", "presentation": [ "http://syrahealth.com/role/ScheduleOfPropertyAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Office Equipment [Member]", "documentation": "Tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine." } } }, "auth_ref": [] }, "SYRA_OmnibusEquityIncentivePlanMember": { "xbrltype": "domainItemType", "nsuri": "http://syrahealth.com/20240331", "localname": "OmnibusEquityIncentivePlanMember", "presentation": [ "http://syrahealth.com/role/CommonStockOptionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Omnibus Equity Incentive Plan [Member]", "documentation": "Omnibus Equity Incentive Plan [Member]" } } }, "auth_ref": [] }, "us-gaap_OperatingExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingExpenses", "crdr": "debit", "calculation": { "http://syrahealth.com/role/StatementsOfOperations": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://syrahealth.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "totalLabel": "Total operating expenses", "label": "Operating Expenses", "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense." } } }, "auth_ref": [] }, "us-gaap_OperatingExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingExpensesAbstract", "presentation": [ "http://syrahealth.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Operating expenses:" } } }, "auth_ref": [] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingIncomeLoss", "crdr": "credit", "calculation": { "http://syrahealth.com/role/StatementsOfOperations": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://syrahealth.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "totalLabel": "Operating loss", "label": "Operating Income (Loss)", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": [ "r100", "r541", "r626", "r627", "r628", "r629", "r630" ] }, "us-gaap_OperatingLeaseExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseExpense", "crdr": "debit", "calculation": { "http://syrahealth.com/role/ScheduleOfLeaseCostExpensesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://syrahealth.com/role/LeaseDetailsNarrative", "http://syrahealth.com/role/RelatedPartyTransactionsDetailsNarrative", "http://syrahealth.com/role/ScheduleOfLeaseCostExpensesDetails" ], "lang": { "en-us": { "role": { "label": "Lease expense", "totalLabel": "Total operating lease cost", "verboseLabel": "Lease rent expense", "documentation": "Amount of operating lease expense. Excludes sublease income." } } }, "auth_ref": [ "r679" ] }, "SYRA_OperatingLeaseInterestExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://syrahealth.com/20240331", "localname": "OperatingLeaseInterestExpense", "crdr": "debit", "calculation": { "http://syrahealth.com/role/ScheduleOfLeaseCostExpensesDetails": { "parentTag": "us-gaap_OperatingLeaseExpense", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://syrahealth.com/role/ScheduleOfLeaseCostExpensesDetails" ], "lang": { "en-us": { "role": { "label": "Interest on lease liability", "documentation": "Operating lease interest expense." } } }, "auth_ref": [] }, "us-gaap_OperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiability", "crdr": "credit", "calculation": { "http://syrahealth.com/role/ScheduleOfSupplementalBalanceSheetsInformationDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://syrahealth.com/role/ScheduleOfSupplementalBalanceSheetsInformationDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total operating lease liability", "label": "Operating Lease, Liability", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease." } } }, "auth_ref": [ "r376" ] }, "us-gaap_OperatingLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityCurrent", "crdr": "credit", "calculation": { "http://syrahealth.com/role/ScheduleOfSupplementalBalanceSheetsInformationDetails": { "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0, "order": 1.0 }, "http://syrahealth.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://syrahealth.com/role/BalanceSheets", "http://syrahealth.com/role/ScheduleOfSupplementalBalanceSheetsInformationDetails" ], "lang": { "en-us": { "role": { "label": "Current portion of operating lease liability, related party", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current." } } }, "auth_ref": [ "r376" ] }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://syrahealth.com/role/ScheduleOfSupplementalBalanceSheetsInformationDetails": { "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://syrahealth.com/role/ScheduleOfSupplementalBalanceSheetsInformationDetails" ], "lang": { "en-us": { "role": { "label": "Noncurrent operating lease liability, related party", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent." } } }, "auth_ref": [ "r376" ] }, "us-gaap_OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "calculation": { "http://syrahealth.com/role/BalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://syrahealth.com/role/BalanceSheets", "http://syrahealth.com/role/ScheduleOfSupplementalBalanceSheetsInformationDetails" ], "lang": { "en-us": { "role": { "label": "Right-of-use asset", "verboseLabel": "Operating lease assets", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } }, "auth_ref": [ "r375" ] }, "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense", "crdr": "debit", "calculation": { "http://syrahealth.com/role/ScheduleOfLeaseCostExpensesDetails": { "parentTag": "us-gaap_OperatingLeaseExpense", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://syrahealth.com/role/ScheduleOfLeaseCostExpensesDetails" ], "lang": { "en-us": { "role": { "label": "Amortization of ROU asset", "documentation": "Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease." } } }, "auth_ref": [ "r615" ] }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "presentation": [ "http://syrahealth.com/role/ScheduleOfSupplementalBalanceSheetsInformationDetails" ], "lang": { "en-us": { "role": { "label": "Weighted-average discount rate (Rate)", "documentation": "Weighted average discount rate for operating lease calculated at point in time." } } }, "auth_ref": [ "r379", "r563" ] }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "presentation": [ "http://syrahealth.com/role/ScheduleOfSupplementalBalanceSheetsInformationDetails" ], "lang": { "en-us": { "role": { "label": "Weighted-average remaining lease term (in years) (Year)", "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r378", "r563" ] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAssetsCurrent", "crdr": "debit", "calculation": { "http://syrahealth.com/role/BalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 3.0 }, "http://syrahealth.com/role/ScheduleOfOtherCurrentAssetsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://syrahealth.com/role/BalanceSheets", "http://syrahealth.com/role/ScheduleOfOtherCurrentAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Other current assets", "totalLabel": "Total other current assets", "documentation": "Amount of current assets classified as other." } } }, "auth_ref": [ "r128", "r564" ] }, "us-gaap_OtherCurrentAssetsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherCurrentAssetsTextBlock", "presentation": [ "http://syrahealth.com/role/OtherCurrentAssets" ], "lang": { "en-us": { "role": { "label": "Other Current Assets", "documentation": "The entire disclosure for other current assets." } } }, "auth_ref": [] }, "us-gaap_OtherNoncashExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherNoncashExpense", "crdr": "debit", "calculation": { "http://syrahealth.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://syrahealth.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Non-cash lease expense", "documentation": "Amount of expense or loss included in net income that result in no cash flow, classified as other." } } }, "auth_ref": [ "r74" ] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://syrahealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r596" ] }, "us-gaap_PayablesAndAccrualsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PayablesAndAccrualsAbstract", "lang": { "en-us": { "role": { "label": "Payables and Accruals [Abstract]" } } }, "auth_ref": [] }, "us-gaap_PaymentsForRent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsForRent", "crdr": "credit", "presentation": [ "http://syrahealth.com/role/LeaseDetailsNarrative", "http://syrahealth.com/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Base monthly rent", "documentation": "Cash payments to lessor's for use of assets under operating leases." } } }, "auth_ref": [ "r3" ] }, "us-gaap_PaymentsOfDebtIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsOfDebtIssuanceCosts", "crdr": "credit", "calculation": { "http://syrahealth.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://syrahealth.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Payment of deferred offering costs", "label": "Payments of Debt Issuance Costs", "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt." } } }, "auth_ref": [ "r14" ] }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://syrahealth.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://syrahealth.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Purchase of property and equipment", "label": "Payments to Acquire Property, Plant, and Equipment", "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets." } } }, "auth_ref": [ "r70" ] }, "us-gaap_PlanNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PlanNameAxis", "presentation": [ "http://syrahealth.com/role/CommonStockOptionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Plan Name [Axis]", "documentation": "Information by plan name for share-based payment arrangement." } } }, "auth_ref": [ "r646", "r647", "r648", "r649", "r650", "r651", "r652", "r653", "r654", "r655", "r656", "r657", "r658", "r659", "r660", "r661", "r662", "r663", "r664", "r665", "r666", "r667", "r668", "r669", "r670", "r671" ] }, "us-gaap_PlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PlanNameDomain", "presentation": [ "http://syrahealth.com/role/CommonStockOptionsDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement." } } }, "auth_ref": [ "r646", "r647", "r648", "r649", "r650", "r651", "r652", "r653", "r654", "r655", "r656", "r657", "r658", "r659", "r660", "r661", "r662", "r663", "r664", "r665", "r666", "r667", "r668", "r669", "r670", "r671" ] }, "SYRA_PopulationHealthMember": { "xbrltype": "domainItemType", "nsuri": "http://syrahealth.com/20240331", "localname": "PopulationHealthMember", "presentation": [ "http://syrahealth.com/role/NatureOfBusinessAndSignificantAccountingPoliciesDetailsNarrative", "http://syrahealth.com/role/ScheduleOfDisaggregationOfRevenueDetails" ], "lang": { "en-us": { "role": { "label": "Population Health [Member]", "documentation": "Population Health [Member]" } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://syrahealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r590" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreCommencementTenderOffer", "presentation": [ "http://syrahealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r592" ] }, "us-gaap_PreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockMember", "presentation": [ "http://syrahealth.com/role/StatementsOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Preferred Stock [Member]", "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company." } } }, "auth_ref": [ "r572", "r573", "r576", "r577", "r578", "r579", "r726", "r730" ] }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockParOrStatedValuePerShare", "presentation": [ "http://syrahealth.com/role/BalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Preferred stock, par value", "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer." } } }, "auth_ref": [ "r56", "r259" ] }, "us-gaap_PreferredStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesAuthorized", "presentation": [ "http://syrahealth.com/role/BalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Preferred stock, shares authorized", "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r56", "r463" ] }, "SYRA_PreferredStockSharesDesignated": { "xbrltype": "sharesItemType", "nsuri": "http://syrahealth.com/20240331", "localname": "PreferredStockSharesDesignated", "presentation": [ "http://syrahealth.com/role/BalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Preferred stock, shares designated", "documentation": "Preferred stock, shares designated." } } }, "auth_ref": [] }, "us-gaap_PreferredStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesIssued", "presentation": [ "http://syrahealth.com/role/BalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Preferred stock, shares issued", "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt." } } }, "auth_ref": [ "r56", "r259" ] }, "us-gaap_PreferredStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesOutstanding", "presentation": [ "http://syrahealth.com/role/BalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Preferred stock, shares outstanding", "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased." } } }, "auth_ref": [ "r56", "r463", "r483", "r730", "r731" ] }, "us-gaap_PreferredStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockValue", "crdr": "credit", "calculation": { "http://syrahealth.com/role/BalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://syrahealth.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Preferred stock, $0.001 par value, 10,000,000 shares authorized, no shares designated, issued and outstanding", "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r56", "r403", "r564" ] }, "us-gaap_PrepaidExpenseCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrepaidExpenseCurrent", "crdr": "debit", "calculation": { "http://syrahealth.com/role/ScheduleOfOtherCurrentAssetsDetails": { "parentTag": "us-gaap_OtherAssetsCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://syrahealth.com/role/ScheduleOfOtherCurrentAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Prepaid expenses", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r127", "r206", "r207", "r537" ] }, "us-gaap_PrepaidTaxes": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrepaidTaxes", "crdr": "debit", "calculation": { "http://syrahealth.com/role/ScheduleOfOtherCurrentAssetsDetails": { "parentTag": "us-gaap_OtherAssetsCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://syrahealth.com/role/ScheduleOfOtherCurrentAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Federal and state income tax receivable", "documentation": "Amount of asset related to consideration paid in advance for income and other taxes that provide economic benefits within a future period of one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r538", "r548", "r636" ] }, "us-gaap_ProceedsFromConvertibleDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromConvertibleDebt", "crdr": "debit", "calculation": { "http://syrahealth.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://syrahealth.com/role/GoingConcernDetailsNarrative", "http://syrahealth.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Proceeds received from convertible notes payable", "verboseLabel": "Convertible notes payable", "documentation": "The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder." } } }, "auth_ref": [ "r13" ] }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOfCommonStock", "crdr": "debit", "presentation": [ "http://syrahealth.com/role/GoingConcernDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Proceeds from commnon stock", "documentation": "The cash inflow from the additional capital contribution to the entity." } } }, "auth_ref": [ "r2" ] }, "us-gaap_ProceedsFromIssuanceOfWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOfWarrants", "crdr": "debit", "presentation": [ "http://syrahealth.com/role/ChangesInStockholdersEquityDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Proceeds from issuance of warrants", "documentation": "The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt)." } } }, "auth_ref": [ "r2" ] }, "us-gaap_ProceedsFromLongTermLinesOfCredit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromLongTermLinesOfCredit", "crdr": "debit", "calculation": { "http://syrahealth.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://syrahealth.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Proceeds received from line of credit", "documentation": "The cash inflow from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer." } } }, "auth_ref": [ "r13" ] }, "us-gaap_ProceedsFromWarrantExercises": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromWarrantExercises", "crdr": "debit", "calculation": { "http://syrahealth.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://syrahealth.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Proceeds received on exercise of warrants", "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants." } } }, "auth_ref": [ "r612" ] }, "us-gaap_ProductInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProductInformationLineItems", "presentation": [ "http://syrahealth.com/role/NatureOfBusinessAndSignificantAccountingPoliciesDetailsNarrative", "http://syrahealth.com/role/ScheduleOfDisaggregationOfRevenueDetails" ], "lang": { "en-us": { "role": { "label": "Product Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "srt_ProductOrServiceAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ProductOrServiceAxis", "presentation": [ "http://syrahealth.com/role/NatureOfBusinessAndSignificantAccountingPoliciesDetailsNarrative", "http://syrahealth.com/role/RelatedPartyTransactionsDetailsNarrative", "http://syrahealth.com/role/ScheduleOfDisaggregationOfRevenueDetails" ], "lang": { "en-us": { "role": { "label": "Product and Service [Axis]" } } }, "auth_ref": [ "r199", "r395", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r535", "r555", "r565", "r567", "r568", "r570", "r571", "r640", "r641", "r645", "r697", "r698", "r699", "r700", "r701", "r702", "r703", "r704", "r705", "r706", "r707", "r708", "r709", "r710", "r711", "r712", "r713", "r714", "r715", "r716", "r717", "r718", "r719", "r720", "r721", "r722", "r723", "r724", "r725" ] }, "srt_ProductsAndServicesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ProductsAndServicesDomain", "presentation": [ "http://syrahealth.com/role/NatureOfBusinessAndSignificantAccountingPoliciesDetailsNarrative", "http://syrahealth.com/role/RelatedPartyTransactionsDetailsNarrative", "http://syrahealth.com/role/ScheduleOfDisaggregationOfRevenueDetails" ], "auth_ref": [ "r199", "r395", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r535", "r555", "r565", "r567", "r568", "r570", "r571", "r640", "r641", "r645", "r697", "r698", "r699", "r700", "r701", "r702", "r703", "r704", "r705", "r706", "r707", "r708", "r709", "r710", "r711", "r712", "r713", "r714", "r715", "r716", "r717", "r718", "r719", "r720", "r721", "r722", "r723", "r724", "r725" ] }, "us-gaap_ProfessionalFees": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProfessionalFees", "crdr": "debit", "calculation": { "http://syrahealth.com/role/StatementsOfOperations": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://syrahealth.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Professional services", "documentation": "A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer." } } }, "auth_ref": [ "r544", "r580", "r728", "r729" ] }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentAbstract", "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Abstract]" } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentByTypeAxis", "presentation": [ "http://syrahealth.com/role/ScheduleOfPropertyAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Long-Lived Tangible Asset [Axis]", "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale." } } }, "auth_ref": [ "r6", "r380" ] }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "presentation": [ "http://syrahealth.com/role/PropertyAndEquipment" ], "lang": { "en-us": { "role": { "label": "Property and Equipment", "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections." } } }, "auth_ref": [ "r79", "r109", "r112", "r113" ] }, "us-gaap_PropertyPlantAndEquipmentGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentGross", "crdr": "debit", "presentation": [ "http://syrahealth.com/role/ScheduleOfPropertyAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Office equipment", "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r80", "r121", "r410" ] }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentLineItems", "presentation": [ "http://syrahealth.com/role/ScheduleOfPropertyAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r380" ] }, "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "calculation": { "http://syrahealth.com/role/BalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://syrahealth.com/role/BalanceSheets", "http://syrahealth.com/role/ScheduleOfPropertyAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Property and equipment, net", "totalLabel": "Total property and equipment, net", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r6", "r380", "r398", "r410", "r564" ] }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "presentation": [ "http://syrahealth.com/role/NatureOfBusinessAndSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "verboseLabel": "Property and Equipment", "label": "Property, Plant and Equipment, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections." } } }, "auth_ref": [ "r6", "r109", "r112", "r408" ] }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentTextBlock", "presentation": [ "http://syrahealth.com/role/PropertyAndEquipmentTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Property and Equipment", "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation." } } }, "auth_ref": [ "r6" ] }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentTypeDomain", "presentation": [ "http://syrahealth.com/role/ScheduleOfPropertyAndEquipmentDetails" ], "lang": { "en-us": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software." } } }, "auth_ref": [ "r80", "r380" ] }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentUsefulLife", "presentation": [ "http://syrahealth.com/role/NatureOfBusinessAndSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Property and equipment useful life", "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment." } } }, "auth_ref": [] }, "SYRA_RadCubeLLCMember": { "xbrltype": "domainItemType", "nsuri": "http://syrahealth.com/20240331", "localname": "RadCubeLLCMember", "presentation": [ "http://syrahealth.com/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "RAD CUBE LLC [Member]", "documentation": "RAD CUBE LLC [Member]" } } }, "auth_ref": [] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeAxis", "presentation": [ "http://syrahealth.com/role/CommonStockOptionsDetailsNarrative", "http://syrahealth.com/role/NotesPayableDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]" } } }, "auth_ref": [ "r216", "r217", "r218", "r219", "r286", "r288", "r317", "r318", "r319", "r325", "r362", "r392", "r393", "r394", "r421", "r422", "r428", "r453", "r454", "r516", "r517", "r518", "r519", "r520", "r530", "r531", "r547", "r554", "r557", "r558", "r559", "r560", "r561", "r567", "r574", "r638", "r644", "r675", "r686", "r687", "r688", "r689", "r690" ] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeMember", "presentation": [ "http://syrahealth.com/role/CommonStockOptionsDetailsNarrative", "http://syrahealth.com/role/NotesPayableDetailsNarrative" ], "auth_ref": [ "r216", "r217", "r218", "r219", "r286", "r288", "r317", "r318", "r319", "r325", "r362", "r392", "r393", "r394", "r421", "r422", "r428", "r453", "r454", "r516", "r517", "r518", "r519", "r520", "r530", "r531", "r547", "r554", "r557", "r558", "r559", "r560", "r561", "r567", "r574", "r638", "r644", "r675", "r686", "r687", "r688", "r689", "r690" ] }, "SYRA_RecognizedExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://syrahealth.com/20240331", "localname": "RecognizedExpense", "crdr": "debit", "presentation": [ "http://syrahealth.com/role/ChangesInStockholdersEquityDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Recognized expense", "documentation": "Recognized expense." } } }, "auth_ref": [] }, "SYRA_RecruitmentAndHumanResourceServicesMember": { "xbrltype": "domainItemType", "nsuri": "http://syrahealth.com/20240331", "localname": "RecruitmentAndHumanResourceServicesMember", "presentation": [ "http://syrahealth.com/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Recruitment and Human Resource Services [Member]", "documentation": "Recruitment and Human Resource Services [Member]" } } }, "auth_ref": [] }, "us-gaap_RelatedPartyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyDomain", "presentation": [ "http://syrahealth.com/role/BalanceSheets", "http://syrahealth.com/role/ChangesInStockholdersEquityDeficitDetailsNarrative", "http://syrahealth.com/role/LeaseDetailsNarrative", "http://syrahealth.com/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest." } } }, "auth_ref": [ "r202", "r287", "r385", "r386", "r400", "r407", "r456", "r457", "r458", "r459", "r460", "r482", "r484", "r515" ] }, "us-gaap_RelatedPartyMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyMember", "presentation": [ "http://syrahealth.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Related Party [Member]", "documentation": "Party related to reporting entity. Includes, but is not limited to, affiliate, entity for which investment is accounted for by equity method, trust for benefit of employees, and principal owner, management, and members of immediate family." } } }, "auth_ref": [ "r147", "r148", "r385", "r386", "r387", "r388", "r400", "r407", "r456", "r457", "r458", "r459", "r460", "r482", "r484", "r515" ] }, "us-gaap_RelatedPartyTransactionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionLineItems", "presentation": [ "http://syrahealth.com/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Related Party Transaction [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r202", "r489", "r490", "r493" ] }, "us-gaap_RelatedPartyTransactionsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionsAbstract", "lang": { "en-us": { "role": { "label": "Related Party Transactions [Abstract]" } } }, "auth_ref": [] }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "presentation": [ "http://syrahealth.com/role/BalanceSheets", "http://syrahealth.com/role/ChangesInStockholdersEquityDeficitDetailsNarrative", "http://syrahealth.com/role/LeaseDetailsNarrative", "http://syrahealth.com/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Related and Nonrelated Parties [Axis]", "documentation": "Information by related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest." } } }, "auth_ref": [ "r202", "r287", "r385", "r386", "r400", "r407", "r456", "r457", "r458", "r459", "r460", "r482", "r484", "r515", "r682" ] }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionsDisclosureTextBlock", "presentation": [ "http://syrahealth.com/role/RelatedPartyTransactions" ], "lang": { "en-us": { "role": { "label": "Related Party Transactions", "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates." } } }, "auth_ref": [ "r382", "r383", "r384", "r386", "r389", "r437", "r438", "r439", "r491", "r492", "r493", "r512", "r514" ] }, "us-gaap_RepaymentsOfDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RepaymentsOfDebt", "crdr": "credit", "presentation": [ "http://syrahealth.com/role/NotesPayableDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Principal repayments", "documentation": "Amount of cash outflow for short-term and long-term debt. Excludes payment of lease obligation." } } }, "auth_ref": [ "r613" ] }, "us-gaap_RepaymentsOfLinesOfCredit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RepaymentsOfLinesOfCredit", "crdr": "credit", "calculation": { "http://syrahealth.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://syrahealth.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Repayments on line of credit", "label": "Repayments of Lines of Credit", "documentation": "Amount of cash outflow for payment of an obligation from a lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements." } } }, "auth_ref": [ "r71", "r617" ] }, "us-gaap_RepaymentsOfNotesPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RepaymentsOfNotesPayable", "crdr": "credit", "calculation": { "http://syrahealth.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://syrahealth.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Repayments on notes payable", "label": "Repayments of Notes Payable", "documentation": "The cash outflow for a borrowing supported by a written promise to pay an obligation." } } }, "auth_ref": [ "r71" ] }, "us-gaap_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "calculation": { "http://syrahealth.com/role/StatementsOfOperations": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://syrahealth.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Research and development expenses", "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity." } } }, "auth_ref": [ "r326", "r532", "r544", "r691" ] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": { "http://syrahealth.com/role/BalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://syrahealth.com/role/BalanceSheets", "http://syrahealth.com/role/GoingConcernDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Accumulated deficit", "negatedLabel": "Accumulated deficit", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r59", "r88", "r405", "r426", "r427", "r436", "r464", "r564" ] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsMember", "presentation": [ "http://syrahealth.com/role/StatementsOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Retained Earnings [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r116", "r150", "r151", "r152", "r154", "r159", "r161", "r163", "r204", "r205", "r208", "r338", "r339", "r340", "r341", "r342", "r344", "r345", "r346", "r352", "r354", "r355", "r357", "r359", "r372", "r374", "r423", "r425", "r440", "r730" ] }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "crdr": "credit", "calculation": { "http://syrahealth.com/role/StatementsOfOperations": { "parentTag": "us-gaap_GrossProfit", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://syrahealth.com/role/NatureOfBusinessAndSignificantAccountingPoliciesDetailsNarrative", "http://syrahealth.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Net revenues", "verboseLabel": "Revenues", "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise." } } }, "auth_ref": [ "r98", "r99", "r178", "r183", "r184", "r195", "r197", "r199", "r200", "r201", "r284", "r285", "r395" ] }, "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerPolicyTextBlock", "presentation": [ "http://syrahealth.com/role/NatureOfBusinessAndSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Revenue Recognition", "documentation": "Disclosure of accounting policy for revenue from contract with customer." } } }, "auth_ref": [ "r114", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r534" ] }, "us-gaap_Revenues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Revenues", "crdr": "credit", "presentation": [ "http://syrahealth.com/role/ScheduleOfDisaggregationOfRevenueDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Net revenues", "label": "Revenues", "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss)." } } }, "auth_ref": [ "r98", "r99", "r136", "r146", "r178", "r183", "r184", "r195", "r197", "r199", "r200", "r201", "r203", "r222", "r223", "r224", "r225", "r226", "r227", "r228", "r229", "r230", "r363", "r397", "r544", "r642" ] }, "SYRA_STLogicsMember": { "xbrltype": "domainItemType", "nsuri": "http://syrahealth.com/20240331", "localname": "STLogicsMember", "presentation": [ "http://syrahealth.com/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "ST Logics [Member]", "documentation": "ST Logics [Member]" } } }, "auth_ref": [] }, "SYRA_STVenturesMember": { "xbrltype": "domainItemType", "nsuri": "http://syrahealth.com/20240331", "localname": "STVenturesMember", "presentation": [ "http://syrahealth.com/role/LeaseDetailsNarrative", "http://syrahealth.com/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "STVentures [Member]", "documentation": "STVentures [Member]" } } }, "auth_ref": [] }, "SYRA_SahasraTechnologiesCorpMember": { "xbrltype": "domainItemType", "nsuri": "http://syrahealth.com/20240331", "localname": "SahasraTechnologiesCorpMember", "presentation": [ "http://syrahealth.com/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Sahasra Technologies Corp [Member]", "documentation": "Sahasra Technologies Corp [Member]" } } }, "auth_ref": [] }, "us-gaap_SalariesAndWages": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SalariesAndWages", "crdr": "debit", "calculation": { "http://syrahealth.com/role/StatementsOfOperations": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://syrahealth.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Salaries and benefits", "documentation": "Amount of expense for salary and wage arising from service rendered by nonofficer employee. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold." } } }, "auth_ref": [ "r610" ] }, "us-gaap_SalesRevenueNetMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SalesRevenueNetMember", "presentation": [ "http://syrahealth.com/role/NatureOfBusinessAndSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Revenue Benchmark [Member]", "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation." } } }, "auth_ref": [ "r201", "r604" ] }, "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "presentation": [ "http://syrahealth.com/role/AccruedExpensesTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Accrued Expenses", "documentation": "Tabular disclosure of the components of accrued liabilities." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "presentation": [ "http://syrahealth.com/role/ScheduleOfDilutedEarningsPerShareDetails" ], "lang": { "en-us": { "role": { "label": "Antidilutive Security, Excluded EPS Calculation [Table]", "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS." } } }, "auth_ref": [ "r21" ] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "presentation": [ "http://syrahealth.com/role/BasicAndDilutedEarningsPerShareTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Diluted Earnings Per Share", "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities." } } }, "auth_ref": [ "r21" ] }, "us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfDefinedBenefitPlansDisclosuresTable", "presentation": [ "http://syrahealth.com/role/LeaseDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Defined Benefit Plan [Table]", "documentation": "Disclosure of information about individual defined benefit pension plan or other postretirement defined benefit plan. It may be appropriate to group certain similar plans. Also includes schedule for fair value of plan assets by major categories of plan assets by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets or liabilities (Level 1), Significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)." } } }, "auth_ref": [ "r8", "r36", "r37", "r38", "r39" ] }, "us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfOtherCurrentAssetsTableTextBlock", "presentation": [ "http://syrahealth.com/role/OtherCurrentAssetsTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Other Current Assets", "documentation": "Tabular disclosure of the carrying amounts of other current assets." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfProductInformationTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfProductInformationTable", "presentation": [ "http://syrahealth.com/role/NatureOfBusinessAndSignificantAccountingPoliciesDetailsNarrative", "http://syrahealth.com/role/ScheduleOfDisaggregationOfRevenueDetails" ], "lang": { "en-us": { "role": { "label": "Nature of Operation, Product Information, Concentration of Risk [Table]", "documentation": "Disclosure of information about concentration risk of product within nature of operation." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "presentation": [ "http://syrahealth.com/role/ScheduleOfPropertyAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Table]", "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation." } } }, "auth_ref": [ "r6", "r380" ] }, "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "presentation": [ "http://syrahealth.com/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Related Party Transaction [Table]", "documentation": "Disclosure of information about related party transaction." } } }, "auth_ref": [ "r42", "r43", "r489", "r490", "r493" ] }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "presentation": [ "http://syrahealth.com/role/CommonStockOptionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]", "documentation": "Disclosure of information about share-based payment arrangement." } } }, "auth_ref": [ "r290", "r291", "r292", "r293", "r294", "r296", "r297", "r298", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r316", "r317", "r318", "r319", "r320" ] }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "presentation": [ "http://syrahealth.com/role/CommonStockOptionsTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Share-Based Compensation, Stock Options Activity", "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value." } } }, "auth_ref": [ "r10", "r11", "r90" ] }, "us-gaap_ScheduleOfStockByClassTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfStockByClassTable", "presentation": [ "http://syrahealth.com/role/ChangesInStockholdersEquityDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Stock, Class of Stock [Table]", "documentation": "Disclosure of information about stock by class. Includes, but is not limited to, common, convertible, and preferred stocks." } } }, "auth_ref": [ "r30", "r31", "r32", "r33", "r34", "r35", "r84", "r86", "r87", "r88", "r124", "r125", "r126", "r180", "r259", "r260", "r261", "r263", "r266", "r271", "r273", "r432", "r433", "r434", "r435", "r554", "r603", "r616" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": [ "http://syrahealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r584" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12gTitle", "presentation": [ "http://syrahealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r588" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": [ "http://syrahealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r587" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityReportingObligation", "presentation": [ "http://syrahealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r593" ] }, "us-gaap_SegmentReportingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentReportingPolicyPolicyTextBlock", "presentation": [ "http://syrahealth.com/role/NatureOfBusinessAndSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Segment Reporting", "documentation": "Disclosure of accounting policy for segment reporting." } } }, "auth_ref": [ "r188", "r189", "r190", "r191", "r192", "r193", "r194", "r198", "r200", "r542", "r543", "r546" ] }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SellingGeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://syrahealth.com/role/StatementsOfOperations": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://syrahealth.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Selling, general and administrative expenses", "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc." } } }, "auth_ref": [ "r68" ] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensation", "crdr": "debit", "calculation": { "http://syrahealth.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://syrahealth.com/role/CommonStockOptionsDetailsNarrative", "http://syrahealth.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Stock-based compensation, stock options", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": [ "r4" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "presentation": [ "http://syrahealth.com/role/CommonStockOptionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Weighted average risk free interest rate", "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares." } } }, "auth_ref": [ "r319" ] }, "SYRA_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://syrahealth.com/20240331", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExercisePrice", "presentation": [ "http://syrahealth.com/role/CommonStockOptionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Weighted average call option value", "documentation": "Weighted average exercise price." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate", "presentation": [ "http://syrahealth.com/role/CommonStockOptionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Weighted average volatility rate", "documentation": "Rate of weighted-average expected volatility for award under share-based payment arrangement." } } }, "auth_ref": [ "r317" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "presentation": [ "http://syrahealth.com/role/CommonStockOptionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r290", "r291", "r292", "r293", "r294", "r296", "r297", "r298", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r316", "r317", "r318", "r319", "r320" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "presentation": [ "http://syrahealth.com/role/ScheduleOfShare-basedCompensationStockOptionsActivityDetails" ], "lang": { "en-us": { "role": { "periodEndLabel": "Exercisable ending balance", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number", "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan." } } }, "auth_ref": [ "r298" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "presentation": [ "http://syrahealth.com/role/ScheduleOfShare-basedCompensationStockOptionsActivityDetails" ], "lang": { "en-us": { "role": { "label": "Weighted average exercise price, exercisable", "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan." } } }, "auth_ref": [ "r298" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod", "presentation": [ "http://syrahealth.com/role/ScheduleOfShare-basedCompensationStockOptionsActivityDetails" ], "lang": { "en-us": { "role": { "label": "Options cancelled", "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements." } } }, "auth_ref": [ "r303" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod", "presentation": [ "http://syrahealth.com/role/CommonStockOptionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Granted options", "documentation": "Net number of share options (or share units) granted during the period." } } }, "auth_ref": [ "r653" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "presentation": [ "http://syrahealth.com/role/ScheduleOfShare-basedCompensationStockOptionsActivityDetails" ], "lang": { "en-us": { "role": { "label": "Options granted", "documentation": "Gross number of share options (or share units) granted during the period." } } }, "auth_ref": [ "r300" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "presentation": [ "http://syrahealth.com/role/ScheduleOfShare-basedCompensationStockOptionsActivityDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Number of options, beginning balance", "periodEndLabel": "Number of options, ending balance", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number", "documentation": "Number of options outstanding, including both vested and non-vested options." } } }, "auth_ref": [ "r296", "r297" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "presentation": [ "http://syrahealth.com/role/ScheduleOfShare-basedCompensationStockOptionsActivityDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Weighted average exercise prices, ending balance", "periodEndLabel": "Weighted average exercise prices, ending balance", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan." } } }, "auth_ref": [ "r296", "r297" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue", "crdr": "debit", "presentation": [ "http://syrahealth.com/role/CommonStockOptionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Aggregate intrinsic value", "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r312" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": [ "http://syrahealth.com/role/ChangesInStockholdersEquityDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": [ "r292", "r293", "r294", "r296", "r297", "r298", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r316", "r317", "r318", "r319", "r320" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice", "presentation": [ "http://syrahealth.com/role/ScheduleOfShare-basedCompensationStockOptionsActivityDetails" ], "lang": { "en-us": { "role": { "label": "Weighted average exercise price, cancelled", "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired." } } }, "auth_ref": [ "r303" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "presentation": [ "http://syrahealth.com/role/ScheduleOfShare-basedCompensationStockOptionsActivityDetails" ], "lang": { "en-us": { "role": { "label": "Weighted average exercise price, granted", "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options." } } }, "auth_ref": [ "r300" ] }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "presentation": [ "http://syrahealth.com/role/NatureOfBusinessAndSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Stock-Based Compensation", "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost." } } }, "auth_ref": [ "r289", "r295", "r314", "r315", "r316", "r317", "r320", "r321", "r322", "r323", "r324" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "presentation": [ "http://syrahealth.com/role/CommonStockOptionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Expected term", "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r316" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "presentation": [ "http://syrahealth.com/role/CommonStockOptionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Granted options term", "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r91" ] }, "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2", "presentation": [ "http://syrahealth.com/role/CommonStockOptionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Remaining contractual life", "documentation": "Weighted average remaining contractual term of outstanding stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r91" ] }, "us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareholdersEquityAndShareBasedPaymentsTextBlock", "presentation": [ "http://syrahealth.com/role/CommonStockOptions" ], "lang": { "en-us": { "role": { "label": "Common Stock Options", "documentation": "The entire disclosure for shareholders' equity and share-based payment arrangement. Includes, but is not limited to, disclosure of policy and terms of share-based payment arrangement, deferred compensation arrangement, and employee stock purchase plan (ESPP)." } } }, "auth_ref": [ "r85", "r89" ] }, "us-gaap_SharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharesOutstanding", "presentation": [ "http://syrahealth.com/role/StatementsOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "periodStartLabel": "Balance, shares", "periodEndLabel": "Balance, shares", "label": "Shares, Outstanding", "documentation": "Number of shares issued which are neither cancelled nor held in the treasury." } } }, "auth_ref": [] }, "SYRA_SignificantConcentrationsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://syrahealth.com/20240331", "localname": "SignificantConcentrationsPolicyTextBlock", "presentation": [ "http://syrahealth.com/role/NatureOfBusinessAndSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Significant Concentrations", "documentation": "Significant Concentrations [Policy Text Block]" } } }, "auth_ref": [] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SolicitingMaterial", "presentation": [ "http://syrahealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r591" ] }, "us-gaap_StatementClassOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementClassOfStockAxis", "presentation": [ "http://syrahealth.com/role/BalanceSheets", "http://syrahealth.com/role/BalanceSheetsParenthetical", "http://syrahealth.com/role/ChangesInStockholdersEquityDeficitDetailsNarrative", "http://syrahealth.com/role/StatementsOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]", "documentation": "Information by the different classes of stock of the entity." } } }, "auth_ref": [ "r115", "r124", "r125", "r126", "r146", "r167", "r168", "r170", "r172", "r180", "r181", "r203", "r222", "r224", "r225", "r226", "r229", "r230", "r259", "r260", "r263", "r266", "r273", "r363", "r432", "r433", "r434", "r435", "r440", "r441", "r442", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r452", "r463", "r486", "r508", "r521", "r522", "r523", "r524", "r525", "r603", "r616", "r625" ] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementEquityComponentsAxis", "presentation": [ "http://syrahealth.com/role/StatementsOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": [ "r9", "r57", "r60", "r61", "r116", "r133", "r134", "r135", "r150", "r151", "r152", "r154", "r159", "r161", "r163", "r179", "r204", "r205", "r208", "r275", "r338", "r339", "r340", "r341", "r342", "r344", "r345", "r346", "r352", "r353", "r354", "r355", "r356", "r357", "r359", "r364", "r365", "r366", "r367", "r368", "r369", "r372", "r374", "r381", "r412", "r423", "r424", "r425", "r440", "r508" ] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementLineItems", "presentation": [ "http://syrahealth.com/role/BalanceSheets", "http://syrahealth.com/role/BalanceSheetsParenthetical", "http://syrahealth.com/role/StatementsOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r150", "r151", "r152", "r179", "r374", "r395", "r430", "r452", "r455", "r456", "r457", "r458", "r459", "r460", "r463", "r466", "r467", "r468", "r469", "r470", "r473", "r474", "r475", "r476", "r478", "r479", "r480", "r481", "r482", "r484", "r487", "r488", "r494", "r495", "r496", "r497", "r498", "r499", "r500", "r501", "r502", "r503", "r504", "r505", "r508", "r575" ] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfFinancialPositionAbstract", "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfStockholdersEquityAbstract", "auth_ref": [] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementTable", "presentation": [ "http://syrahealth.com/role/BalanceSheets", "http://syrahealth.com/role/BalanceSheetsParenthetical", "http://syrahealth.com/role/StatementsOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Statement [Table]", "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity." } } }, "auth_ref": [ "r150", "r151", "r152", "r179", "r202", "r374", "r395", "r430", "r452", "r455", "r456", "r457", "r458", "r459", "r460", "r463", "r466", "r467", "r468", "r469", "r470", "r473", "r474", "r475", "r476", "r478", "r479", "r480", "r481", "r482", "r484", "r487", "r488", "r494", "r495", "r496", "r497", "r498", "r499", "r500", "r501", "r502", "r503", "r504", "r505", "r508", "r575" ] }, "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesIssuedForServices", "presentation": [ "http://syrahealth.com/role/StatementsOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Class A common stock awarded for services, shares", "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesNewIssues", "presentation": [ "http://syrahealth.com/role/StatementsOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Warrants exercised for cash, shares", "documentation": "Number of new stock issued during the period." } } }, "auth_ref": [ "r9", "r56", "r57", "r88", "r432", "r508", "r522" ] }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross", "presentation": [ "http://syrahealth.com/role/ChangesInStockholdersEquityDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Restricted stock awarded", "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards." } } }, "auth_ref": [ "r9", "r88" ] }, "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueIssuedForServices", "crdr": "credit", "presentation": [ "http://syrahealth.com/role/StatementsOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Class A common stock awarded for services", "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueNewIssues", "crdr": "credit", "presentation": [ "http://syrahealth.com/role/CommonStockOptionsDetailsNarrative", "http://syrahealth.com/role/StatementsOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Warrants exercised for cash", "verboseLabel": "Shares issued", "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering." } } }, "auth_ref": [ "r9", "r56", "r57", "r88", "r440", "r508", "r522", "r581" ] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquity", "crdr": "credit", "calculation": { "http://syrahealth.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://syrahealth.com/role/BalanceSheets", "http://syrahealth.com/role/StatementsOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "totalLabel": "Total stockholders\u2019 equity (deficit)", "periodStartLabel": "Balance", "periodEndLabel": "Balance", "label": "Equity, Attributable to Parent", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": [ "r57", "r60", "r61", "r78", "r465", "r483", "r509", "r510", "r564", "r582", "r618", "r635", "r676", "r730" ] }, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityAbstract", "presentation": [ "http://syrahealth.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Stockholders\u2019 equity (deficit):" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityNoteDisclosureTextBlock", "presentation": [ "http://syrahealth.com/role/ChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Changes in Stockholders\u2019 Equity (Deficit)", "documentation": "The entire disclosure for equity." } } }, "auth_ref": [ "r85", "r145", "r258", "r260", "r262", "r263", "r264", "r265", "r266", "r267", "r268", "r269", "r270", "r272", "r275", "r358", "r511", "r513", "r526" ] }, "us-gaap_SubsequentEventsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventsAbstract", "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SubsequentEventsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventsTextBlock", "presentation": [ "http://syrahealth.com/role/SubsequentEvents" ], "lang": { "en-us": { "role": { "label": "Subsequent Events", "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business." } } }, "auth_ref": [ "r390", "r391" ] }, "us-gaap_SubstantialDoubtAboutGoingConcernTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubstantialDoubtAboutGoingConcernTextBlock", "presentation": [ "http://syrahealth.com/role/GoingConcern" ], "lang": { "en-us": { "role": { "label": "Going Concern", "documentation": "The entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern." } } }, "auth_ref": [ "r46" ] }, "SYRA_SupplementalBalanceSheetsInformationTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://syrahealth.com/20240331", "localname": "SupplementalBalanceSheetsInformationTableTextBlock", "presentation": [ "http://syrahealth.com/role/LeaseTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Supplemental Balance Sheets Information", "documentation": "Supplemental balance sheets information table text block." } } }, "auth_ref": [] }, "us-gaap_SupplementalCashFlowInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SupplementalCashFlowInformationAbstract", "presentation": [ "http://syrahealth.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "SUPPLEMENTAL INFORMATION:" } } }, "auth_ref": [] }, "us-gaap_TaxCreditCarryforwardAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TaxCreditCarryforwardAxis", "presentation": [ "http://syrahealth.com/role/OtherCurrentAssetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Tax Credit Carryforward [Axis]", "documentation": "Information by specific tax credit related to an unused tax credit." } } }, "auth_ref": [ "r336" ] }, "us-gaap_TaxCreditCarryforwardLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TaxCreditCarryforwardLineItems", "presentation": [ "http://syrahealth.com/role/OtherCurrentAssetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Tax Credit Carryforward [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r336" ] }, "us-gaap_TaxCreditCarryforwardNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TaxCreditCarryforwardNameDomain", "presentation": [ "http://syrahealth.com/role/OtherCurrentAssetsParenthetical" ], "lang": { "en-us": { "role": { "documentation": "The name of the tax credit carryforward." } } }, "auth_ref": [ "r336" ] }, "us-gaap_TaxCreditCarryforwardTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TaxCreditCarryforwardTable", "presentation": [ "http://syrahealth.com/role/OtherCurrentAssetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Tax Credit Carryforward [Table]", "documentation": "Disclosure of information about tax credit carryforward available to reduce future taxable income. Includes, but is not limited to, description, amount, expiration date, limitation on use, and related deferred tax asset and valuation allowance." } } }, "auth_ref": [ "r336" ] }, "us-gaap_TradeAndOtherAccountsReceivablePolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TradeAndOtherAccountsReceivablePolicy", "presentation": [ "http://syrahealth.com/role/NatureOfBusinessAndSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Accounts Receivable", "documentation": "Disclosure of accounting policy for accounts receivable." } } }, "auth_ref": [ "r102", "r103", "r104", "r632", "r633", "r634" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": [ "http://syrahealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "SYRA_TwoInvestorsMember": { "xbrltype": "domainItemType", "nsuri": "http://syrahealth.com/20240331", "localname": "TwoInvestorsMember", "presentation": [ "http://syrahealth.com/role/ChangesInStockholdersEquityDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Two Investors [Member]", "documentation": "Two Investors [Member]" } } }, "auth_ref": [] }, "SYRA_TwoThouandTwentyTwoPlanMember": { "xbrltype": "domainItemType", "nsuri": "http://syrahealth.com/20240331", "localname": "TwoThouandTwentyTwoPlanMember", "presentation": [ "http://syrahealth.com/role/CommonStockOptionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "2022 Plan [Member]", "documentation": "2022 Plan [Member]" } } }, "auth_ref": [] }, "us-gaap_TypeOfArrangementAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TypeOfArrangementAxis", "presentation": [ "http://syrahealth.com/role/NotesPayableDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]", "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": [ "r347" ] }, "us-gaap_UnamortizedDiscountsOnAcceptancesExecuted": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UnamortizedDiscountsOnAcceptancesExecuted", "crdr": "credit", "presentation": [ "http://syrahealth.com/role/CommonStockOptionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Unamortized expenses", "documentation": "The amount of the unearned (fee) income on the financial institution's issuance of short-term negotiable time drafts (also known as Banker's Acceptances)." } } }, "auth_ref": [ "r93" ] }, "us-gaap_UseOfEstimates": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UseOfEstimates", "presentation": [ "http://syrahealth.com/role/NatureOfBusinessAndSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Use of Estimates", "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles." } } }, "auth_ref": [ "r25", "r26", "r27", "r106", "r107", "r110", "r111" ] }, "us-gaap_WarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WarrantMember", "presentation": [ "http://syrahealth.com/role/ScheduleOfDilutedEarningsPerShareDetails" ], "lang": { "en-us": { "role": { "label": "Warrant [Member]", "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount." } } }, "auth_ref": [ "r572", "r573", "r576", "r577", "r578", "r579" ] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "presentation": [ "http://syrahealth.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Weighted average common shares outstanding - diluted", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": [ "r166", "r172" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "presentation": [ "http://syrahealth.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Weighted average common shares outstanding - basic", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": [ "r165", "r172" ] }, "SYRA_WorkingCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://syrahealth.com/20240331", "localname": "WorkingCapital", "crdr": "credit", "presentation": [ "http://syrahealth.com/role/GoingConcernDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Working capital", "documentation": "Working capital." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "WrittenCommunications", "presentation": [ "http://syrahealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r601" ] } } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "4", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482338/360-10-05-4" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(g)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "825", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-1" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "20", "Topic": "715", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-4" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-5" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-20" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481142/505-10-45-2" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-10" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-4" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-5" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "715", "SubTopic": "20", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-2" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "715", "SubTopic": "20", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-3" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "715", "SubTopic": "20", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-4" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "715", "SubTopic": "20", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-20" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "21", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "850", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "850", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "470", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "825", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478898/942-825-50-1" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "40", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/205-40/tableOfContent" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(2)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/235/tableOfContent" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "275", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/275/tableOfContent" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "275", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18" }, "r78": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2" }, "r79": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/360/tableOfContent" }, "r80": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r81": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.CC)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480091/360-10-S99-2" }, "r82": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "440", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/440/tableOfContent" }, "r83": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/470/tableOfContent" }, "r84": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1" }, "r85": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/505/tableOfContent" }, "r86": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6" }, "r87": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7" }, "r88": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r89": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/718/tableOfContent" }, "r90": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r91": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(e)(1)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r92": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r93": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r94": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r95": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r96": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r97": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r98": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r99": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r100": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r101": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r102": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-11B" }, "r103": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-15" }, "r104": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-6" }, "r105": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "SubTopic": "210", "Topic": "946", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-20" }, "r106": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r107": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r108": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r109": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-1" }, "r110": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11" }, "r111": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12" }, "r112": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-6" }, "r113": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-7" }, "r114": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "606", "Publisher": "FASB", "URI": "https://asc.fasb.org/606/tableOfContent" }, "r115": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "a", "Publisher": "SEC" }, "r116": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r117": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7" }, "r118": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r119": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5" }, "r120": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r121": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r122": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r123": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r124": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r125": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r126": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r127": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r128": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r129": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r130": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r131": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r132": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-1" }, "r133": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r134": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r135": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r136": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r137": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r138": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17" }, "r139": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r140": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r141": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2" }, "r142": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A" }, "r143": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8" }, "r144": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r145": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(e)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r146": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r147": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(k)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r148": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(k)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r149": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3" }, "r150": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r151": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r152": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r153": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r154": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r155": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r156": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r157": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3" }, "r158": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4" }, "r159": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r160": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r161": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r162": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8" }, "r163": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9" }, "r164": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/260/tableOfContent" }, "r165": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10" }, "r166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16" }, "r167": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2" }, "r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-3" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-24" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "36", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-36" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482955/340-10-05-5" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483032/340-10-45-1" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-17" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-18" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-18" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-19" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-4" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(n)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/718/tableOfContent" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1D", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.C.Q3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.1.Q5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.2.Q6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.3.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "720", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-25" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-28" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12A", "Subparagraph": "(a)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12A", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-19" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-20" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-22" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "808", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483013/835-20-50-1" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/842-20/tableOfContent" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "12A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-1" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/850/tableOfContent" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-6" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/855/tableOfContent" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.W.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "825", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(h)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-2" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-5" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-6" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-2" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "27", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-27" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-21" }, "r452": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4" }, "r453": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r454": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r455": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r457": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r458": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r459": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r460": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r461": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r462": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r463": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r464": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r465": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r466": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r467": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r468": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r469": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r470": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r471": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r472": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(5)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r473": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r474": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r475": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r476": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r477": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r478": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r479": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r480": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r481": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r482": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r483": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r484": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3" }, "r485": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7" }, "r486": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478297/946-220-50-3" }, "r487": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r488": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r489": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r490": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r491": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r492": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r493": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r494": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r495": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r496": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r497": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r498": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r499": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r500": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r501": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r502": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r503": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r504": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r505": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r506": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r507": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r508": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r509": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r510": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r511": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r512": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r513": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r514": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r515": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1" }, "r516": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r517": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r518": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r519": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r520": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r521": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-1" }, "r522": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r523": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r524": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r525": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r526": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6" }, "r527": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479196/954-310-45-1" }, "r528": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478785/954-310-50-2" }, "r529": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "440", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1" }, "r530": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1" }, "r531": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1" }, "r532": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "985", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2" }, "r533": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r534": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4" }, "r535": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(a)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H" }, "r536": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r537": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r538": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r539": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52" }, "r540": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r541": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, "r542": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r543": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r544": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "48", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48" }, "r545": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "49", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49" }, "r546": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r547": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A" }, "r548": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482955/340-10-05-5" }, "r549": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r550": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B" }, "r551": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C" }, "r552": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69E" }, "r553": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69F" }, "r554": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r555": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r556": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r557": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8" }, "r558": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "103", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103" }, "r559": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r560": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r561": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r562": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8" }, "r563": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "53", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53" }, "r564": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10" }, "r565": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2" }, "r566": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H" }, "r567": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F" }, "r568": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r569": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r570": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E" }, "r571": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18" }, "r572": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r573": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r574": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1" }, "r575": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1" }, "r576": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r577": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r578": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r579": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r580": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10" }, "r581": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11" }, "r582": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12" }, "r583": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r584": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r585": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r586": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r587": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r588": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r589": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r590": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r591": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14a", "Subsection": "12" }, "r592": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r593": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r594": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r595": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r596": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r597": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r598": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r599": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r600": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r601": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r602": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" }, "r603": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3" }, "r604": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18" }, "r605": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "SubTopic": "825", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B" }, "r606": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(1)", "SubTopic": "20", "Topic": "842", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r607": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Topic": "705", "Publisher": "FASB", "URI": "https://asc.fasb.org/705/tableOfContent" }, "r608": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r609": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r610": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r611": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r612": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r613": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r614": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r615": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r616": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r617": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r618": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r619": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(k)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r620": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(k)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r621": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r622": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r623": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r624": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r625": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "55", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-55" }, "r626": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r627": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r628": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r629": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r630": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r631": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2" }, "r632": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2" }, "r633": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2" }, "r634": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481569/310-20-50-1" }, "r635": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r636": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483032/340-10-45-1" }, "r637": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/405-30/tableOfContent" }, "r638": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10" }, "r639": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/450/tableOfContent" }, "r640": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r641": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r642": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r643": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r644": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r645": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5" }, "r646": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r647": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r648": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r649": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r650": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r651": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r652": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r653": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r654": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r655": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r656": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r657": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r658": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r659": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r660": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r661": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r662": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r663": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r664": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r665": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r666": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r667": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r668": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r669": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r670": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r671": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r672": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "720", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483384/720-30-45-1" }, "r673": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12" }, "r674": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r675": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r676": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r677": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2" }, "r678": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1" }, "r679": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-4" }, "r680": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3" }, "r681": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r682": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3" }, "r683": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r684": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r685": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r686": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r687": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r688": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r689": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r690": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r691": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "912", "SubTopic": "730", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1" }, "r692": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r693": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r694": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r695": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r696": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r697": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B" }, "r698": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r699": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r700": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C" }, "r701": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D" }, "r702": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4G", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G" }, "r703": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r704": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r705": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r706": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r707": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r708": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r709": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r710": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r711": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r712": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r713": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r714": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r715": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r716": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r717": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r718": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r719": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r720": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r721": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r722": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r723": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r724": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r725": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r726": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r727": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r728": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(k)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3" }, "r729": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r730": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r731": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" } } } ZIP 65 0001493152-24-018382-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-24-018382-xbrl.zip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�M"+W!->1/*J@ MKXMW0A^<7S6SS[Y+ITP%[76?R73$*\( ^;&WN+C6V:G(TJ&@"+X_#T&P7MSN M_(*+UJ&#XO+60GX5=7= 50%H0/2QJ [J#ADHI-N@"I%1"1JG0$,(1V-=PQ%SHV_%LS ^QAY6:81,N<_M/=.$ M.:\]1Q;\N'';^=(KTG/Y;.A(WP =[8\E4GW@EL3Q!A%%&7)6Y# M2:*+%LCO7GH6#!Z74K@\M;,M<,XFE1!/#P#29M?3Q26FEU1Z9Q7>S#55)V-! MP?>H-!]&\+\$[K;8M+..=/E_LQ?%HJ3C$!S"$ M4/'OZ%S6I8H/W,''$?@4W>5004]&)V+2UDF6BXD*QF-$\C67!' \ MQU:N_5PN&5^]>?ZR+TYO,]\UQA*W!H*JP9 :%>9?+59B/6?QV^I=P"CFOUJL M>/%NWGZ'];7][=9W)BI=T;O@HVR:S!T/2HWCF=K5 O;Y\\U?0D7.R3BD7! 7#E@[SJ@]>')OXZ!CR+]">UC0_N]R[U#F<01T[ZM03*BV_&" MK#W:)5*O+_BCB'E"ZI.7:N\51*=)>=00Y7+[ZD]=XA,VB#,;1*<-7#=VCR8- MLI239 +D))FHCN.?@E@9M8%H\T"6<).-)=OJM.P#R1,=M75=);FOHN/3 M9P7_>O54_;P8<.+',OTQ9P3.9[Z()R^1,0H=H@\,^>V>")':(0^RP_WV+Q%$^K*,/JLE(07 M)\3)27@1 \:.>WAQ9%R>A!=Q#"^.C(F2\"(>X46\V,;/@)W39Y5#!Q5+&U:1 MG[=*@H(X^D[Q" KBQ8F)4Q\#QHRA4W](+DV<\I@XY8=D@L2ICD=QSW[(?I0' M R)'3K(A$;?8(?)>#]K"X,[(V0]W>T5[HL$]:?"$SQ,^/VE][C=H+G$< M&K<+ R\."&]H=&,2-Q]7W.Q&P21T/@KSM-)A+1';1&P3L0UH;9>:3<4AXW6, MLA59M/]A57S"*['AE2/QXC=&JR?(* $CST2C)%R2Z!)ONJ0B#(1Y7N5D6<1A ME8D6\:1%$OY(],&=./'. M<>D=0U4#B.8CSUEZBI57UIGH%Q\YE81'$CVRS".9-$,>S^GA,)"+5APE/%K#-#EE583N &TJR* \$H)9E97R\6FYQ(DF$*.2; M$/O3CL)**HL+/=3KJ?T7F_[;B(G$5CH=>[-XJ','T<4=L;L=G&F6EKY/+MGG M,4>KD""A=RSH'?F\*ZAQ\E#I+.C]"T*J*\<<4.] \>7%'XCF)DDBH+GI(=!I M,FMX".:GA/H'IOZ2'V 2Q9VW)X'G QE:^BI3+5VF0:$9/ MFC'A\H3+3U^7MP"GZ(*&,%"2^%M]Q$HMH,JZP@%G7J^C4'QRLGSN&1^'Y78[ M%1)][DF?)YR>&718^&L!#:U8 MECKLI*P 7C@!4SM?2AF:PVE?5MY9A;>Y^MO6GF@O;RP$+Y9' E/]=594D,2CWJ ?8I[4FL6.YJO5(U%4FF8GU<: M)G6F,:#^:J5AWJ]'N')/^"$&->>9I#8YACQ#!> 9*C*>6=B6A%-BP"G+MB6B M*G;GDRHU2=4A>CC0E.$JIS>"!/^ L7<);8(,\%RK$^ &%#<7 MJ885%DNHBM:]%R1AI(^6JRM.FTE0[44+K<-@"MR\TXZ%4&LJ$D[TS(GL).'$ MRR4L))P8/2>Z]HC^$!QXO,P1X_[%SMF[SKMX=JGG:$"CK@1^+QL M".VM+S;)C*)L#VM.V&>#H2[+4-H53>B)P! \+)'7Q\\M&S0-YIR-"S\Y@[BT MW\8X$1]AZ=J&B8_% 3&=[+05VS&R%UE5G1W:W9!L"0O&I M=TZH1N-?&3-R>T$BXY&==8EP2# MV(_MRBKQ1H!5=05<":JI3UT]+ST;.<'XY/JZANSS>QA*\)^ (( M6M/Y);SP!AEF#:'HSKH^ @JKR>O6QOO:5\%S>*;MC16 :N"E+>_'TBY>^)7_ CC-+ EX^_Z(G:U _+W\G@CY\*OF50(*?9D5A M(%T2R E#JOJ;.F8E^_O3?3RT\G(;!/A:59@! ^#SJ__[#Y4COW[[@AYX]>W+ M^.K0*S- ^)]TFK@1@,A?$BU=!.DF.P!$.GWU#6+?@NY=X+4A H_\YWSIAYZL M0%H9P%R++/="9. *5%D4^&4,(*#,BRU C>NIBZQUQP)%B/#F_]O ^[($WZ&Q M=[I\$<;*"FAEWWI7C_5:IUHY:W=*G6K[VY?>U8FNLUTM/[9JG5JU?5:J5XCJ M[_)MJ?Z]2I0;]_>U=KO6J)_@XFES\4^E]FVM_KW3J*?.*F6")K.9X@DN]_2E M]:;1NC\SGHC\_OZ+(] -V%Q;O6/!;PGI1KNPOC'&%_C3,I4'>^W3/*B]G#0E\_DCT MT]"X=?@N483?HLJA?\^A5X[^'K,\;_WM>_4VAVWN=W&R*+)C%8)C?<*AQC=- M\?]\G/CF6-%"%D2S&;=\TWC_C[/C'1%CO@#R@LX*TOK[1@+/BR!4#ES1>L45 MK?>@LPKD!W': F-9T9P5X(]JXW?SST@2[G.!%:#1K_+?\:0MZK- M1JM#-!];[<=2O4-T&@3TR#K0[2(HAFBT""K[B?],-&Z(SFV56#AK"T>M5.Z@ MGZDBDUG2/Q W\/\4(US%TGIUROKH-%:&7!E9.=.&@'BU9((PLGT$D'C $ZOB M7EX1]R:^N&KDB9V%_0]W6\Q6?][;3?"^X8\.YT"5@'2BLSGG61^ M"=#S*VA$N2'!4*FU%6975G@CJ%!JG^&+;N WJO,:._>3B?0HO?>+X3AT!:?79RTW M8^Y^#,)T]?JLJ*[Z>D7'*'@%2M/9RYRDL]=IE>KM&G+G$F\O,24;O#UM+A66 MNXUSX;X3Z_J@"1?6=1B=-V';13(&.2 MDOXG0LD)-=(Z/ ,6EQBPPTYJ9HTIAXFYR;LJZL5BL=?/S'[TP[%KS#IGN0!T M?E7(IC,DG2\6LQZY:AX!'ESE0&2=ADWYA$4=XT96"!F&:@KQ5U<$E1?P"6-H M=NT&!^/P-%8NV!7>' '*@)6$&?[NLVWA.^F,(])DI\/7M8O61?L"(\=L Z^< M*",O*U>\LKI\L<:]\5&>>_:3/X;D[A^I'X>AMCK])9Y7@*J:_[D3)$ Y^UM MN"T\/,U>W^Z8,HZ"ZXA&^EXJ]Q?=(O__PQW%/XEG-%P K T#A(O,!*;,1AV['H M2<-*[T%=F(MPV=!<(EE3AL06_PAC]P3!0%/)^L_FL_ _#)1)81-?2)L0*%31BS(@$F@,/CK.#7:.:#^ODCB=<^4 ]9$P., M^/.S(_LEV\-'LC('MZI@:DADR$L*8-UU8K'Y5W\M9L#O"1>.3ERJ@+._'S)= M)L=\=M&":Z!NB@_W\NCZ;2*'I-J7:E)683B_8C+9 M=*&8)3_87M*GQ=;1__VG0%/YK^J9!D0P1K@A)(R<% &UN*BC31."A;2'^+>K MF!/"QH=2*=3*]HSA:@NR= ,_ .4.#%BQH1C\ 13 N^\!OV;?AO?E&^V^%HZL M,@ZE"-[@.[^JR]H9.T:=&Y"Q^VC2;*#F#"$OA6,GH!"LX9,1K,1;7_5Q_3*! M:K:AA8[WQ<[)DR%PUBK"NJCLH# M-!G>;&Q@4/2GWF?DI:,RM!*G79ZJ5)Q,>8!+8-%CN9>!(NL2C]XE*Y?$^U#0 MP'KLN-+.H+?:SL# G:^5,H5];.QV!$T$5E )6&Y(<*A_702;ZX=/P4= )&H_ M1%)8)#AX/>WIJ">+G]3/"8F\+2M#[H-$R$5:$B,P,4P_ >T!5!KPFX71"#&- MM:OB\OZ>B%&XXD*3I@MM&MTI1?>PJG)VDW,_^QS]LZ,W[\+)]S-+M9*K,)Q? MX1Z?&)4EPNCT2>!6GRGB?\D+DJ2(,:L0;ZRHN[O)80CNH:4U+I"ZY4-,O6FH M3&?.^?FJ7%=*Q>DU"'YT9XESENK 3["KQ"3X/AZ?"F\"4%A M/@F1 TA'\WS>0-$A=58 I^>6]$,BV?8>1? :V$4[?..-04.<-S?O6,^MINE&BB+A/S0]^' M%H%$N",3;BA.+"%"" '!/X,JFR > 3X.&$R%C0 P4^5T;$N:O%W U (/&@[X@X4/6*I)WM--)DU_= M ,0_4U^MRUPO.#,O6 // F#^).0'F!>[P&I=*4A8=T%]TTO3EF=CN3,H2W]Q M>/9*,O2^*^MV26E9B<]LJ">_[A#S8Z#6^#O4?"T3\GFU9>,1!H297&R/U%FD M#Q>)I07!,6A'2/10<]&[BFB42<+R6D\(I0P)-Y"5J;,#2-\.?_TI-Y[;2C:\ M)!!^.683SGSY6C[(H?1Z"5H4[RV9=SOK199L#)T-195Q*%!?@L]/!]635:+Q M%(D$*N]05\AK*Q!)=-OE%>!=-)KE.@(E8BA74E MX@AG(&62[-4<34ZG?^:>/$%%WT;*AUA.^0A]IU0N3N#" %*2D$BMQ BNB,!7U74&0HM%H M/*OP*H%. @J\6X$C\XG][)A#<6VF; K#9-&KTNA6["RQ8O.O-N4?[QZJP>N> MO7749(H.(KL&I>>.FB>>.CH5^?2?]Z8", MPZD(.XR>K74B_WZQ4QP8_1F8_' KE SI2 +A6768DIT?R@]R,^+ M7-,-WAF$T*R5 6QX[OF2J)3F VJS:3*W(@0KX@(QQ,L:#S@!1L'GA/E!_?>\ M5K\Y)]!H2?Q(:XAH+I6AJ51N<73; M>2CM-4@BND.GA=H;<.R^>HH:+H$KX^'?%HVIK2UYD!2F> MR5"W)H)'>DK)K5^0G1![.+^$5)35QR_4XTGK)Y&40>\33692-%-(T=GL9QL/ MPRO0:_\]IP-(6L1L@9!4:G4PK+4+XJ96+]7+M=(= ?WA1NN^U%F=ZWN$;:1" M[;CG1/NG74^A'5SV/P2H)\)M&S1-W*A9T\ ( T==' 7W?6.)H8+B__^H+UV2 MI,ZO;N;[";@C(#YQ\>T+>]3Z\"9-)H#_C&O9*X #.#-M7L$D*C11 MH4E*K.)JCP&CDU4Y2FIROFF M/'V4F_+Y\ZM[5F('6!_.CS14!)73514=)$!>94EBQ:DJ8-=TH4:1:C7.%*)K M6D#5Q=44[+'KU,3Y/ J>3C3J26I4YB@U:N'\Z@&=A1:@EXEZ9R+E"+\0K;^1 M;A5E54<'RDH]6=>L+LPM07TYC,(L)OHMUAR6Z+>3U&^9H]1O19RVU!19-(:: M-169 SQ29XGR.@F-<$2@GK[RBOEIEV7=0)'G^/P+4:M=$(W.;;6U?/ %J8=# M''ZAR$1')#KB9'5$W*AYW.=4*.K\"D^W-3P;/(#@0*Y-HK=BSCF)WCI-O54Z M2L5%GU^A'!*!NO7(RM$GWY'V2[+O\>?"1 F>I!(\ROU,BCF_>I1LH]?;K CP MIJ19K;P84YX(:NZW)IHUD2S'CNHB69-]C5] M:=;,^54%]%E0I401)HKPV$%-%.'!%&'N*!5A_ORJ.AD*/>%0+;TH*E%7L6:81%WMHJYB M70FRK H*YU=M^!I6.UQ56(C.D',;E8,.VHI!YWCZ*]$8XT,>E^@MYM2GK\0O M5M31SQ^LL?PZ#RZ][OPJ;4>FA<:O1&<..WI&U]F#Q_(GWK>U?ETB,JNRNUGL_JC4Z5:%6_EUJ56OT[<=-H M/<&/Z;M&XR?ZN]TI=:KWU7JG393J%:)6KSRV.ZUGHE+JE)8J]@[UMP9"NK9@\XJ$,GBE&CAD<&$+!$WLC*"UZ0?\(@@5C"ZJKVS M"I\69?G%' =HG::&<'%#@E4 7!@/EJ8"HK/8*ML'Q)!5H(8V1@>JN$V;W">L MF8%TOG1F#D=;I)71>#1T$55DF!3JD F5).Y_\0E=A\XLTN37YB[H!H%.KA K%P=CB-?"(DW<*$8AV15= 43IPM1-8V@J%T(5H0CJB_%2'5ZF(.G3X!*? &8O]!:6TW16%*=G+#=$A,*X,XA,8!8P M^B#"]]G71_#&"31C+*&!7G><72!6UQ$X"^CAJQ V.<21\&G]/E (A")%P-#T M%7GD @I:S2ZP(/KVS&';^&'R1H*?.>'U19+?)1.OQF[2,_<0_Q5S^6)(V9F(885"AF$SE?'2H.*QK"Z:$EBZFRPV*Q(*KI[;FZAF=)-N\VQ8T'#5NQ5%Q1# M.R=<<-Q

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end XML 67 form10-q_htm.xml IDEA: XBRL DOCUMENT 0001922335 2024-01-01 2024-03-31 0001922335 2024-05-06 0001922335 2024-03-31 0001922335 2023-12-31 0001922335 us-gaap:NonrelatedPartyMember 2024-03-31 0001922335 us-gaap:NonrelatedPartyMember 2023-12-31 0001922335 us-gaap:RelatedPartyMember 2024-03-31 0001922335 us-gaap:RelatedPartyMember 2023-12-31 0001922335 us-gaap:CommonClassAMember 2024-03-31 0001922335 us-gaap:CommonClassAMember 2023-12-31 0001922335 SYRA:ConvertibleClassBCommonStockMember 2024-03-31 0001922335 SYRA:ConvertibleClassBCommonStockMember 2023-12-31 0001922335 2023-01-01 2023-03-31 0001922335 us-gaap:PreferredStockMember 2022-12-31 0001922335 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2022-12-31 0001922335 SYRA:ConvertibleClassBCommonStockMember us-gaap:CommonStockMember 2022-12-31 0001922335 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001922335 us-gaap:RetainedEarningsMember 2022-12-31 0001922335 2022-12-31 0001922335 us-gaap:PreferredStockMember 2023-12-31 0001922335 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2023-12-31 0001922335 SYRA:ConvertibleClassBCommonStockMember us-gaap:CommonStockMember 2023-12-31 0001922335 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001922335 us-gaap:RetainedEarningsMember 2023-12-31 0001922335 us-gaap:PreferredStockMember 2023-01-01 2023-03-31 0001922335 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2023-01-01 2023-03-31 0001922335 SYRA:ConvertibleClassBCommonStockMember us-gaap:CommonStockMember 2023-01-01 2023-03-31 0001922335 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-03-31 0001922335 us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0001922335 us-gaap:PreferredStockMember 2024-01-01 2024-03-31 0001922335 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2024-01-01 2024-03-31 0001922335 SYRA:ConvertibleClassBCommonStockMember us-gaap:CommonStockMember 2024-01-01 2024-03-31 0001922335 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-03-31 0001922335 us-gaap:RetainedEarningsMember 2024-01-01 2024-03-31 0001922335 us-gaap:PreferredStockMember 2023-03-31 0001922335 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2023-03-31 0001922335 SYRA:ConvertibleClassBCommonStockMember us-gaap:CommonStockMember 2023-03-31 0001922335 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0001922335 us-gaap:RetainedEarningsMember 2023-03-31 0001922335 2023-03-31 0001922335 us-gaap:PreferredStockMember 2024-03-31 0001922335 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2024-03-31 0001922335 SYRA:ConvertibleClassBCommonStockMember us-gaap:CommonStockMember 2024-03-31 0001922335 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0001922335 us-gaap:RetainedEarningsMember 2024-03-31 0001922335 SYRA:FamilyAndSocialServicesAdministrationMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-03-31 0001922335 SYRA:FamilyAndSocialServicesAdministrationMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-03-31 0001922335 SYRA:FSSANeuroDiagnosticInstituteMember SYRA:HealthcareWorkforceMember 2024-01-01 2024-03-31 0001922335 SYRA:FSSANeuroDiagnosticInstituteMember SYRA:HealthcareWorkforceMember 2023-01-01 2023-03-31 0001922335 SYRA:FSSADivisionOfMentalHealthAndAddictionMember SYRA:PopulationHealthMember 2024-01-01 2024-03-31 0001922335 SYRA:FSSADivisionOfMentalHealthAndAddictionMember SYRA:PopulationHealthMember 2023-01-01 2023-03-31 0001922335 SYRA:FamilyAndSocialServicesAdministrationMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-03-31 0001922335 SYRA:FamilyAndSocialServicesAdministrationMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-12-31 0001922335 SYRA:HealthcareWorkforceMember 2024-01-01 2024-03-31 0001922335 SYRA:HealthcareWorkforceMember 2023-01-01 2023-03-31 0001922335 SYRA:PopulationHealthMember 2024-01-01 2024-03-31 0001922335 SYRA:PopulationHealthMember 2023-01-01 2023-03-31 0001922335 SYRA:DigitalHealthMember 2024-01-01 2024-03-31 0001922335 SYRA:DigitalHealthMember 2023-01-01 2023-03-31 0001922335 SYRA:BehavioralAndMentalServicesMember 2024-01-01 2024-03-31 0001922335 SYRA:BehavioralAndMentalServicesMember 2023-01-01 2023-03-31 0001922335 SYRA:HealtheducationMember 2024-01-01 2024-03-31 0001922335 SYRA:HealtheducationMember 2023-01-01 2023-03-31 0001922335 2023-01-01 2023-04-30 0001922335 2023-10-03 2023-10-03 0001922335 SYRA:SahasraTechnologiesCorpMember 2024-01-01 2024-03-31 0001922335 SYRA:STLogicsMember 2024-03-31 0001922335 SYRA:STLogicsMember 2023-12-31 0001922335 SYRA:STVenturesMember 2021-07-01 0001922335 SYRA:STVenturesMember 2022-05-01 2022-05-01 0001922335 SYRA:STVenturesMember 2024-01-01 2024-03-31 0001922335 SYRA:STVenturesMember 2023-01-01 2023-03-31 0001922335 SYRA:InformationTechnologyServicesMember SYRA:RadCubeLLCMember 2024-01-01 2024-03-31 0001922335 SYRA:InformationTechnologyServicesMember SYRA:RadCubeLLCMember 2023-01-01 2023-03-31 0001922335 SYRA:RecruitmentAndHumanResourceServicesMember SYRA:NLogixMember 2024-01-01 2024-03-31 0001922335 SYRA:RecruitmentAndHumanResourceServicesMember SYRA:NLogixMember 2023-01-01 2023-03-31 0001922335 us-gaap:WarrantMember 2024-01-01 2024-03-31 0001922335 us-gaap:WarrantMember 2023-01-01 2023-03-31 0001922335 us-gaap:EmployeeStockOptionMember 2024-01-01 2024-03-31 0001922335 us-gaap:EmployeeStockOptionMember 2023-01-01 2023-03-31 0001922335 SYRA:EmployeeRetentionTaxCreditMember 2024-01-01 2024-03-31 0001922335 SYRA:EconomicDevelopmentGrowingEconomyMember 2024-01-01 2024-03-31 0001922335 us-gaap:OfficeEquipmentMember 2024-03-31 0001922335 us-gaap:OfficeEquipmentMember 2023-12-31 0001922335 SYRA:STVenturesMember 2024-03-31 0001922335 SYRA:STVenturesMember 2022-05-01 0001922335 SYRA:STVenturesMember 2022-07-01 2022-07-01 0001922335 SYRA:STVenturesMember 2021-07-01 2021-07-01 0001922335 SYRA:STVenturesMember 2022-07-01 0001922335 SYRA:InsurancePolicyFinancingArrangementsMember 2023-12-31 0001922335 srt:MinimumMember SYRA:InsurancePolicyFinancingArrangementsMember 2023-12-31 0001922335 srt:MaximumMember SYRA:InsurancePolicyFinancingArrangementsMember 2023-12-31 0001922335 SYRA:InsurancePolicyFinancingArrangementsMember 2023-01-01 2023-12-31 0001922335 SYRA:TwoInvestorsMember us-gaap:CommonClassAMember 2024-03-31 0001922335 SYRA:TwoInvestorsMember us-gaap:CommonClassAMember 2024-01-01 2024-03-31 0001922335 SYRA:NovemberTwoThousandTwentyThreeMember 2024-01-01 2024-03-31 0001922335 SYRA:ConvertibleCommonStockBMember 2024-03-31 0001922335 SYRA:ConvertibleClassBCommonStockMember 2022-05-03 0001922335 SYRA:ConvertibleClassBCommonStockMember 2022-05-03 2022-05-03 0001922335 srt:MaximumMember SYRA:OmnibusEquityIncentivePlanMember 2022-04-11 2022-04-11 0001922335 SYRA:TwoThouandTwentyTwoPlanMember 2024-01-01 2024-03-31 0001922335 SYRA:TwoThouandTwentyTwoPlanMember 2024-03-31 iso4217:USD shares iso4217:USD shares utr:sqft pure false --12-31 Q1 0001922335 P5Y P3Y P3Y P3Y 10-Q true 2024-03-31 2024 false 001-41822 SYRA HEALTH CORP. DE 85-4027995 1119 Keystone Way N. #201 Carmel IN 46032 (463) 345-8950 Not applicable Class A Common Stock, $0.001 par value SYRA NASDAQ No Yes Non-accelerated Filer true true false false 6421632 3237957 3280075 745683 1060634 82124 50614 82124 50614 381887 389787 4447651 4781110 72048 78974 31826 63199 4551525 4923283 645567 462991 319698 198978 6108 31826 63199 99021 184904 1102220 910072 1102220 910072 0.001 0.001 10000000 10000000 0 0 0 0 0 0 0.001 0.001 100000000 100000000 5769087 5769087 5588298 5588298 5769 5588 0.001 0.001 5000000 5000000 833334 833334 833334 833334 833 833 833 833 9954708 9071745 -6512005 -5064955 3449305 4013211 4551525 4923283 1752340 1188351 1573053 1041195 179287 147156 736303 457745 194580 236660 277548 402265 215463 12545 11763 1623241 921631 -1443954 -774475 981 2 4077 11419 -3096 -11417 -1447050 -785892 6495213 6495213 4353717 4353717 -0.22 -0.22 -0.18 -0.18 3568758 3569 833334 833 2832308 -2126612 710198 18246 18246 -785892 -785892 3568758 3569 833334 833 2850554 -2912504 -57249 5588298 5588 833334 833 9071745 -5064955 4013211 5588298 5588 833334 833 9071745 -5064955 4013211 130789 131 849998 850129 50000 50 18825 18875 14140 14140 -1447050 -1447050 5769087 5769 833334 833 9954708 -6512005 3449305 5769087 5769 833334 833 9954708 -6512005 3449305 -1447050 -785892 12545 11763 18875 31373 29624 14140 1367 -314951 -835456 31510 -7900 103025 182576 31775 -1600 6108 120720 -34906 -31373 -29624 -800745 -45062 5619 9659 -5619 -9659 850129 155260 300000 751952 85883 1255000 764246 647788 -42118 593067 3280075 3344 3237957 596411 4077 9850 <p id="xdx_809_eus-gaap--BusinessDescriptionAndAccountingPoliciesTextBlock_zTSESWKooPt5" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 1 – <span id="xdx_822_zkVxHYxQ9C0d">Nature of Business and Significant Accounting Policies</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Nature of Business </span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Syra Health Corp. (“Syra” or the “Company”) was incorporated in the state of Indiana on November 20, 2020 to provide workforce staffing solutions, health education and healthcare research consulting services to mental health hospitals and organizations, including government agencies, integrated health networks, managed care entities and pharmaceutical manufacturers. On March 11, 2022, the Company redomiciled to Delaware. The Company’s corporate office is located in Carmel, Indiana.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84D_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zNEFjnkEquJk" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_86A_zYUac4NMtMTa">Basis of Presentation</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The accompanying interim consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) and should be read in conjunction with the financial statements and notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2023, which was filed with the Securities and Exchange Commission (“SEC”) on March 25, 2024. Certain information and footnote disclosures normally included in the financial statements prepared in accordance with U.S. GAAP have been omitted from this report on Form 10-Q pursuant to the rules and regulations of the SEC.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Results for the interim periods in this report are not necessarily indicative of future financial results and have not been audited by our independent registered public accounting firm. In the opinion of management, the accompanying unaudited consolidated financial statements include all adjustments necessary to present fairly our interim financial statements as of March 31, 2024, and for the three ended March 31, 2024 and 2023. These adjustments are of a normal recurring nature and consistent with the adjustments recorded to prepare the annual audited financial statements as of December 31, 2023.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_846_eus-gaap--UseOfEstimates_z8Ho5y2QRslk" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_861_zEUU1ZPuh6gh">Use of Estimates</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that may affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SYRA HEALTH CORP.</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES TO CONDENSED FINANCIAL STATEMENTS</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Unaudited)</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84F_eus-gaap--ConcentrationRiskCreditRisk_ztt6pmuaE45c" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_86E_zXrEcPxCmcf1">Concentrations of Credit Risk</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company maintains cash in bank deposit accounts, the balances of which at times may exceed federally insured limits. Accounts are guaranteed by the Federal Deposit Insurance Corporation (“FDIC”) up to $<span id="xdx_900_eus-gaap--CashFDICInsuredAmount_iI_c20240331_zfTbk9PwTNo6" title="FDIC insured amount">250,000</span> under current regulations. The Company did not have any cash in excess of FDIC insured limits at March 31, 2024. The Company has not experienced any losses in such accounts.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_847_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zBYlkin86Z5f" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_866_zn0kOJWWSMc4">Fair Value of Financial Instruments</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounting Standards Codification (“ASC”) 820 defines fair value, establishes a three-level valuation hierarchy for disclosures of fair value measurement and enhances disclosure requirements for fair value measures. The three levels are defined as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 1 inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 2 inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the financial instrument.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 3 inputs to valuation methodology are unobservable and significant to the fair measurement.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The carrying value of the Company’s financial assets and liabilities, such as cash, accounts receivable and accounts payable are estimated by management to approximate fair value primarily due to the short-term nature of the instruments. The Company’s advances from related party approximates the fair value of such instruments based upon management’s best estimate of interest rates that would be available to the Company for similar financial arrangements at March 31, 2024 and December 31, 2023.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84B_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zcaZPfc9DoLe" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_868_ze0f3L8gU9jh">Cash and Cash Equivalents</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash equivalents include money market accounts which have maturities of three months or less when acquired. For the purpose of the statements of cash flows, all highly liquid investments with an original maturity of three months or less are considered to be cash equivalents. Cash equivalents are stated at cost plus accrued interest, which approximates market value. There were <span id="xdx_90D_eus-gaap--CashEquivalentsAtCarryingValue_iI_do_c20240331_zSePGbcUPhrd" title="Cash equivalents"><span id="xdx_909_eus-gaap--CashEquivalentsAtCarryingValue_iI_do_c20231231_zJjNGiYA6yRa" title="Cash equivalents">no</span></span> cash equivalents on hand at March 31, 2024 and December 31, 2023.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84A_eus-gaap--TradeAndOtherAccountsReceivablePolicy_zenbLc9f8GKe" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_868_zit1UssByp1j">Accounts Receivable</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounts receivable is carried at their estimated collectible amounts. Accounts receivable is periodically evaluated for collectability based on past credit history with customers and their current financial condition. The Company had an allowance of $<span id="xdx_905_eus-gaap--AccountsReceivableNet_iI_c20240331_z0ACFBBnd4Kh" title="Accounts receivable"><span id="xdx_906_eus-gaap--AccountsReceivableNet_iI_c20231231_zSklKFkTIop3" title="Accounts receivable">5,520</span></span> at March 31, 2024 and December 31, 2023.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_848_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zZXFESQpjHz2" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_860_zy3FkGo3Pgk6">Property and Equipment</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property and equipment is stated at cost, less accumulated depreciation. The cost of office equipment is depreciated using the straight-line method based on a <span id="xdx_90B_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dxL_c20240331_z1xfaFdrimMh" title="Property and equipment useful life::XDX::P5Y"><span style="-sec-ix-hidden: xdx2ixbrl0501">five</span></span>-year life expectancy.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Repairs and maintenance expenditures are charged to operations as incurred. Major improvements and replacements, which extend the useful life of an asset, are capitalized and depreciated over the remaining estimated useful life of the asset. When assets are retired or sold, the cost and related accumulated depreciation are eliminated and any resulting gain or loss is reflected in operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_842_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_z1pj2BAG8Co9" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_860_zkO8xysGHqa2">Impairment of Long-Lived Assets</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In accordance with the provisions of ASC Topic 360, “<i>Impairment or Disposal of Long-Lived Assets</i>”, all long-lived assets such as property and equipment held and used by the Company are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is evaluated by a comparison of the carrying amount of an asset to its estimated future undiscounted cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amounts of the assets exceed the fair value of the assets.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SYRA HEALTH CORP.</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES TO CONDENSED FINANCIAL STATEMENTS</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Unaudited)</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_843_eus-gaap--LesseeLeasesPolicyTextBlock_zIXZL9fPGcVh" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><span style="text-decoration: underline"><span id="xdx_860_zcnrU8wmR8G7">Leases</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company accounts for its leases under ASC 842 - <i>Leases</i>. The Company determines if an arrangement is a lease at inception. Operating leases are included in operating lease right-of-use (“ROU”) assets, current portion of obligations under operating leases, and obligations under operating leases, non-current on the Company’s balance sheets.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating lease ROU assets and operating lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at commencement date, adjusted by the deferred rent liabilities at the adoption date. As the Company’s lease does not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at commencement date in determining the present value of future payments. The operating lease ROU asset also includes any lease payments made and excludes lease incentives and initial direct costs incurred. The Company’s terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Operating lease expense is recognized on a straight-line basis over the lease term.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84F_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zFxMWH2CnRx5" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_86A_zX9zPuJoJtu7">Segment Reporting</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ASC Topic 280, “<i>Segment Reporting</i>,” requires annual and interim reporting for an enterprise’s operating segments and related disclosures about its products, services, geographic areas and major customers. An operating segment is defined as a component of an enterprise that engages in business activities from which it may earn revenues and expenses, and about which separate financial information is regularly evaluated by the chief operating decision maker in deciding how to allocate resources. The Company operates as a single segment and will evaluate additional segment disclosure requirements as it expands its operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_846_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_zlDsrCt4UTBj" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_865_zabXt6F3sZ5">Revenue Recognition</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company recognizes revenue in accordance with ASC 606, the core principle of which is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled to receive in exchange for those goods or services. To achieve this core principle, five basic criteria must be met before revenue can be recognized: (1) identify the contract with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to performance obligations in the contract; and (5) recognize revenue when or as the Company satisfies a performance obligation.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company accounts for revenues when both parties to the contract have approved the contract, the rights and obligations of the parties are identified, payment terms are identified, and collectability of consideration is probable. Payment terms vary by client and the services offered.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has the following main forms of revenue:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">–</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Healthcare Workforce;</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">–</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Population Health</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">–</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Digital Health</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">–</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Behavioral and Mental Health Services</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">–</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Health Education</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2.25pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company primarily provides its services to state health and social service agencies and universities. Healthcare Workforce, Health Education and Behavioral Mental Health Service contracts are primarily accounted for as a single performance obligation satisfied over time because the customer simultaneously receives and consumes the benefits of our medical staffing on an hourly or daily basis. Population Health and Digital Health contracts generally consist of multiple performance obligations that are distinct, such as to provide data analytics and reporting, training, or develop technology for implementation and maintenance with the customer. The Company allocates the transaction price across the performance obligations based on the estimated fair value of the distinct performance obligations. Depending on the performance obligation, revenue is recognized at a point in time when the customer obtains the benefit of the services are provide, or over time in the case of digital health revenue where the customer simultaneously receives and consumes benefits of the contract, such as ongoing performance of our technology product.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The contracts generally stipulate bi-weekly or monthly billing, and the Company has elected the “as invoiced” practical expedient to recognize revenue based on the hours incurred at the contractual rate as the Company has the right to payment in an amount that corresponds directly with the value of performance completed to date. The Company may also be subject to penalties for violations of certain ethical standards and non-performance measures within these state contracts. The Company recognizes revenue net of penalties.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Disaggregated revenue data</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_892_eus-gaap--DisaggregationOfRevenueTableTextBlock_zWSmXELpTmlg" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s revenue consists of the following revenue services within its industry:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B6_zbXadz5TLgTi" style="display: none">Schedule of Disaggregation of Revenue</span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold"> </td> <td colspan="6" style="font-weight: bold; text-align: center">Three Months Ended</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify">Net revenues:</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">March 31, 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">March 31, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; width: 60%; text-align: justify">Healthcare workforce</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--Revenues_c20240101__20240331__srt--ProductOrServiceAxis__custom--HealthcareWorkforceMember_zCLx0nvml3E2" style="width: 16%; text-align: right" title="Revenues">1,417,661</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--Revenues_c20230101__20230331__srt--ProductOrServiceAxis__custom--HealthcareWorkforceMember_zmd8xdUMdsjk" style="width: 16%; text-align: right" title="Revenues">1,110,840</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: justify">Population health</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--Revenues_c20240101__20240331__srt--ProductOrServiceAxis__custom--PopulationHealthMember_zg87d25xqbk4" style="text-align: right" title="Revenues">230,756</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--Revenues_c20230101__20230331__srt--ProductOrServiceAxis__custom--PopulationHealthMember_z4EfRK1vDP22" style="text-align: right" title="Revenues">74,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: justify">Digital health</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--Revenues_c20240101__20240331__srt--ProductOrServiceAxis__custom--DigitalHealthMember_z5HEJTqS2GUb" style="text-align: right" title="Revenues">92,250</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--Revenues_c20230101__20230331__srt--ProductOrServiceAxis__custom--DigitalHealthMember_zIiTJBr8XJV7" style="text-align: right" title="Revenues"><span style="-sec-ix-hidden: xdx2ixbrl0523">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: justify">Behavioral and mental services</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--Revenues_c20240101__20240331__srt--ProductOrServiceAxis__custom--BehavioralAndMentalServicesMember_zaOZULrYoNqf" style="text-align: right" title="Revenues">1,673</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--Revenues_c20230101__20230331__srt--ProductOrServiceAxis__custom--BehavioralAndMentalServicesMember_zuacO9IiK6ih" style="text-align: right" title="Revenues">1,730</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: justify; padding-bottom: 1.5pt">Health education</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98A_eus-gaap--Revenues_c20240101__20240331__srt--ProductOrServiceAxis__custom--HealtheducationMember_zNl337bNi0gh" style="border-bottom: Black 1.5pt solid; text-align: right" title="Net revenues">10,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--Revenues_c20230101__20230331__srt--ProductOrServiceAxis__custom--HealtheducationMember_zOMb4CpuMXgd" style="border-bottom: Black 1.5pt solid; text-align: right" title="Net revenues">1,781</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 2.5pt">Net revenues</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_eus-gaap--Revenues_c20240101__20240331_zlpJAp7jdil7" style="border-bottom: Black 2.5pt double; text-align: right" title="Net revenues">1,752,340</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_eus-gaap--Revenues_c20230101__20230331_zoJjAurgzHBb" style="border-bottom: Black 2.5pt double; text-align: right" title="Net revenues">1,188,351</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8AD_zxDAncozDABk" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"></p><p id="xdx_849_eus-gaap--CostOfSalesPolicyTextBlock_zIcQOXfmFG7l" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_863_zGLXsZMJVjNk">Cost of Services</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The cost of services includes wages and related payroll taxes, employee benefits and certain other employee-related costs of the Company’s contract service employees, while the employees work on contract assignments.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_848_ecustom--SignificantConcentrationsPolicyTextBlock_ziv17YUarcOd" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_868_zSDOd3iRZUJ7">Significant Concentrations</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The majority of accounts receivable and revenue contracts are between the Company and different divisions within the Indiana Family and Social Services Administration (“FSSA”). Most contracts require monthly payments as the projects progress. The Company generally does not require collateral or advance payments. For the three months ended March 31, 2024 and 2023, FSSA accounted for approximately <span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_dp_c20240101__20240331__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--FamilyAndSocialServicesAdministrationMember_zy5yI5QjtqU8" title="Risk percentage">67</span>% and <span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_dp_c20230101__20230331__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--FamilyAndSocialServicesAdministrationMember_zWjqCKZ62tX4" title="Risk percentage">99.6</span>% of revenues, respectively, which was derived through a combination of divisions within the State of Indiana, including the FSSA-NeuroDiagnostic Institute, representing $<span id="xdx_909_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20240101__20240331__srt--ProductOrServiceAxis__custom--HealthcareWorkforceMember__srt--MajorCustomersAxis__custom--FSSANeuroDiagnosticInstituteMember_zbJaE6GB00Ch" title="Revenues">1,108,230</span> and $<span id="xdx_90D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230101__20230331__srt--ProductOrServiceAxis__custom--HealthcareWorkforceMember__srt--MajorCustomersAxis__custom--FSSANeuroDiagnosticInstituteMember_zZF6U53o18q5" title="Revenues">1,109,960</span> of the Company’s Healthcare Workforce revenue for three months ended March 31, 2024 and 2023, respectively, and the FSSA-Division of Mental Health and Addiction, representing $<span id="xdx_903_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20240101__20240331__srt--ProductOrServiceAxis__custom--PopulationHealthMember__srt--MajorCustomersAxis__custom--FSSADivisionOfMentalHealthAndAddictionMember_z4B58iExzK4i" title="Revenues">71,000</span> and $<span id="xdx_901_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230101__20230331__srt--ProductOrServiceAxis__custom--PopulationHealthMember__srt--MajorCustomersAxis__custom--FSSADivisionOfMentalHealthAndAddictionMember_ztqI69wfBVR8" title="Revenues">74,000</span> of the Company’s Population Health revenues for the three months ended March 31, 2024 and 2023, respectively. In addition, the combined divisions of the FSSA (NeuroDiagnostic Institute and Division of Mental Health and Addiction), the Washington D.C. Department of Behavioral Health and Coordinated Care Corporation, doing business as Managed Health Services, owed <span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_dp_c20240101__20240331__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__srt--MajorCustomersAxis__custom--FamilyAndSocialServicesAdministrationMember_zQRgToY0lbDc" title="Risk percentage">50</span>% of the Company’s accounts receivable, respectively, at March 31, 2024, and FSSA represented <span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_dp_c20230101__20231231__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__srt--MajorCustomersAxis__custom--FamilyAndSocialServicesAdministrationMember_znbccT88TNX4" title="Risk percentage">30</span>% of outstanding accounts receivable as of December 31, 2023.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SYRA HEALTH CORP.</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES TO CONDENSED FINANCIAL STATEMENTS</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Unaudited)</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"></p> <p id="xdx_84C_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_z7aMxYlWaFll" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_869_zx5o3VlakJQk">Stock-Based Compensation</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company accounts for equity instruments issued to employees and non-employees in accordance with the provisions of ASC 718 Stock Compensation (“ASC 718”). All transactions in which the consideration provided in exchange for the purchase of goods or services consists of the issuance of equity instruments are accounted for based on the fair value of the consideration received or the fair value of the equity instrument issued, whichever is more reliably measurable.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_841_eus-gaap--EarningsPerSharePolicyTextBlock_zT8eT9HLxpb6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_867_zbA2gQ0nxUFl">Basic and Diluted Loss Per Share</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic earnings per share (“EPS”) are computed by dividing net income (the numerator) by the weighted average number of common shares outstanding for the period (the denominator). Weighted average shares for basic EPS are calculated based on weighted average Class B shares outstanding. Diluted EPS is computed by dividing net income by the weighted average number of common shares and potential common shares outstanding (if dilutive) during each period. Potential common shares include stock options, warrants, conversion of Class B shares and restricted stock. The number of potential common shares outstanding relating to stock options, warrants, conversion of Class B shares and restricted stock is computed using the treasury stock method. For the periods presented, potential dilutive securities had an anti-dilutive effect and were not included in the calculation of diluted net loss per common share.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84F_eus-gaap--IncomeTaxPolicyTextBlock_zaxSHYYsgOKb" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_860_zcFM01UfPrte">Income Taxes</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company accounts for income taxes under the Financial Accounting Standards Board (“FASB”) ASC 740 Income Taxes (“ASC 740”), which requires use of the liability method. FASB ASC 740-10-25 provides that deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. A valuation allowance is provided for significant deferred tax assets when it is more likely than not, that such asset will not be recovered through future operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"></p><p id="xdx_843_eus-gaap--IncomeTaxUncertaintiesPolicy_zmc8pCzgsNH6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_86D_z6qfhhPb8IIh">Uncertain Tax Positions</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In accordance with ASC 740, the Company recognizes the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be capable of withstanding examination by the taxing authorities based on the technical merits of the position. These standards prescribe a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. These standards also provide guidance on de-recognition, classification, interest and penalties, accounting in interim periods, disclosure, and transition.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Various taxing authorities may periodically audit the Company’s income tax returns. These audits include questions regarding the Company’s tax filing positions, including the timing and amount of deductions and the allocation of income to various tax jurisdictions. In evaluating the exposures connected with various tax filing positions, including state and local taxes, the Company records allowances for probable exposures. A number of years may elapse before a particular matter, for which an allowance has been established, is audited and fully resolved. The Company has not yet undergone an examination by any taxing authorities. <span style="background-color: white">The Company recognizes interest and penalties related to uncertain tax positions, if any, as an income tax expense.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The assessment of the Company’s tax position relies on the judgment of management to estimate the exposures associated with the Company’s various filing positions.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SYRA HEALTH CORP.</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES TO CONDENSED FINANCIAL STATEMENTS</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Unaudited)</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_846_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zpSkL5UxiGyh" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_861_z4HRhjQ21Efc">Recent Accounting Standards</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From time to time, new accounting pronouncements are issued by the FASB that are adopted by the Company as of the specified effective date.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Management does not believe that any recently issued, but not yet effective, accounting pronouncements, if currently adopted, would have a material effect on the Company’s financial statements.</span></p> <p id="xdx_85B_zMavzLA6ULuk" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84D_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zNEFjnkEquJk" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_86A_zYUac4NMtMTa">Basis of Presentation</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The accompanying interim consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) and should be read in conjunction with the financial statements and notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2023, which was filed with the Securities and Exchange Commission (“SEC”) on March 25, 2024. Certain information and footnote disclosures normally included in the financial statements prepared in accordance with U.S. GAAP have been omitted from this report on Form 10-Q pursuant to the rules and regulations of the SEC.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Results for the interim periods in this report are not necessarily indicative of future financial results and have not been audited by our independent registered public accounting firm. In the opinion of management, the accompanying unaudited consolidated financial statements include all adjustments necessary to present fairly our interim financial statements as of March 31, 2024, and for the three ended March 31, 2024 and 2023. These adjustments are of a normal recurring nature and consistent with the adjustments recorded to prepare the annual audited financial statements as of December 31, 2023.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_846_eus-gaap--UseOfEstimates_z8Ho5y2QRslk" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_861_zEUU1ZPuh6gh">Use of Estimates</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that may affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SYRA HEALTH CORP.</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES TO CONDENSED FINANCIAL STATEMENTS</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Unaudited)</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84F_eus-gaap--ConcentrationRiskCreditRisk_ztt6pmuaE45c" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_86E_zXrEcPxCmcf1">Concentrations of Credit Risk</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company maintains cash in bank deposit accounts, the balances of which at times may exceed federally insured limits. Accounts are guaranteed by the Federal Deposit Insurance Corporation (“FDIC”) up to $<span id="xdx_900_eus-gaap--CashFDICInsuredAmount_iI_c20240331_zfTbk9PwTNo6" title="FDIC insured amount">250,000</span> under current regulations. The Company did not have any cash in excess of FDIC insured limits at March 31, 2024. The Company has not experienced any losses in such accounts.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 250000 <p id="xdx_847_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zBYlkin86Z5f" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_866_zn0kOJWWSMc4">Fair Value of Financial Instruments</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounting Standards Codification (“ASC”) 820 defines fair value, establishes a three-level valuation hierarchy for disclosures of fair value measurement and enhances disclosure requirements for fair value measures. The three levels are defined as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 1 inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 2 inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the financial instrument.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 3 inputs to valuation methodology are unobservable and significant to the fair measurement.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The carrying value of the Company’s financial assets and liabilities, such as cash, accounts receivable and accounts payable are estimated by management to approximate fair value primarily due to the short-term nature of the instruments. The Company’s advances from related party approximates the fair value of such instruments based upon management’s best estimate of interest rates that would be available to the Company for similar financial arrangements at March 31, 2024 and December 31, 2023.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84B_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zcaZPfc9DoLe" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_868_ze0f3L8gU9jh">Cash and Cash Equivalents</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash equivalents include money market accounts which have maturities of three months or less when acquired. For the purpose of the statements of cash flows, all highly liquid investments with an original maturity of three months or less are considered to be cash equivalents. Cash equivalents are stated at cost plus accrued interest, which approximates market value. There were <span id="xdx_90D_eus-gaap--CashEquivalentsAtCarryingValue_iI_do_c20240331_zSePGbcUPhrd" title="Cash equivalents"><span id="xdx_909_eus-gaap--CashEquivalentsAtCarryingValue_iI_do_c20231231_zJjNGiYA6yRa" title="Cash equivalents">no</span></span> cash equivalents on hand at March 31, 2024 and December 31, 2023.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 0 0 <p id="xdx_84A_eus-gaap--TradeAndOtherAccountsReceivablePolicy_zenbLc9f8GKe" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_868_zit1UssByp1j">Accounts Receivable</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounts receivable is carried at their estimated collectible amounts. Accounts receivable is periodically evaluated for collectability based on past credit history with customers and their current financial condition. The Company had an allowance of $<span id="xdx_905_eus-gaap--AccountsReceivableNet_iI_c20240331_z0ACFBBnd4Kh" title="Accounts receivable"><span id="xdx_906_eus-gaap--AccountsReceivableNet_iI_c20231231_zSklKFkTIop3" title="Accounts receivable">5,520</span></span> at March 31, 2024 and December 31, 2023.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 5520 5520 <p id="xdx_848_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zZXFESQpjHz2" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_860_zy3FkGo3Pgk6">Property and Equipment</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property and equipment is stated at cost, less accumulated depreciation. The cost of office equipment is depreciated using the straight-line method based on a <span id="xdx_90B_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dxL_c20240331_z1xfaFdrimMh" title="Property and equipment useful life::XDX::P5Y"><span style="-sec-ix-hidden: xdx2ixbrl0501">five</span></span>-year life expectancy.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Repairs and maintenance expenditures are charged to operations as incurred. Major improvements and replacements, which extend the useful life of an asset, are capitalized and depreciated over the remaining estimated useful life of the asset. When assets are retired or sold, the cost and related accumulated depreciation are eliminated and any resulting gain or loss is reflected in operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_842_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_z1pj2BAG8Co9" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_860_zkO8xysGHqa2">Impairment of Long-Lived Assets</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In accordance with the provisions of ASC Topic 360, “<i>Impairment or Disposal of Long-Lived Assets</i>”, all long-lived assets such as property and equipment held and used by the Company are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is evaluated by a comparison of the carrying amount of an asset to its estimated future undiscounted cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amounts of the assets exceed the fair value of the assets.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SYRA HEALTH CORP.</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES TO CONDENSED FINANCIAL STATEMENTS</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Unaudited)</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_843_eus-gaap--LesseeLeasesPolicyTextBlock_zIXZL9fPGcVh" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><span style="text-decoration: underline"><span id="xdx_860_zcnrU8wmR8G7">Leases</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company accounts for its leases under ASC 842 - <i>Leases</i>. The Company determines if an arrangement is a lease at inception. Operating leases are included in operating lease right-of-use (“ROU”) assets, current portion of obligations under operating leases, and obligations under operating leases, non-current on the Company’s balance sheets.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating lease ROU assets and operating lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at commencement date, adjusted by the deferred rent liabilities at the adoption date. As the Company’s lease does not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at commencement date in determining the present value of future payments. The operating lease ROU asset also includes any lease payments made and excludes lease incentives and initial direct costs incurred. The Company’s terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Operating lease expense is recognized on a straight-line basis over the lease term.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84F_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zFxMWH2CnRx5" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_86A_zX9zPuJoJtu7">Segment Reporting</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ASC Topic 280, “<i>Segment Reporting</i>,” requires annual and interim reporting for an enterprise’s operating segments and related disclosures about its products, services, geographic areas and major customers. An operating segment is defined as a component of an enterprise that engages in business activities from which it may earn revenues and expenses, and about which separate financial information is regularly evaluated by the chief operating decision maker in deciding how to allocate resources. The Company operates as a single segment and will evaluate additional segment disclosure requirements as it expands its operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_846_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_zlDsrCt4UTBj" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_865_zabXt6F3sZ5">Revenue Recognition</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company recognizes revenue in accordance with ASC 606, the core principle of which is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled to receive in exchange for those goods or services. To achieve this core principle, five basic criteria must be met before revenue can be recognized: (1) identify the contract with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to performance obligations in the contract; and (5) recognize revenue when or as the Company satisfies a performance obligation.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company accounts for revenues when both parties to the contract have approved the contract, the rights and obligations of the parties are identified, payment terms are identified, and collectability of consideration is probable. Payment terms vary by client and the services offered.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has the following main forms of revenue:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">–</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Healthcare Workforce;</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">–</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Population Health</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">–</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Digital Health</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">–</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Behavioral and Mental Health Services</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">–</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Health Education</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2.25pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company primarily provides its services to state health and social service agencies and universities. Healthcare Workforce, Health Education and Behavioral Mental Health Service contracts are primarily accounted for as a single performance obligation satisfied over time because the customer simultaneously receives and consumes the benefits of our medical staffing on an hourly or daily basis. Population Health and Digital Health contracts generally consist of multiple performance obligations that are distinct, such as to provide data analytics and reporting, training, or develop technology for implementation and maintenance with the customer. The Company allocates the transaction price across the performance obligations based on the estimated fair value of the distinct performance obligations. Depending on the performance obligation, revenue is recognized at a point in time when the customer obtains the benefit of the services are provide, or over time in the case of digital health revenue where the customer simultaneously receives and consumes benefits of the contract, such as ongoing performance of our technology product.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The contracts generally stipulate bi-weekly or monthly billing, and the Company has elected the “as invoiced” practical expedient to recognize revenue based on the hours incurred at the contractual rate as the Company has the right to payment in an amount that corresponds directly with the value of performance completed to date. The Company may also be subject to penalties for violations of certain ethical standards and non-performance measures within these state contracts. The Company recognizes revenue net of penalties.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Disaggregated revenue data</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_892_eus-gaap--DisaggregationOfRevenueTableTextBlock_zWSmXELpTmlg" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s revenue consists of the following revenue services within its industry:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B6_zbXadz5TLgTi" style="display: none">Schedule of Disaggregation of Revenue</span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold"> </td> <td colspan="6" style="font-weight: bold; text-align: center">Three Months Ended</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify">Net revenues:</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">March 31, 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">March 31, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; width: 60%; text-align: justify">Healthcare workforce</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--Revenues_c20240101__20240331__srt--ProductOrServiceAxis__custom--HealthcareWorkforceMember_zCLx0nvml3E2" style="width: 16%; text-align: right" title="Revenues">1,417,661</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--Revenues_c20230101__20230331__srt--ProductOrServiceAxis__custom--HealthcareWorkforceMember_zmd8xdUMdsjk" style="width: 16%; text-align: right" title="Revenues">1,110,840</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: justify">Population health</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--Revenues_c20240101__20240331__srt--ProductOrServiceAxis__custom--PopulationHealthMember_zg87d25xqbk4" style="text-align: right" title="Revenues">230,756</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--Revenues_c20230101__20230331__srt--ProductOrServiceAxis__custom--PopulationHealthMember_z4EfRK1vDP22" style="text-align: right" title="Revenues">74,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: justify">Digital health</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--Revenues_c20240101__20240331__srt--ProductOrServiceAxis__custom--DigitalHealthMember_z5HEJTqS2GUb" style="text-align: right" title="Revenues">92,250</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--Revenues_c20230101__20230331__srt--ProductOrServiceAxis__custom--DigitalHealthMember_zIiTJBr8XJV7" style="text-align: right" title="Revenues"><span style="-sec-ix-hidden: xdx2ixbrl0523">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: justify">Behavioral and mental services</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--Revenues_c20240101__20240331__srt--ProductOrServiceAxis__custom--BehavioralAndMentalServicesMember_zaOZULrYoNqf" style="text-align: right" title="Revenues">1,673</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--Revenues_c20230101__20230331__srt--ProductOrServiceAxis__custom--BehavioralAndMentalServicesMember_zuacO9IiK6ih" style="text-align: right" title="Revenues">1,730</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: justify; padding-bottom: 1.5pt">Health education</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98A_eus-gaap--Revenues_c20240101__20240331__srt--ProductOrServiceAxis__custom--HealtheducationMember_zNl337bNi0gh" style="border-bottom: Black 1.5pt solid; text-align: right" title="Net revenues">10,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--Revenues_c20230101__20230331__srt--ProductOrServiceAxis__custom--HealtheducationMember_zOMb4CpuMXgd" style="border-bottom: Black 1.5pt solid; text-align: right" title="Net revenues">1,781</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 2.5pt">Net revenues</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_eus-gaap--Revenues_c20240101__20240331_zlpJAp7jdil7" style="border-bottom: Black 2.5pt double; text-align: right" title="Net revenues">1,752,340</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_eus-gaap--Revenues_c20230101__20230331_zoJjAurgzHBb" style="border-bottom: Black 2.5pt double; text-align: right" title="Net revenues">1,188,351</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8AD_zxDAncozDABk" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"></p> <p id="xdx_892_eus-gaap--DisaggregationOfRevenueTableTextBlock_zWSmXELpTmlg" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s revenue consists of the following revenue services within its industry:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B6_zbXadz5TLgTi" style="display: none">Schedule of Disaggregation of Revenue</span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold"> </td> <td colspan="6" style="font-weight: bold; text-align: center">Three Months Ended</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify">Net revenues:</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">March 31, 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">March 31, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; width: 60%; text-align: justify">Healthcare workforce</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--Revenues_c20240101__20240331__srt--ProductOrServiceAxis__custom--HealthcareWorkforceMember_zCLx0nvml3E2" style="width: 16%; text-align: right" title="Revenues">1,417,661</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--Revenues_c20230101__20230331__srt--ProductOrServiceAxis__custom--HealthcareWorkforceMember_zmd8xdUMdsjk" style="width: 16%; text-align: right" title="Revenues">1,110,840</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: justify">Population health</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--Revenues_c20240101__20240331__srt--ProductOrServiceAxis__custom--PopulationHealthMember_zg87d25xqbk4" style="text-align: right" title="Revenues">230,756</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--Revenues_c20230101__20230331__srt--ProductOrServiceAxis__custom--PopulationHealthMember_z4EfRK1vDP22" style="text-align: right" title="Revenues">74,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: justify">Digital health</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--Revenues_c20240101__20240331__srt--ProductOrServiceAxis__custom--DigitalHealthMember_z5HEJTqS2GUb" style="text-align: right" title="Revenues">92,250</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--Revenues_c20230101__20230331__srt--ProductOrServiceAxis__custom--DigitalHealthMember_zIiTJBr8XJV7" style="text-align: right" title="Revenues"><span style="-sec-ix-hidden: xdx2ixbrl0523">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: justify">Behavioral and mental services</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--Revenues_c20240101__20240331__srt--ProductOrServiceAxis__custom--BehavioralAndMentalServicesMember_zaOZULrYoNqf" style="text-align: right" title="Revenues">1,673</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--Revenues_c20230101__20230331__srt--ProductOrServiceAxis__custom--BehavioralAndMentalServicesMember_zuacO9IiK6ih" style="text-align: right" title="Revenues">1,730</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: justify; padding-bottom: 1.5pt">Health education</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98A_eus-gaap--Revenues_c20240101__20240331__srt--ProductOrServiceAxis__custom--HealtheducationMember_zNl337bNi0gh" style="border-bottom: Black 1.5pt solid; text-align: right" title="Net revenues">10,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--Revenues_c20230101__20230331__srt--ProductOrServiceAxis__custom--HealtheducationMember_zOMb4CpuMXgd" style="border-bottom: Black 1.5pt solid; text-align: right" title="Net revenues">1,781</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 2.5pt">Net revenues</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_eus-gaap--Revenues_c20240101__20240331_zlpJAp7jdil7" style="border-bottom: Black 2.5pt double; text-align: right" title="Net revenues">1,752,340</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_eus-gaap--Revenues_c20230101__20230331_zoJjAurgzHBb" style="border-bottom: Black 2.5pt double; text-align: right" title="Net revenues">1,188,351</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 1417661 1110840 230756 74000 92250 1673 1730 10000 1781 1752340 1188351 <p id="xdx_849_eus-gaap--CostOfSalesPolicyTextBlock_zIcQOXfmFG7l" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_863_zGLXsZMJVjNk">Cost of Services</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The cost of services includes wages and related payroll taxes, employee benefits and certain other employee-related costs of the Company’s contract service employees, while the employees work on contract assignments.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_848_ecustom--SignificantConcentrationsPolicyTextBlock_ziv17YUarcOd" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_868_zSDOd3iRZUJ7">Significant Concentrations</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The majority of accounts receivable and revenue contracts are between the Company and different divisions within the Indiana Family and Social Services Administration (“FSSA”). Most contracts require monthly payments as the projects progress. The Company generally does not require collateral or advance payments. For the three months ended March 31, 2024 and 2023, FSSA accounted for approximately <span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_dp_c20240101__20240331__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--FamilyAndSocialServicesAdministrationMember_zy5yI5QjtqU8" title="Risk percentage">67</span>% and <span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_dp_c20230101__20230331__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--FamilyAndSocialServicesAdministrationMember_zWjqCKZ62tX4" title="Risk percentage">99.6</span>% of revenues, respectively, which was derived through a combination of divisions within the State of Indiana, including the FSSA-NeuroDiagnostic Institute, representing $<span id="xdx_909_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20240101__20240331__srt--ProductOrServiceAxis__custom--HealthcareWorkforceMember__srt--MajorCustomersAxis__custom--FSSANeuroDiagnosticInstituteMember_zbJaE6GB00Ch" title="Revenues">1,108,230</span> and $<span id="xdx_90D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230101__20230331__srt--ProductOrServiceAxis__custom--HealthcareWorkforceMember__srt--MajorCustomersAxis__custom--FSSANeuroDiagnosticInstituteMember_zZF6U53o18q5" title="Revenues">1,109,960</span> of the Company’s Healthcare Workforce revenue for three months ended March 31, 2024 and 2023, respectively, and the FSSA-Division of Mental Health and Addiction, representing $<span id="xdx_903_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20240101__20240331__srt--ProductOrServiceAxis__custom--PopulationHealthMember__srt--MajorCustomersAxis__custom--FSSADivisionOfMentalHealthAndAddictionMember_z4B58iExzK4i" title="Revenues">71,000</span> and $<span id="xdx_901_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230101__20230331__srt--ProductOrServiceAxis__custom--PopulationHealthMember__srt--MajorCustomersAxis__custom--FSSADivisionOfMentalHealthAndAddictionMember_ztqI69wfBVR8" title="Revenues">74,000</span> of the Company’s Population Health revenues for the three months ended March 31, 2024 and 2023, respectively. In addition, the combined divisions of the FSSA (NeuroDiagnostic Institute and Division of Mental Health and Addiction), the Washington D.C. Department of Behavioral Health and Coordinated Care Corporation, doing business as Managed Health Services, owed <span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_dp_c20240101__20240331__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__srt--MajorCustomersAxis__custom--FamilyAndSocialServicesAdministrationMember_zQRgToY0lbDc" title="Risk percentage">50</span>% of the Company’s accounts receivable, respectively, at March 31, 2024, and FSSA represented <span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_dp_c20230101__20231231__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__srt--MajorCustomersAxis__custom--FamilyAndSocialServicesAdministrationMember_znbccT88TNX4" title="Risk percentage">30</span>% of outstanding accounts receivable as of December 31, 2023.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SYRA HEALTH CORP.</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES TO CONDENSED FINANCIAL STATEMENTS</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Unaudited)</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"></p> 0.67 0.996 1108230 1109960 71000 74000 0.50 0.30 <p id="xdx_84C_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_z7aMxYlWaFll" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_869_zx5o3VlakJQk">Stock-Based Compensation</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company accounts for equity instruments issued to employees and non-employees in accordance with the provisions of ASC 718 Stock Compensation (“ASC 718”). All transactions in which the consideration provided in exchange for the purchase of goods or services consists of the issuance of equity instruments are accounted for based on the fair value of the consideration received or the fair value of the equity instrument issued, whichever is more reliably measurable.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_841_eus-gaap--EarningsPerSharePolicyTextBlock_zT8eT9HLxpb6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_867_zbA2gQ0nxUFl">Basic and Diluted Loss Per Share</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic earnings per share (“EPS”) are computed by dividing net income (the numerator) by the weighted average number of common shares outstanding for the period (the denominator). Weighted average shares for basic EPS are calculated based on weighted average Class B shares outstanding. Diluted EPS is computed by dividing net income by the weighted average number of common shares and potential common shares outstanding (if dilutive) during each period. Potential common shares include stock options, warrants, conversion of Class B shares and restricted stock. The number of potential common shares outstanding relating to stock options, warrants, conversion of Class B shares and restricted stock is computed using the treasury stock method. For the periods presented, potential dilutive securities had an anti-dilutive effect and were not included in the calculation of diluted net loss per common share.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84F_eus-gaap--IncomeTaxPolicyTextBlock_zaxSHYYsgOKb" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_860_zcFM01UfPrte">Income Taxes</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company accounts for income taxes under the Financial Accounting Standards Board (“FASB”) ASC 740 Income Taxes (“ASC 740”), which requires use of the liability method. FASB ASC 740-10-25 provides that deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. A valuation allowance is provided for significant deferred tax assets when it is more likely than not, that such asset will not be recovered through future operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"></p> <p id="xdx_843_eus-gaap--IncomeTaxUncertaintiesPolicy_zmc8pCzgsNH6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_86D_z6qfhhPb8IIh">Uncertain Tax Positions</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In accordance with ASC 740, the Company recognizes the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be capable of withstanding examination by the taxing authorities based on the technical merits of the position. These standards prescribe a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. These standards also provide guidance on de-recognition, classification, interest and penalties, accounting in interim periods, disclosure, and transition.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Various taxing authorities may periodically audit the Company’s income tax returns. These audits include questions regarding the Company’s tax filing positions, including the timing and amount of deductions and the allocation of income to various tax jurisdictions. In evaluating the exposures connected with various tax filing positions, including state and local taxes, the Company records allowances for probable exposures. A number of years may elapse before a particular matter, for which an allowance has been established, is audited and fully resolved. The Company has not yet undergone an examination by any taxing authorities. <span style="background-color: white">The Company recognizes interest and penalties related to uncertain tax positions, if any, as an income tax expense.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The assessment of the Company’s tax position relies on the judgment of management to estimate the exposures associated with the Company’s various filing positions.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SYRA HEALTH CORP.</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES TO CONDENSED FINANCIAL STATEMENTS</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Unaudited)</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_846_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zpSkL5UxiGyh" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_861_z4HRhjQ21Efc">Recent Accounting Standards</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From time to time, new accounting pronouncements are issued by the FASB that are adopted by the Company as of the specified effective date.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Management does not believe that any recently issued, but not yet effective, accounting pronouncements, if currently adopted, would have a material effect on the Company’s financial statements.</span></p> <p id="xdx_80B_eus-gaap--SubstantialDoubtAboutGoingConcernTextBlock_zJrN9C8pGME1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 2 – <span id="xdx_827_zPGuIJjKzm1d">Going Concern</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As shown in the accompanying financial statements, as of March 31, 2024, the Company had a cash balance of $<span id="xdx_906_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_c20240331_zH0MMMxcVHWd" title="Cash">3,237,957</span>, working capital of $<span id="xdx_90F_ecustom--WorkingCapital_iI_c20240331_zHkjjAmELt81" title="Working capital">3,345,431</span> and an accumulated deficit of $<span id="xdx_90A_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_di_c20240331_zf5BrBqDg518" title="Accumulated deficit">6,512,005</span> since inception. The Company is too early in its development stage to project revenue with a necessary level of certainty. Therefore, the Company may not have sufficient funds to sustain its operations for the next twelve months from the issuance date of these financial statements and may need to raise additional cash to fund its operations. These factors raise substantial doubt about the Company’s ability to continue as a going concern. The Company has commenced sales and continues to develop its operations. In the event sales do not materialize at the expected rates, management would seek additional financing or would attempt to conserve cash by further reducing expenses. There can be no assurance that the Company will be successful in achieving these objectives.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company continues to pursue sources of additional capital through debt and financing transactions or arrangements, including equity financing or other means. The Company may not be successful in identifying suitable funding transactions in a sufficient time period or at all, and may not obtain the required capital by other means. If the Company does not succeed in raising additional capital, resources may not be sufficient to fund its business. The Company’s ability to scale production and distribution capabilities and further increase the value of its brands, is largely dependent on its success in raising additional capital. From January through April of 2023, the Company raised a total of $<span id="xdx_90C_eus-gaap--ProceedsFromConvertibleDebt_c20230101__20230430_zSqA8ba6E799" title="Convertible notes payable">1,455,000</span> of capital from the sale of convertible notes. On October 3, 2023 the Company completed IPO received net proceeds of approximately $<span id="xdx_904_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20231003__20231003_zSWJwIB3p9W1" title="Proceeds from commnon stock">5,332,283</span>. In October 2023, the convertible notes were converted into Class A common stock in accordance with the terms of the convertible promissory notes as a result of the IPO.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The financial statements do not include any adjustments that might result from the outcome of any uncertainty as to the Company’s ability to continue as a going concern. These financial statements also do not include any adjustments relating to the recoverability and classification of recorded asset amounts, or amounts and classifications of liabilities that might be necessary should the Company be unable to continue as a going concern.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> 3237957 3345431 -6512005 1455000 5332283 <p id="xdx_801_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zot1mCJLhF98" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 3 – <span id="xdx_826_zI9MXNmS4Ln5">Related Party Transactions</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The Company pays for payroll and related costs for its employees that provide services to Sahasra Technologies Corp., doing business as STLogics to service contracts of STLogics, which is an entity beneficially owned by the principal owners and management team of Syra. During the three months ended March 31, 2024, the Company paid $<span id="xdx_905_eus-gaap--LoansAssumed1_c20240101__20240331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SahasraTechnologiesCorpMember_zIVOVbpJmtc1" title="Advanced balance of loan">82,214</span> of payroll and related costs for these employees, and had a receivable from STLogics of $<span id="xdx_90E_eus-gaap--AccountsReceivableNetCurrent_iI_c20240331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--STLogicsMember_zxTrwMGSr2W4" title="Receivable from related party">82,124</span> and $<span id="xdx_901_eus-gaap--AccountsReceivableNetCurrent_iI_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--STLogicsMember_zAMgIgStlX9l" title="Receivable from related party">50,614</span> for additional costs incurred as of March 31, 2024 and December 31, 2023, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Office Lease</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The Company leases its current corporate headquarters under a <span id="xdx_90C_eus-gaap--LesseeOperatingLeaseTermOfContract_iI_dxL_c20210701__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--STVenturesMember_zyegMG1hLTN7" title="Lease term::XDX::P3Y"><span style="-sec-ix-hidden: xdx2ixbrl0587">three-year</span></span> lease from STVentures, LLC (“STVentures”)</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">, an entity beneficially owned by the principal owners and the management team of Syra and their affiliates<span style="background-color: white">. The lease commenced on July 1, 2021 and, as amended on May 1, 2022, provides for a base monthly rent of $<span id="xdx_906_eus-gaap--PaymentsForRent_c20220501__20220501__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--STVenturesMember_zxBCprnm3h5g" title="Base monthly rent">10,711</span> over the three-year term of the lease. A total of $<span id="xdx_908_eus-gaap--OperatingLeaseExpense_c20240101__20240331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--STVenturesMember_zRxat2SGrpAb" title="Lease expense"><span id="xdx_908_eus-gaap--OperatingLeaseExpense_c20230101__20230331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--STVenturesMember_zZqmzmo3YqO2" title="Lease expense">32,132</span></span> was included in selling, general and administrative expenses for the three months ended March 31, 2024 and 2023, respectively.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Information Technology (“IT”) Services</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company incurred a total of $<span id="xdx_90C_eus-gaap--CostOfGoodsAndServicesSold_c20240101__20240331__srt--ProductOrServiceAxis__custom--InformationTechnologyServicesMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RadCubeLLCMember_zQOjYsZNdn0c" title="Service cost">0</span> and $<span id="xdx_905_eus-gaap--CostOfGoodsAndServicesSold_c20230101__20230331__srt--ProductOrServiceAxis__custom--InformationTechnologyServicesMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RadCubeLLCMember_zCi29CwY1U9d" title="Service cost">3,320</span> of services from RAD CUBE LLC, which is an entity beneficially owned by the principal owners and the management team of Syra and their affiliates, for outsourced IT services which have been presented within selling, general and administrative expenses in the statements of operations during the three months ended March 31, 2024 and 2023, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Recruitment and Human Resource Services</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company paid a total of $<span id="xdx_90A_eus-gaap--CostOfGoodsAndServicesSold_c20240101__20240331__srt--ProductOrServiceAxis__custom--RecruitmentAndHumanResourceServicesMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NLogixMember_zNLmKIY81Z2l" title="Service cost">145,318</span> and $<span id="xdx_90A_eus-gaap--CostOfGoodsAndServicesSold_c20230101__20230331__srt--ProductOrServiceAxis__custom--RecruitmentAndHumanResourceServicesMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NLogixMember_zbYPg3Hv8W41" title="Service cost">66,713</span> for recruitment and human resource services from NLogix, which is an entity beneficially owned by the principal owners and the management team of Syra and their affiliates, which have been presented within cost of sales in the statements of operations during the three months ended March 31, 2024 and 2023, respectively<span style="background-color: white">.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SYRA HEALTH CORP.</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES TO CONDENSED FINANCIAL STATEMENTS</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Unaudited)</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 82214 82124 50614 10711 32132 32132 0 3320 145318 66713 <p id="xdx_80E_eus-gaap--EarningsPerShareTextBlock_zbjD7fiGRcF9" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 4 – <span id="xdx_820_zJ5yQ80LU235">Basic and Diluted Earnings per Share</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the three months ended March 31, 2024, the Company used the two-class method to compute net loss per common share because it had issued securities, other than a single class of common stock, that contractually entitled the holders to participate in dividends and earnings. These participating securities included the Company’s Class A common stock, which was authorized pursuant to the Company’s amendment to its Certificate of Incorporation on May 2, 2022, and convertible Class B common stock which are entitled to share equally, on a per share basis, in all assets of the Company of whatever kind available for distribution to the holders of common stock. The two-class method requires earnings for the period to be allocated between common stock and participating securities based upon their respective rights to receive distributed and undistributed earnings.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under the two-class method, for periods with net income, basic net income per common share is computed by dividing the net income attributable to common stockholders by the weighted average number of shares of common stock outstanding during the period. Net income attributable to common stockholders is computed by subtracting from net income the portion of current period earnings that the participating securities would have been entitled to receive pursuant to their dividend rights had all of the period’s earnings been distributed. No such adjustment to earnings is made during periods with a net loss, as the holders of the participating securities have no obligation to fund losses.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company reports the more dilutive of the approaches (two-class or “if-converted”) as its diluted net income per share during the period. For the periods presented, potential dilutive securities had an anti-dilutive effect and were not included in the calculation of diluted net loss per common share.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_890_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zumLIz1gbgm7" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Common shares consisting of shares potentially dilutive that are excluded from the calculated of diluted earnings per share because they are anti-dilutive as of March 31, 2024 and 2023 are as follows: </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B9_zDnxit7LM401" style="display: none">Schedule of Diluted Earnings Per Share</span> </span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_499_20240101__20240331_zR8j3EWqqSB9" style="border-bottom: Black 1.5pt solid; text-align: center">March 31, 2024</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49F_20230101__20230331_zF1eoSANphYj" style="border-bottom: Black 1.5pt solid; text-align: center">March 31, 2023</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_407_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zqrBrpLlObAh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: justify">Warrants</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">1,760,350</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0608">-</span></td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_z84CUj6ZCFof" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1.5pt">Stock options</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">164,750</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">28,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_zrRobzzea0Qg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">1,925,100</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">28,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8AA_z8paoxtaD6V1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p id="xdx_890_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zumLIz1gbgm7" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Common shares consisting of shares potentially dilutive that are excluded from the calculated of diluted earnings per share because they are anti-dilutive as of March 31, 2024 and 2023 are as follows: </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B9_zDnxit7LM401" style="display: none">Schedule of Diluted Earnings Per Share</span> </span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_499_20240101__20240331_zR8j3EWqqSB9" style="border-bottom: Black 1.5pt solid; text-align: center">March 31, 2024</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49F_20230101__20230331_zF1eoSANphYj" style="border-bottom: Black 1.5pt solid; text-align: center">March 31, 2023</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_407_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zqrBrpLlObAh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: justify">Warrants</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">1,760,350</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0608">-</span></td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_z84CUj6ZCFof" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1.5pt">Stock options</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">164,750</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">28,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_zrRobzzea0Qg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">1,925,100</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">28,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 1760350 164750 28000 1925100 28000 <p id="xdx_801_eus-gaap--OtherCurrentAssetsTextBlock_zZgipwMIExF6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 5 – <span id="xdx_829_znQPP2sxdt5k">Other Current Assets</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89A_eus-gaap--ScheduleOfOtherCurrentAssetsTableTextBlock_zCubhG3bHzig" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other current assets included the following as of March 31, 2024 and December 31, 2023:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BB_zwdNpmDcyPT6" style="display: none">Schedule of Other Current Assets</span></span> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" id="xdx_493_20240331_zRyysTaF7kqi" style="text-align: center">March 31,</td><td> </td><td> </td> <td colspan="2" id="xdx_49B_20231231_zPStoB02E2I1" style="text-align: center">December 31,</td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2024</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_408_eus-gaap--PrepaidTaxes_iI_maOACzG3O_zkDoTohYZUg9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Federal and state income tax receivable <sup id="xdx_F40_zIXHT7OmAnBb">(1) (2)</sup></span></td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">148,401</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">73,069</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--PrepaidExpenseCurrent_iI_maOACzG3O_z3rmBAzAxxX8" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Prepaid expenses</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">233,486</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">316,718</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--OtherAssetsCurrent_iTI_mtOACzG3O_zxPEZTkjyTe8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Total other current assets</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">381,887</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">389,787</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 15pt; text-align: right"><span id="xdx_F07_zZ5uNZHjD44e" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>(1)</sup></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span id="xdx_F1E_zqOFOyPnGrN9" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIE90aGVyIEN1cnJlbnQgQXNzZXRzIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_900_eus-gaap--IncomeTaxReconciliationTaxCredits_c20240101__20240331__us-gaap--TaxCreditCarryforwardAxis__custom--EmployeeRetentionTaxCreditMember_zgBBDuOhGhIe" title="Tax credits">50,000</span> for a federal refundable payroll tax credit, called the Employee Retention Tax Credit (“ERTC”) Tax Credit, which provides a credit to businesses who kept employees, or were negatively impacted, during the COVID-19 pandemic.</span></td> </tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td id="xdx_F03_z9krWkGOrtok" style="width: 15pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>(2)</sup></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span id="xdx_F15_zOaSJe4uHRig" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIE90aGVyIEN1cnJlbnQgQXNzZXRzIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90B_eus-gaap--IncomeTaxReconciliationTaxCredits_c20240101__20240331__us-gaap--TaxCreditCarryforwardAxis__custom--EconomicDevelopmentGrowingEconomyMember_zwgXJDQgZqP4" title="Tax credits">75,332</span> for a refundable corporate income tax credit from the State of Indiana, called the Economic Development for a Growing Economy (“EDGE”) Tax Credit, which provides an incentive to businesses to support jobs creation, capital investment and to improve the standard of living for Indiana residents.</span></td> </tr></table> <p id="xdx_8A3_zwE3UU3GXFAc" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SYRA HEALTH CORP.</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES TO CONDENSED FINANCIAL STATEMENTS</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Unaudited)</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89A_eus-gaap--ScheduleOfOtherCurrentAssetsTableTextBlock_zCubhG3bHzig" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other current assets included the following as of March 31, 2024 and December 31, 2023:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BB_zwdNpmDcyPT6" style="display: none">Schedule of Other Current Assets</span></span> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" id="xdx_493_20240331_zRyysTaF7kqi" style="text-align: center">March 31,</td><td> </td><td> </td> <td colspan="2" id="xdx_49B_20231231_zPStoB02E2I1" style="text-align: center">December 31,</td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2024</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_408_eus-gaap--PrepaidTaxes_iI_maOACzG3O_zkDoTohYZUg9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Federal and state income tax receivable <sup id="xdx_F40_zIXHT7OmAnBb">(1) (2)</sup></span></td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">148,401</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">73,069</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--PrepaidExpenseCurrent_iI_maOACzG3O_z3rmBAzAxxX8" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Prepaid expenses</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">233,486</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">316,718</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--OtherAssetsCurrent_iTI_mtOACzG3O_zxPEZTkjyTe8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Total other current assets</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">381,887</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">389,787</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 15pt; text-align: right"><span id="xdx_F07_zZ5uNZHjD44e" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>(1)</sup></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span id="xdx_F1E_zqOFOyPnGrN9" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIE90aGVyIEN1cnJlbnQgQXNzZXRzIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_900_eus-gaap--IncomeTaxReconciliationTaxCredits_c20240101__20240331__us-gaap--TaxCreditCarryforwardAxis__custom--EmployeeRetentionTaxCreditMember_zgBBDuOhGhIe" title="Tax credits">50,000</span> for a federal refundable payroll tax credit, called the Employee Retention Tax Credit (“ERTC”) Tax Credit, which provides a credit to businesses who kept employees, or were negatively impacted, during the COVID-19 pandemic.</span></td> </tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td id="xdx_F03_z9krWkGOrtok" style="width: 15pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>(2)</sup></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span id="xdx_F15_zOaSJe4uHRig" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIE90aGVyIEN1cnJlbnQgQXNzZXRzIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90B_eus-gaap--IncomeTaxReconciliationTaxCredits_c20240101__20240331__us-gaap--TaxCreditCarryforwardAxis__custom--EconomicDevelopmentGrowingEconomyMember_zwgXJDQgZqP4" title="Tax credits">75,332</span> for a refundable corporate income tax credit from the State of Indiana, called the Economic Development for a Growing Economy (“EDGE”) Tax Credit, which provides an incentive to businesses to support jobs creation, capital investment and to improve the standard of living for Indiana residents.</span></td> </tr></table> 148401 73069 233486 316718 381887 389787 50000 75332 <p id="xdx_807_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_z0mq3wdH8tQi" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 6 – <span id="xdx_828_zM2a1uGFGNPg">Property and Equipment</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89B_eus-gaap--PropertyPlantAndEquipmentTextBlock_znKvGkpiZDm1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property and equipment at March 31, 2024 and December 31, 2023, consisted of the following:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B5_zOZVnZoqk7S7" style="display: none">Schedule of Property and Equipment</span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" id="xdx_49D_20240331_zc90A5y7y783" style="text-align: center">March 31,</td><td> </td><td> </td> <td colspan="2" id="xdx_49B_20231231_zIRWkVxNARna" style="text-align: center">December 31,</td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2024</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_40A_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zOsO7P569om8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Office equipment</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">148,419</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">142,800</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_zy1LSdul9WZ7" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Less: Accumulated depreciation</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(76,371</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(63,826</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_408_eus-gaap--PropertyPlantAndEquipmentNet_iTI_zIOAJStSZpCe" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 10pt">Total property and equipment, net</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">72,048</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">78,974</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A3_zr7be4s5Smc4" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Depreciation of property and equipment was $<span id="xdx_90A_eus-gaap--Depreciation_c20240101__20240331_zYxXgXctytc2" title="Depreciation">12,545</span> and $<span id="xdx_90A_eus-gaap--Depreciation_c20230101__20230331_zTiy4f5dR4K7" title="Depreciation">11,763</span> for the three months ended March 31, 2024 and 2023, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89B_eus-gaap--PropertyPlantAndEquipmentTextBlock_znKvGkpiZDm1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property and equipment at March 31, 2024 and December 31, 2023, consisted of the following:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B5_zOZVnZoqk7S7" style="display: none">Schedule of Property and Equipment</span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" id="xdx_49D_20240331_zc90A5y7y783" style="text-align: center">March 31,</td><td> </td><td> </td> <td colspan="2" id="xdx_49B_20231231_zIRWkVxNARna" style="text-align: center">December 31,</td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2024</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_40A_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zOsO7P569om8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Office equipment</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">148,419</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">142,800</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_zy1LSdul9WZ7" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Less: Accumulated depreciation</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(76,371</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(63,826</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_408_eus-gaap--PropertyPlantAndEquipmentNet_iTI_zIOAJStSZpCe" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 10pt">Total property and equipment, net</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">72,048</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">78,974</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 148419 142800 76371 63826 72048 78974 12545 11763 <p id="xdx_801_eus-gaap--AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_z2nRCaEjcZwe" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 7 – <span id="xdx_821_zmUsczJxy8u1">Accrued Expenses</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89C_eus-gaap--ScheduleOfAccruedLiabilitiesTableTextBlock_zHVN1VGjcpti" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued expenses at March 31, 2024 and December 31, 2023, consisted of the following:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B6_z5yrSg8w4kTg" style="display: none">Schedule of Accrued Expenses</span> </span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" id="xdx_494_20240331_zqoFwgWUioX5" style="text-align: center">March 31,</td><td> </td><td> </td> <td colspan="2" id="xdx_498_20231231_zGx00JlUFTrj" style="text-align: center">December 31,</td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2024</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_403_eus-gaap--AccruedPayrollTaxesCurrent_iI_maALCz1hd_zUndMrhhSQoi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Accrued payroll and taxes</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">312,576</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">148,924</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--AccruedEmployeeBenefitsCurrent_iI_maALCz1hd_zt1Hrm7YpWxh" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Accrued expenses</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">7,122</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">50,054</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--AccruedLiabilitiesCurrent_iTI_mtALCz1hd_zbWW8CXL63Gk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 10pt">Total accrued expenses</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">319,698</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">198,978</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8AC_zwZOcMTqLwY9" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The Company provides postretirement benefits pursuant to IRS code section 401(k) for employees meeting specified criteria. The Company matches <span id="xdx_905_eus-gaap--DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_pid_dp_uPure_c20240101__20240331_ztbforRtj6v9" title="Employers contribution percentage match">100</span>% of the employees’ contributions that are not in excess of <span id="xdx_906_eus-gaap--DefinedContributionPlanEmployerMatchingContributionPercent_pid_dp_uPure_c20240101__20240331_z1tGEkcVkacb" title="Employees contribution percentage">4</span>% of the employee’s contributions. These matching contributions are fully vested and paid pursuant to the employees’ bi-weekly or semi-monthly pay periods. The Company does not prefund these benefits and has the right to modify or terminate certain of these benefits in the future. For the three months ended March 31, 2024, the Company incurred $<span id="xdx_90B_ecustom--InvestmentRetirementAccountContributionExpenses_c20240101__20240331_zMJiJUXWYc95" title="Investment retirement account contribution expenses">26,485</span> of IRA contribution expenses pursuant to the Company’s matching contributions, including $<span id="xdx_903_ecustom--AccruedRetirementContributions_iI_c20240331_zhtG6NGHuDt4" title="Accrued retirement contributions">0</span>, as accrued at March 31, 2024.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SYRA HEALTH CORP.</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES TO CONDENSED FINANCIAL STATEMENTS</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Unaudited)</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89C_eus-gaap--ScheduleOfAccruedLiabilitiesTableTextBlock_zHVN1VGjcpti" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued expenses at March 31, 2024 and December 31, 2023, consisted of the following:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B6_z5yrSg8w4kTg" style="display: none">Schedule of Accrued Expenses</span> </span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" id="xdx_494_20240331_zqoFwgWUioX5" style="text-align: center">March 31,</td><td> </td><td> </td> <td colspan="2" id="xdx_498_20231231_zGx00JlUFTrj" style="text-align: center">December 31,</td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2024</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_403_eus-gaap--AccruedPayrollTaxesCurrent_iI_maALCz1hd_zUndMrhhSQoi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Accrued payroll and taxes</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">312,576</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">148,924</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--AccruedEmployeeBenefitsCurrent_iI_maALCz1hd_zt1Hrm7YpWxh" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Accrued expenses</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">7,122</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">50,054</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--AccruedLiabilitiesCurrent_iTI_mtALCz1hd_zbWW8CXL63Gk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 10pt">Total accrued expenses</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">319,698</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">198,978</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 312576 148924 7122 50054 319698 198978 1 0.04 26485 0 <p id="xdx_802_eus-gaap--LesseeOperatingLeasesTextBlock_z7R9Ji04duub" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 8 – <span id="xdx_824_zasCiwcVJXad">Lease</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The Company leases its current corporate headquarters under a <span id="xdx_909_eus-gaap--LesseeOperatingLeaseTermOfContract_iI_dxL_c20240331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--STVenturesMember_zcPSBMBhMHK5" title="Lease term::XDX::P3Y"><span style="-sec-ix-hidden: xdx2ixbrl0675">three</span></span>-year lease from STVentures, a related party. The lease, as amended on May 1, 2022 to expand its office space from <span id="xdx_90A_eus-gaap--AreaOfLand_iI_uSqft_c20220501__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--STVenturesMember_zZrNfXqDHI8f" title="Office space">2,976</span> square feet to approximately <span id="xdx_903_eus-gaap--AreaOfLand_iI_uSqft_c20210701__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--STVenturesMember_z2c7X7ncLmXj" title="Office space">5,978</span> square feet, commenced on July 1, 2021, and provides for a base monthly rent of $<span id="xdx_90D_eus-gaap--PaymentsForRent_c20220701__20220701__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--STVenturesMember_zavjAeQPjwY3" title="Base monthly rent">10,711</span>, as increased from $<span id="xdx_909_ecustom--IncreaseDecreaseInPaymentsForRent_c20210701__20210701__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--STVenturesMember_z88tpf3hiPta" title="Increased base monthly rent">5,332</span> per month, over the <span id="xdx_900_eus-gaap--LesseeOperatingLeaseTermOfContract_iI_dxL_c20220701__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--STVenturesMember_z2DF8fB9gBZe" title="Lease term::XDX::P3Y"><span style="-sec-ix-hidden: xdx2ixbrl0685">three</span></span>-year term of the lease. The Company is occupying the space for executive and administrative offices. Rent expense for the three months ended </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 31, 2024 and 2023 <span style="background-color: white">was $<span id="xdx_90E_eus-gaap--OperatingLeaseExpense_c20240101__20240331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--STVenturesMember_z3rxw9bh98m9" title="Lease rent expense"><span id="xdx_90C_eus-gaap--OperatingLeaseExpense_c20230101__20230331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--STVenturesMember_zoSEfOknkQwb" title="Lease rent expense">32,132</span></span></span>, which is included in selling, general and administrative expenses within the statements of operations<span style="background-color: white">.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_899_eus-gaap--LeaseCostTableTextBlock_z1IbfDQTGcoh" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The components of lease expense were as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B1_zAVHGnuXnAbj" style="display: none">Schedule of Lease Cost expenses</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_496_20240101__20240331_zCfh0BQXYQ8a" style="border-bottom: Black 1.5pt solid; text-align: center">2024</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49C_20230101__20230331_z8o2S4Y6qrf3" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="6" style="text-align: center">For the Three Months Ended</td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">March 31,</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2024</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Operating lease cost:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--OperatingLeaseRightOfUseAssetAmortizationExpense_maOLEzYEO_zdfHW29lQ2Gh" style="vertical-align: bottom; background-color: White"> <td style="width: 60%; text-align: justify; padding-left: 10pt">Amortization of ROU asset</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">31,373</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">121,089</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_404_ecustom--OperatingLeaseInterestExpense_maOLEzYEO_zw6Cu2xQdKQj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1.5pt; padding-left: 10pt">Interest on lease liability</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">759</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">7,438</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--OperatingLeaseExpense_iT_mtOLEzYEO_zVBhf7WB1csb" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 2.5pt">Total operating lease cost</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">32,132</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">128,527</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A3_zrcotpiy9tW7" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89C_ecustom--SupplementalBalanceSheetsInformationTableTextBlock_z3vJtEun7IRf" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Supplemental balance sheet information related to leases was as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B5_zkvLpEbb0Mf9" style="display: none">Schedule of Supplemental Balance Sheets Information</span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" id="xdx_49E_20240331_zknEeSaaGcU8" style="text-align: center">March 31,</td><td> </td><td> </td> <td colspan="2" id="xdx_49A_20231231_zIjFm93XeyVc" style="text-align: center">December 31,</td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2024</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Operating lease:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--OperatingLeaseRightOfUseAsset_iI_zFSERJrFuLza" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; width: 60%; text-align: justify; padding-bottom: 2.5pt">Operating lease assets</td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 16%; text-align: right">31,826</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 16%; text-align: right">63,199</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--OperatingLeaseLiabilityCurrent_iI_maOLLzW6A_zOLzyZQuFDb6" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: justify">Current portion of operating lease liability, related party</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">31,826</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">63,199</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_maOLLzW6A_zi0u6LsPJom2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: justify; padding-bottom: 1.5pt">Noncurrent operating lease liability, related party</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0710">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0711">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--OperatingLeaseLiability_iTI_mtOLLzW6A_zDI8jSPCpLD3" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 20pt; text-align: justify; padding-bottom: 2.5pt">Total operating lease liability</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">31,826</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">63,199</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Weighted average remaining lease term:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: justify">Operating leases</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20240331_zpywhS7vhRkk" title="Weighted-average remaining lease term (in years) (Year)">0.25</span> years</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20231231_zCtc33mgBUK8" title="Weighted-average remaining lease term (in years) (Year)">0.5</span> years</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Weighted average discount rate:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: justify">Operating lease</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_900_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20240331_zQRso8iCwHIc" title="Weighted-average discount rate (Rate)">5.75</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_900_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20231231_zqx6Cnx7PUd7" title="Weighted-average discount rate (Rate)">5.75</span></td><td style="text-align: left">%</td></tr> </table> <p id="xdx_8A4_zFHdXbfSpdi1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SYRA HEALTH CORP.</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES TO CONDENSED FINANCIAL STATEMENTS</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Unaudited)</span></p> 2976 5978 10711 5332 32132 32132 <p id="xdx_899_eus-gaap--LeaseCostTableTextBlock_z1IbfDQTGcoh" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The components of lease expense were as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B1_zAVHGnuXnAbj" style="display: none">Schedule of Lease Cost expenses</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_496_20240101__20240331_zCfh0BQXYQ8a" style="border-bottom: Black 1.5pt solid; text-align: center">2024</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49C_20230101__20230331_z8o2S4Y6qrf3" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="6" style="text-align: center">For the Three Months Ended</td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">March 31,</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2024</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Operating lease cost:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--OperatingLeaseRightOfUseAssetAmortizationExpense_maOLEzYEO_zdfHW29lQ2Gh" style="vertical-align: bottom; background-color: White"> <td style="width: 60%; text-align: justify; padding-left: 10pt">Amortization of ROU asset</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">31,373</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">121,089</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_404_ecustom--OperatingLeaseInterestExpense_maOLEzYEO_zw6Cu2xQdKQj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1.5pt; padding-left: 10pt">Interest on lease liability</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">759</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">7,438</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--OperatingLeaseExpense_iT_mtOLEzYEO_zVBhf7WB1csb" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 2.5pt">Total operating lease cost</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">32,132</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">128,527</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 31373 121089 759 7438 32132 128527 <p id="xdx_89C_ecustom--SupplementalBalanceSheetsInformationTableTextBlock_z3vJtEun7IRf" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Supplemental balance sheet information related to leases was as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B5_zkvLpEbb0Mf9" style="display: none">Schedule of Supplemental Balance Sheets Information</span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" id="xdx_49E_20240331_zknEeSaaGcU8" style="text-align: center">March 31,</td><td> </td><td> </td> <td colspan="2" id="xdx_49A_20231231_zIjFm93XeyVc" style="text-align: center">December 31,</td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2024</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Operating lease:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--OperatingLeaseRightOfUseAsset_iI_zFSERJrFuLza" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; width: 60%; text-align: justify; padding-bottom: 2.5pt">Operating lease assets</td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 16%; text-align: right">31,826</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 16%; text-align: right">63,199</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--OperatingLeaseLiabilityCurrent_iI_maOLLzW6A_zOLzyZQuFDb6" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: justify">Current portion of operating lease liability, related party</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">31,826</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">63,199</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_maOLLzW6A_zi0u6LsPJom2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: justify; padding-bottom: 1.5pt">Noncurrent operating lease liability, related party</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0710">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0711">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--OperatingLeaseLiability_iTI_mtOLLzW6A_zDI8jSPCpLD3" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 20pt; text-align: justify; padding-bottom: 2.5pt">Total operating lease liability</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">31,826</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">63,199</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Weighted average remaining lease term:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: justify">Operating leases</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20240331_zpywhS7vhRkk" title="Weighted-average remaining lease term (in years) (Year)">0.25</span> years</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20231231_zCtc33mgBUK8" title="Weighted-average remaining lease term (in years) (Year)">0.5</span> years</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Weighted average discount rate:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: justify">Operating lease</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_900_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20240331_zQRso8iCwHIc" title="Weighted-average discount rate (Rate)">5.75</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_900_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20231231_zqx6Cnx7PUd7" title="Weighted-average discount rate (Rate)">5.75</span></td><td style="text-align: left">%</td></tr> </table> 31826 63199 31826 63199 31826 63199 P0Y3M P0Y6M 0.0575 0.0575 <p id="xdx_806_eus-gaap--DebtDisclosureTextBlock_zTaKOK9bOFaf" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 9 – <span id="xdx_828_zSDn3ozWMR2a">Notes Payable</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In 2023, the Company entered into three insurance policy financing arrangements to purchase various insurance policies. The total principal of these arrangements was $<span id="xdx_906_eus-gaap--NotesPayable_iI_c20231231__us-gaap--TypeOfArrangementAxis__custom--InsurancePolicyFinancingArrangementsMember_zKuec76rhLQ4" title="Principal amount">370,596</span> with interest rates ranging from <span id="xdx_90B_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_c20231231__srt--RangeAxis__srt--MinimumMember__us-gaap--TypeOfArrangementAxis__custom--InsurancePolicyFinancingArrangementsMember_zRjT5GwBFHpa" title="Interest rate percentage">10.38</span>% through <span id="xdx_900_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_c20231231__srt--RangeAxis__srt--MaximumMember__us-gaap--TypeOfArrangementAxis__custom--InsurancePolicyFinancingArrangementsMember_zNKgi6JOYWR7" title="Interest rate percentage">14.05</span>% and monthly payments totaling $<span id="xdx_90E_eus-gaap--DebtInstrumentPeriodicPaymentInterest_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--InsurancePolicyFinancingArrangementsMember_zgQLNRB9uJNd" title="Periodic interest payment">32,328</span> are due through July 2024. The Company made principal repayments of $<span id="xdx_900_eus-gaap--RepaymentsOfDebt_c20240101__20240331_zF3m6p6MWlb5" title="Principal repayments">85,883</span> and incurred interest expense of $<span id="xdx_90A_eus-gaap--InterestExpense_c20240101__20240331_zqhGxhqiTU4" title="Interest expense">4,077</span> during the three months ended March 31, 2024. As of March 31, 2024 and December 31, 2023, the remaining balance was $<span id="xdx_907_eus-gaap--NotesPayableCurrent_iI_c20240331_zY830WZh13A" title="Notes payable">99,021</span> and $<span id="xdx_90F_eus-gaap--NotesPayableCurrent_iI_c20231231_zbcNSdiVYMWk" title="Notes payable">184,904</span>, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 370596 0.1038 0.1405 32328 85883 4077 99021 184904 <p id="xdx_803_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zpl9jjPMeas" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 10 – <span id="xdx_827_zSvpVPKqp0b3">Commitments and Contingencies</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Legal Contingencies</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From time to time, we may be involved in various disputes and litigation matters that arise in the ordinary course of business. The Company is currently not a party to any material legal proceedings.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In January 2024, a former employee filed a wrongful termination lawsuit against the Company in the U.S. District Court, Southern District of Indiana. The Company plans to vigorously defend itself against the claims, which it believes are without merit.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_806_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zsupDEtB4yv1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 11 – <span id="xdx_828_zP0AhPM7Kwug">Changes in Stockholders’ Equity (Deficit)</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Class A Common Stock</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has <span id="xdx_900_eus-gaap--CommonStockSharesAuthorized_iI_c20240331__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zp09vhMs5lI7" title="Common stock, shares authorized">100,000,000</span> authorized shares of $<span id="xdx_905_eus-gaap--CommonStockParOrStatedValuePerShare_iI_uUSDPShares_c20240331__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zEbSgMmDzsz3" title="Common stock, par value">0.001</span> par value Class A common stock, and <span id="xdx_90D_eus-gaap--CommonStockSharesIssued_iI_c20240331__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zvgP8CTXX1Od" title="Common stock, shares issued"><span id="xdx_907_eus-gaap--CommonStockSharesOutstanding_iI_c20240331__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zHrGPb9lE4w1" title="Common stock, shares outstanding">5,769,087</span></span> shares were issued and outstanding as of March 31, 2024.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the three months ended March 31, 2024, two investors exercised <span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_pid_c20240331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--TwoInvestorsMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zuNd8hjbmKAi" title="Warrants to purchase">130,789</span> warrants to purchase Class A Common stock pursuant to which the Company received cash proceeds of $<span id="xdx_90A_eus-gaap--ProceedsFromIssuanceOfWarrants_c20240101__20240331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--TwoInvestorsMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zFXzm7ZCfdH2" title="Proceeds from issuance of warrants">850,129</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the three months ended March 31, 2024, the Company issued <span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_pid_c20240101__20240331__us-gaap--AwardTypeAxis__custom--NovemberTwoThousandTwentyThreeMember_zyv6btSqmazd" title="Restricted stock awarded">50,000</span> shares pursuant to the restricted stock award from November 2023. These shares vest quarterly over a one-year period. The Company recognized expense of $<span id="xdx_90E_ecustom--RecognizedExpense_c20240101__20240331_zgJi5uzXbrYj" title="Recognized expense">18,875</span> for these awards and expects to recognize an additional $<span id="xdx_903_ecustom--AdditionalRecognizedExpenseAtVestingPeriod_c20240101__20240331_zPWmbizme9Xf" title="Additional recognized expense at vesting period">48,503</span> through the end of the vesting period.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Convertible Class B Common Stock</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has <span id="xdx_90A_eus-gaap--CommonStockSharesAuthorized_iI_c20240331__us-gaap--StatementClassOfStockAxis__custom--ConvertibleCommonStockBMember_zeAp3c1ZEBt8" title="Common stock, shares authorized">5,000,000</span> authorized shares of $<span id="xdx_90A_eus-gaap--CommonStockParOrStatedValuePerShare_iI_uUSDPShares_c20240331__us-gaap--StatementClassOfStockAxis__custom--ConvertibleCommonStockBMember_z84uNOJqlYtb" title="Common stock, par value">0.001</span> par value convertible Class B common stock, and had <span id="xdx_900_eus-gaap--CommonStockSharesIssued_iI_pid_c20240331__us-gaap--StatementClassOfStockAxis__custom--ConvertibleCommonStockBMember_zwPz3EiPdII9" title="Common stock, shares issued"><span id="xdx_90C_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20240331__us-gaap--StatementClassOfStockAxis__custom--ConvertibleCommonStockBMember_zqUIh8LJPfv" title="Common stock, shares outstanding">833,334</span></span> shares issued and outstanding as of March 31, 2024, as retrospectively applied, pursuant to the Company’s subsequent recapitalization in 2022 and effective as of May 3, 2022, whereby the founders exchanged their <span id="xdx_90D_eus-gaap--CommonStockSharesIssued_iI_pid_c20220503__us-gaap--StatementClassOfStockAxis__custom--ConvertibleClassBCommonStockMember_zk6nD5rKmLLd" title="Common stock, shares issued">83,334</span> Founders Shares for <span id="xdx_907_eus-gaap--ConversionOfStockSharesConverted1_pid_c20220503__20220503__us-gaap--StatementClassOfStockAxis__custom--ConvertibleClassBCommonStockMember_zaXTLZ5t4qa6" title="Conversion of stock, shares converted">833,334</span> shares of convertible Class B common stock.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SYRA HEALTH CORP.</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES TO CONDENSED FINANCIAL STATEMENTS</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Unaudited)</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 100000000 0.001 5769087 5769087 130789 850129 50000 18875 48503 5000000 0.001 833334 833334 83334 833334 <p id="xdx_80E_eus-gaap--ShareholdersEquityAndShareBasedPaymentsTextBlock_zPOdBVGcYPV2" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 12 – <span id="xdx_826_zz7VbMmklcc3">Common Stock Options</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Omnibus Equity Incentive Plan</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On April 11, 2022, the Company’s board of directors adopted, and the Company’s stockholders approved, the Syra Health Corp. 2022 Omnibus Equity Incentive Plan, as amended on April 19, 2023 (as amended, the “2022 Plan”). No more than <span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20220411__20220411__us-gaap--PlanNameAxis__custom--OmnibusEquityIncentivePlanMember__srt--RangeAxis__srt--MaximumMember_z6MnScDtIgjl" title="Shares issued">1,041,667</span> shares of the Company’s Class A common stock shall be issued pursuant to the exercise of incentive stock options under the 2022 Plan.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Class A Common Stock Option Awards</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the three months ended March 31, 2024, the Company granted options to purchase an aggregate <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20240101__20240331__us-gaap--PlanNameAxis__custom--TwoThouandTwentyTwoPlanMember_zqyps3GDbVq" title="Granted options">24,000</span> shares of the Company’s Class A common stock at an exercise price of $<span id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20240331__us-gaap--PlanNameAxis__custom--TwoThouandTwentyTwoPlanMember_z1ccsKwD9E05" title="Exercise price">1.88</span> per share for a term of <span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20240331__us-gaap--PlanNameAxis__custom--TwoThouandTwentyTwoPlanMember_zg9VJrAjvBrf" title="Granted options term">10</span> years under the 2022 Plan. These options will vest <span id="xdx_90D_ecustom--NumberOfOptionsVested_pid_dp_uPure_c20240101__20240331_zSvgFPOwFll1" title="Number of options vested">25</span>% on each anniversary until fully vested. The options had no intrinsic value. The aggregate estimated value using the Black-Scholes Pricing Model, based on an expected term of <span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240101__20240331_zXlEx2Q3Rrma" title="Expected term">6.25</span> years, a weighted average volatility rate of <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_pid_dp_uPure_c20240101__20240331_zeLAZcOYzrrd" title="Weighted average volatility rate">110</span>%, a weighted average risk-free interest rate of <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20240101__20240331_zwkHNDQfCfja" title="Weighted average risk free interest rate">4.16</span>%, and a weighted average call option value of $<span id="xdx_908_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExercisePrice_c20240101__20240331_zVQArvJ4pvKe" title="Weighted average call option value">1.498</span>, was $<span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_iI_c20240331_zfc1Oh1zbG6a" title="Aggregate intrinsic value">35,945</span>. During the three months ended March 31, 2024 and 2023, the Company recognized expense of $<span id="xdx_905_eus-gaap--ShareBasedCompensation_c20240101__20240331_z3VxxoHmfox3" title="Stock-based compensation, stock options">14,140</span> and $<span id="xdx_904_eus-gaap--ShareBasedCompensation_c20230101__20230331_z97wFrRDjzde" title="Stock-based compensation, stock options">1,367</span> related to common stock options. As of March 31, 2024, a total of $<span id="xdx_902_eus-gaap--UnamortizedDiscountsOnAcceptancesExecuted_iI_c20240331_z0uEvG763Sj9" title="Unamortized expenses">218,760</span> of unamortized expenses are expected to be expensed over the vesting period.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_893_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zjFrUcGZJ5o9" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following is a summary of activity of outstanding stock options:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B5_zCsDxvKfUN8l" style="display: none">Schedule of Share-Based Compensation, Stock Options Activity</span> </span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center">Weighted</td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center">Average</td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td> </td> <td colspan="2" style="text-align: center">Number</td><td> </td><td> </td> <td colspan="2" style="text-align: center">Exercise</td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">of Shares</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Prices</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: justify">Balance, December 31, 2023</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20240101__20240331_zELHgPXRPHLd" style="width: 16%; text-align: right" title="Number of options, beginning balance">140,750</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20240101__20240331_zZsGhL5Qs1xj" style="width: 16%; text-align: right" title="Weighted average exercise prices, ending balance">1.82</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: justify">Options granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20240101__20240331_zcg6xDu81ozg" style="text-align: right" title="Options granted">24,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20240101__20240331_zpevmyDxfjcg" style="text-align: right" title="Weighted average exercise price, granted">1.88</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: justify; padding-bottom: 1.5pt">Options cancelled</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_c20240101__20240331_zbwbZdaZSJi" style="border-bottom: Black 1.5pt solid; text-align: right" title="Options cancelled"><span style="-sec-ix-hidden: xdx2ixbrl0814">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c20240101__20240331_zH3c3LRWkA3d" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average exercise price, cancelled"><span style="-sec-ix-hidden: xdx2ixbrl0816">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 2.5pt">Balance, March 31, 2024</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20240101__20240331_zLZ0LA365Bya" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of options, ending balance">164,750</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20240101__20240331_zpuvl2HFsWp3" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise prices, ending balance">1.83</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 2.5pt">Exercisable, March 31, 2024</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_c20240101__20240331_zJjQbD27AKSa" style="border-bottom: Black 2.5pt double; text-align: right" title="Exercisable ending balance"><span style="-sec-ix-hidden: xdx2ixbrl0822">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_c20240331_zrc3IHqU3Daa" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, exercisable"><span style="-sec-ix-hidden: xdx2ixbrl0824">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8AD_zwmR2u8OEegg" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The options had a weighted average remaining life of <span id="xdx_900_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20240101__20240331_z3zBEYGKSUl" title="Remaining contractual life">9.42</span> years and no intrinsic value as of March 31, 2024.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 1041667 24000 1.88 P10Y 0.25 P6Y3M 1.10 0.0416 1.498 35945 14140 1367 218760 <p id="xdx_893_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zjFrUcGZJ5o9" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following is a summary of activity of outstanding stock options:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B5_zCsDxvKfUN8l" style="display: none">Schedule of Share-Based Compensation, Stock Options Activity</span> </span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center">Weighted</td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center">Average</td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td> </td> <td colspan="2" style="text-align: center">Number</td><td> </td><td> </td> <td colspan="2" style="text-align: center">Exercise</td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">of Shares</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Prices</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: justify">Balance, December 31, 2023</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20240101__20240331_zELHgPXRPHLd" style="width: 16%; text-align: right" title="Number of options, beginning balance">140,750</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20240101__20240331_zZsGhL5Qs1xj" style="width: 16%; text-align: right" title="Weighted average exercise prices, ending balance">1.82</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: justify">Options granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20240101__20240331_zcg6xDu81ozg" style="text-align: right" title="Options granted">24,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20240101__20240331_zpevmyDxfjcg" style="text-align: right" title="Weighted average exercise price, granted">1.88</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: justify; padding-bottom: 1.5pt">Options cancelled</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_c20240101__20240331_zbwbZdaZSJi" style="border-bottom: Black 1.5pt solid; text-align: right" title="Options cancelled"><span style="-sec-ix-hidden: xdx2ixbrl0814">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c20240101__20240331_zH3c3LRWkA3d" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average exercise price, cancelled"><span style="-sec-ix-hidden: xdx2ixbrl0816">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 2.5pt">Balance, March 31, 2024</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20240101__20240331_zLZ0LA365Bya" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of options, ending balance">164,750</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20240101__20240331_zpuvl2HFsWp3" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise prices, ending balance">1.83</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 2.5pt">Exercisable, March 31, 2024</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_c20240101__20240331_zJjQbD27AKSa" style="border-bottom: Black 2.5pt double; text-align: right" title="Exercisable ending balance"><span style="-sec-ix-hidden: xdx2ixbrl0822">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_c20240331_zrc3IHqU3Daa" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, exercisable"><span style="-sec-ix-hidden: xdx2ixbrl0824">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 140750 1.82 24000 1.88 164750 1.83 P9Y5M1D <p id="xdx_80F_eus-gaap--SubsequentEventsTextBlock_zxu27eUOW275" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 13 – <span id="xdx_82B_zn7K9nXdoOSg">Subsequent Events</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company evaluates events that have occurred after the balance sheet date through the date these financial statements were issued.</span></p> Includes $50,000 for a federal refundable payroll tax credit, called the Employee Retention Tax Credit (“ERTC”) Tax Credit, which provides a credit to businesses who kept employees, or were negatively impacted, during the COVID-19 pandemic. Includes $75,332 for a refundable corporate income tax credit from the State of Indiana, called the Economic Development for a Growing Economy (“EDGE”) Tax Credit, which provides an incentive to businesses to support jobs creation, capital investment and to improve the standard of living for Indiana residents.